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Abstract
Anthropogenic pollution poses a threat to marine organisms and ecosystems
worldwide. Common chemical pollutants that enter the marine environment include
legacy contaminants, which are well known and heavily regulated or banned pollutants,
and emerging contaminants, which are more recently recognized as pollutants and often
lack regulatory limits for their use and discharge. Wastewater treatment plant (WWTP)
effluent is a major source of various contaminants of concern, particularly pharmaceutical
and personal care products (PPCPs) that are not fully removed during treatment. PPCPs
exist at low concentrations in the environment and may have unknown and subtle effects
on marine life. Data gaps exist on occurrence, effects, and remediation options, especially
in coastal areas with low surrounding populations. Additionally, few studies focus on
environmentally relevant conditions and organism, population and ecosystem level
impacts.
The overarching goal of my dissertation research is to examine unexplored
aspects of PPCP occurrence, effects, and pollution reduction in the Pacific Northwest.
Through a field experiment, I compared PPCP accumulation in and health of Pacific
oysters transplanted near WWTP outfalls and aquaculture areas in OR and WA. I also
examined small-scale spatial variation in PPCP occurrence and effects along a pollution
gradient near those outfalls. To identify organismal effects of PPCP mixtures on oysters,
I designed and carried out a lab experiment exposing oysters to environmentally relevant
concentrations of effluent from two OR coastal WWTPs. I measured growth, health, and
feeding rate over a 12-week exposure period. I also compared PPCP detections and
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concentrations in effluent from both WWTPs and oyster tissues after effluent exposure.
Lastly, I explored a potential opportunity for reducing pharmaceutical pollution with
improved drug disposal practices through use and establishment of drug take-back boxes
in pharmacies. I conducted surveys with pharmacy customers, interviews with
pharmacists, and a focus group with other pharmacy professionals regarding drug
disposal behaviors, recommendations, and obstacles.
In the field experiment, two pharmaceuticals (miconazole and virginiamycin M1)
and four alkylphenols (NP1EO, NP2EO, NP and OP) were detected at low concentrations
relative to other studies. Alkylphenols and virginiamycin were detected at one oyster
aquaculture site indicating potential for human exposure. Oyster condition was highest at
one aquaculture site, compared to other aquaculture and wastewater sites. During the 12week lab experiment, effluent exposure had some effects on oyster growth and feeding
rate, but concentration level (10%, 25%, 50%) did not drive these differences. Three
alkylphenols and 30 PPCPs were detected in effluent, and four alkylphenols and 13
PPCPs were detected in oyster tissues. Despite the lack of effects observed, oysters
accumulated several PPCPs in their tissues. Through customer surveys I found awareness
and use of drug take-back boxes was low, but marginally improved at locations with an
onsite dropbox. Pharmacist recommendations at locations with drug take-back boxes
were more consistent and safe compared to locations without dropboxes. Focus group
participants emphasized the importance of increasing drug take-back box locations in OR
through legislative action to address improper disposal. This research fills important data
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gaps on PPCP occurrence in WWTP effluent and accumulation in shellfish, organismal
effects of PPCP mixtures, and possible pollution reduction options.
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with journal expectations, I use “we” in these chapters to include partners and co-authors.
Personal reflections on field and lab experiences are included in Appendix A4 and B2.
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Chapter 1: Introduction
Coastal ecosystems provide a multitude of benefits to both humans and marine
species yet are among the most heavily impacted marine environments (Millennium
Ecosystem Assessment 2005). Human populations near the ocean are consistently
growing and approximately 10% of the global population resides in coastal zones below
10 m of elevation (Neumann et al. 2015). In the United States, 40% of people live within
60 miles of the coast (NOAA Office for Coastal Management 2016). With growing
populations, human impacts from habitat loss, eutrophication, fisheries, pollution and
global climate change are having negative and potentially irreversible effects on marine
environments (Crain et al. 2009). All of these factors can impact organisms and
ecosystems as stressors, defined as environmental influences that interfere with the
function of an ecosystem (Breitburg and Riedel 2005) and/or impair structure and
function of organisms resulting in reduced fitness (Calow 1989). Organisms and
ecosystems respond to stress in one of two ways: resistance, defined as the ability to
withstand disturbance/stress, and resilience, the capacity to recover from and return to a
stable state (Pimm 1984). Given that many of these variables occur simultaneously, it is
important to consider the cumulative effects of multiple stressors, which may be additive
(effect = A + B), synergistic (effect > A+B), or antagonistic (effect < A+B) (Folt et al.
1999).
Pollution is considered one of the top threats to coastal ecosystems (Crain et al.
2009). For centuries the ocean has served as a sink for solid waste, sewage, chemical
discharge, excess nutrients, oil, and other pollutants. Two major categories of chemical
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contaminants are found in marine environments: legacy and emerging contaminants.
Legacy contaminants include compounds that are currently banned, or heavily regulated
but continue to persist in the environment, such as polychlorinated biphenyls (PCBs),
heavy metals, and legacy pesticides such as dichlorodiphenyltrichloroethane (DDT). In
contrast, contaminants of emerging concern (CECs) are more recently recognized as
pollutants and have little regulation in their use or discharge (US EPA 2008). Some
examples include pharmaceutical and personal care products (PPCPs), polybrominated
diphenyl ethers (PBDEs), endocrine disrupting chemicals (EDCs), and most current use
pesticides (US EPA 2008). In the United States (US), contaminants are regulated by the
1976 Toxic Substances Control Act (TSCA) which allows the US Environmental
Protection Agency to prevent environmental pollution by requiring and overseeing
evaluation of risks of these substances (Schierow 2009). If a chemical is deemed
potentially harmful to humans or the environment, the EPA may require the manufacturer
to test the chemical for environmental impacts (Schierow 2009). With tens of thousands
of chemicals on the market, only a few are heavily scrutinized. In addition, most CECs,
such as drugs and personal care products, are not included in this legislation and therefore
are not subject to assessment of environmental risks before or after production and
release into the market (Schierow 2009).
There are many sources of contaminants to the coastal marine environment.
Wastewater treatment plant (WWTP) and industrial effluent contain various CECs,
particularly PPCPs, as most are not removed during the treatment process (Lara-Martín et
al. 2014). Contaminants that readily bind to sediments during wastewater treatment may
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be redistributed when sludge is applied as fertilizer in agricultural settings, which
frequently occurs with PPCPs (Gaw et al. 2014). Hospitals, veterinary facilities, and
pharmaceutical manufacturers can be an important source of PPCPs to the environment
as well (Daughton and Ternes 1999). CECs can leach into groundwater from failing or
inadequately maintained septic systems which are commonly used in rural coastal areas
(Gaw et al. 2014). Stormwater and agricultural runoff are large sources of CECs such as
veterinary pharmaceuticals and pesticides. Landfill leachate can be a source of
pharmaceuticals and other chemicals that are thrown away, especially if the landfill lacks
proper lining and maintenance. Many chemicals bind to sediments in aquatic and marine
environments and may be resuspended when perturbed, thus becoming a secondary
source of contamination (Gaw et al. 2014).
Contaminants in the marine environment have the potential for bioaccumulation
in organisms, or an increase in concentration within an organism. For some compounds,
biomagnification may also occur, where organisms higher in the food chain (e.g., apex
predators) contain elevated concentrations of contaminants from trophic transfer (Dodder
et al. 2014). Many factors can affect the bioaccumulation and biomagnification potential
of compounds, including individual chemical properties, surrounding environmental
factors (e.g., pH, salinity, temperature), and organism behavior, habitat, and trophic level.
Compounds that are more hydrophobic/lipophilic tend to bioaccumulate more readily,
while hydrophilic/lipophobic compounds are less likely to accumulate in organism
tissues, though there are many exceptions to these general predictions and hydrophilic
compounds can negatively affect organisms (e.g., (Oliveira et al. 2017). Higher pH
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values can increase the lipophilic nature of some chemicals (e.g., pharmaceuticals) by
decreasing the amount that can ionize and dissociate in the surrounding water, indicating
marine organisms may have a higher potential for bioaccumulation (Fabbri and
Franzellitti 2016). At higher salinities, some chemicals bind to sediment more readily,
which could make this a more significant source of contamination to the marine
environment (Fabbri and Franzellitti 2016). Sessile and benthic organisms may have
higher exposure to chemical contaminants due to inability to move long distances from
sources and proximity to the sediment, indicating high potential for bioaccumulation.
Organisms at higher trophic levels that consume benthic organisms are at highest risk for
bioaccumulation, particularly those living in estuaries and nearshore environments. For
example, (Gu et al. 2016) found higher concentrations of 4-nonylphenol, a surfactant
with demonstrated endocrine disruption, in benthic mollusks compared to fish, and higher
concentrations of other alkylphenols in fish that consumed benthic organisms compared
to fish that do not consume benthic organisms.
PPCPs were first identified as environmental pollutants in the 1970s (e.g.,
(Hignite and Azarnoff 1977), but research on their occurrence and effects was not
prominent in the literature until the late 1990s and early 2000s, when analytical methods
were developed and improved to detect concentrations in the ng-ug/L range (Daughton
and Ternes 1999). In 1999, Daughton and Ternes wrote the first publication calling for
scientists to increase research focused on presence, effects, and potential environmental
risk of PPCPs. Since then, hundreds of studies have characterized the occurrence of
PPCPs in effluent, surface water, sediments, and animal tissues. Though fewer studies
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have focused on PPCPs in marine environments compared to freshwater (Mezzelani et al.
2018), research is increasing in this area with approximately 233 PPCPs being
investigated worldwide in seawater, sediment, and animal tissue as of 2016 (Arpin-Pont
et al. 2016). A more recent review of pharmaceuticals and their metabolites in seawater
reported a total of 151 drugs detected in marine waters worldwide (Madikizela et al.
2020). Regionally, four studies on the U.S. West coast detected over 50 PPCPs in fish
and bivalve tissues (Dodder et al. 2014; Granek et al. 2016; Meador et al. 2016; James et
al. 2020). In general, PPCPs have lower bioaccumulative potential due to their high
ionization properties and low lipophilicity yet are frequently found to accumulate in
tissues of marine organisms. Higher pH and salinity in marine environments, along with
other chemical and environmental factors, may contribute to this pattern. While most
PPCPs are less persistent in the environment than legacy contaminants, consistent
discharge from multiple sources leads to a constant presence of contaminants at low
concentrations. This continual replenishment, or pseudo-persistence, exposes biota to a
suite of potentially toxic compounds on a regular basis (Daughton and Ternes 1999).
While consumer excretion has received the most attention as a source of
pharmaceuticals in wastewater, household disposal of leftover medications can also
contribute to the environmental presence of these compounds (Bound and Voulvoulis
2005). In the US, current recommendations for leftover drug disposal include flushing
down the drain, throwing in the trash, and taking to semi-annual drug take-back events.
The first two options pose environmental contamination risks, while the third presents a
public health issue as stored drugs can end up being consumed by unintended users
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through illegal usage or accidental ingestion, potentially leading to overdose. Efforts to
improve proper disposal of pharmaceuticals can alleviate public health concerns and
partially address the issue of environmental contamination.
PPCPs are of particular concern in the marine environment due to their yearround use, widespread occurrence in populated coastal areas, and designed use in
eliciting a biological response in organisms (Daughton and Ternes 1999; Fabbri and
Franzellitti 2016). PPCPs are expected to have effects on organisms due to their modes of
action (MOA), or specific pathways of producing a therapeutic effect in humans (Fabbri
and Franzellitti 2016). Some receptors (e.g., tissues, organs, biomolecules) targeted by
the MOA of certain drugs in humans exist in other vertebrates, with the majority of
known targets identified in fish (Fent et al. 2006). It is expected that drugs would have
similar effects on organisms with these pathways, which can be useful in predicting
effects and designing ecotoxicological experiments. However, several drugs have
multiple target pathways or unknown therapeutic mechanisms, making it difficult to use
this approach (Daughton and Ternes 1999). Additionally, information about target
pathways for human drugs is largely unknown in invertebrates (Fent et al. 2006).
Toxic effects of contaminants on organisms are typically identified by examining
acute (short duration) and chronic (extended duration) toxicity endpoints and dose
response curves that identify the lowest observed effect concentration (LOEC) and/or the
concentration that results in 50% mortality in a single exposure (LC50). Because they are
present at such low concentrations (e.g., ng/L), traditional toxicity endpoints are not
applicable to PPCPs (Daughton and Ternes 1999). The LOECs for pharmaceuticals tend

6

to be in the mg/L range, which is much higher than typical concentrations detected in
wastewater effluent (Fent et al. 2006). Therefore, effects are more likely to be sublethal
after chronic exposure to low levels for longer periods of time (Fent et al. 2006). Some
effects have been observed in both freshwater and marine organisms under chronic
exposure to environmentally relevant concentrations, but there is a paucity of research
addressing the sublethal chronic effects of multiple PPCPs on marine organisms
(Mezzelani et al. 2018).
A few PPCPs and many other CECs have been identified as endocrine disruptors
(e.g., triclosan), or chemicals that interact with hormone receptors (Fagin 2012). Many of
these compounds do not demonstrate a traditional dose response curve with more
pronounced effects at higher concentrations and instead have non-monotonic responses
where the curve changes from negative to positive or vice versa at some point during the
exposure (Fagin 2012). In many cases, lower or mid-range concentrations have worse
effects than high concentrations (e.g., Hayes et al. 2002; Jenkins et al. 2011). This pattern
is emerging in more studies, including pharmaceuticals that are not considered endocrine
disruptors. For example, two experiments that evaluated molecular and cellular level
effects of pain medication (ibuprofen and acetaminophen) on Pacific oysters found more
pronounced effects in the lowest concentrations of these drugs (Serrano et al. 2015;
Bebianno et al. 2017), demonstrating the importance of including low, environmentally
relevant concentrations of PPCPs in toxicological experiments.
Reducing PPCP pollution in marine and aquatic environments will require various
interventions. For pharmaceuticals, there are several options to address both excretion

7

and disposal. Studies have shown that adding tertiary treatment to wastewater treatment
plants can improve the removal of PPCPs (Rout et al. 2021, Castiglioni et al. 2006;
Ternes et al. 2003). These improvements to wastewater treatment technologies would
likely be the most effective solution, but are the most impractical given the costs of
adding them to facilities. Medical professionals can play a large role in reducing the
amounts of drugs that are consumed, excreted, and disposed. For example, implementing
sustainable prescription practices, which refers to prescribing the lowest effective dosage,
choosing drugs types that degrade more readily, and considering the duration of treatment
(Daughton and Ruhoy 2013) can play a role. Additionally, development of “green
pharmaceuticals,” or drugs that degrade quickly in the environment, is underway for a
handful of drug types (Kummerer 2019), and could be effective if manufacturers are
incentivized to participate (Straub 2016). Lastly, to address disposal of leftover drugs,
convenient disposal options, such as drug take-back boxes in pharmacies, need to be
implemented on a broader scale (Ehrhart et al. 2020). For personal care products, changes
to public usage patterns may be helpful in reducing these loadings. Requirements for
listing ingredients and risks on personal care and cleaning products, or including
certifications that they are environmentally benign, such as the EPA Safer Choice label
(US EPA 2020), combined with consumer education could reduce some chemical
pollution from these products.
Several regional data gaps exist in the occurrence, effects and remediation of
PPCPs in the marine environment. In the Pacific Northwest, there is a lack of occurrence
data for PPCPs, particularly in coastal areas with small human populations, which
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represent most of the OR and WA coastlines. Additionally, Pacific Northwest estuaries
have high tidal influence, short residence times, and are affected by seasonal upwelling in
the summer (Lee II and Brown 2009), which may impact contaminant occurrence.
Bioaccumulation and effects of direct exposure to effluent in bivalves has not been
explored with effluent from WWTPs that serve small coastal populations. Lastly, the
effectiveness of remediation strategies for disposed pharmaceuticals remains unknown.
The research in this dissertation aims to fill some of these gaps by focusing on PPCP
occurrence in estuaries in OR and WA, chronic effects on organisms, and leftover drug
disposal practices and recommendations. In chapter 2, I investigated PPCP occurrence
and small scale spatial variation near wastewater sources. To do this, I conducted a field
experiment comparing PPCP accumulation in Pacific oysters transplanted near WWTP
outfalls and oyster aquaculture. In chapter 3, I examined uptake and effects of PPCPs in
coastal wastewater treatment plant effluent on oysters under environmentally relevant
conditions. I conducted a lab experiment where oysters were exposed to low
concentrations of effluent containing a complex mixture of PPCPs for 12 weeks. I
measured organism level effects and concentrations of PPCPs in effluent and oyster
tissue. In chapter 4, I explored the role of drug take-back boxes in proper drug disposal
among consumers. I administered surveys to customers and interviewed pharmacists
regarding disposal practices and recommendations, and compared results from pharmacy
locations with and without drug take-back receptacles.
The results of this research show that PPCPs are present in marine environments
with low coastal populations, oysters accumulate toxins in their tissues following
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exposure but show minimal organism-level effects, and drug take-back boxes in
pharmacies may reduce pharmaceutical pollution from disposal. In chapter 2, I found that
oysters in OR and WA accumulated two pharmaceuticals and four alkylphenols, but with
fewer detections and lower concentrations compared to studies with higher surrounding
populations. Concentrations were similar among sites indicating that proximity to
wastewater did not drive differences at small spatial scales. In chapter 3, I also observed
that oysters accumulated PPCPs from effluent, but at a higher rate than in the field.
Specifically, there were 30 PPCPs detected in effluent, with 13 of those detected in the
tissue. In chapters 2 and 3, exposure to wastewater had subtle effects on oysters. Oysters
transplanted near wastewater had lower condition index than oysters at aquaculture sites.
In the lab, oysters exposed to wastewater from one treatment plant experienced
suppressed shell growth. In chapter 4, customers reported high rates of storing drugs at
home and low awareness of drug take-back boxes, but this was marginally improved at
locations with drug take-back boxes. Additionally, pharmacists at drug take-back box
locations gave consistent and safe disposal recommendations, indicating that presence of
a dropbox can improve drug disposal messaging to consumers. These results support
legislative and funding efforts to increase drug take-back box presence in pharmacies for
safe and convenient year-round disposal. Overall, the findings from my research address
data gaps in occurrence, effects, and remediation options for PPCP pollution in the
Pacific Northwest by reporting concentrations near sources in OR and WA, effects on
and accumulation by bivalves, and consumer and pharmacist behaviors regarding drug
disposal.
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Chapter 2: Pharmaceuticals and alkylphenols in transplanted Pacific oysters
(Crassostrea gigas): spatial variation and growth effects
Under review in the peer-reviewed journal, Marine Pollution Bulletin.

Abstract
Pharmaceutical and personal care products in wastewater discharge can be stressors to
estuarine species and ecosystems. We transplanted newly settled juvenile Pacific oysters
(Crassostrea gigas) to sites near wastewater treatment plant outfalls and oyster
aquaculture to assess small scale spatial variation in pharmaceutical and alkylphenol
occurrence and oyster condition. Oysters were transplanted in July 2016 to sites in Coos
and Netarts Bays, OR and Grays Harbor, WA, then collected after 9 (April) and 12 (July)
months. Two pharmaceuticals (miconazole and virginiamycin M1) were detected in April
samples and four alkylphenols (NP1EO, NP2EO, NP and OP) were detected in July
samples, but concentrations were low relative to other studies. Both alkylphenols and
virginiamycin were detected at one oyster growout site indicating potential for human
exposure. Oyster condition was highest at another oyster growout site. This research fills
important data gaps on contaminant accumulation in shellfish at sites exposed to
wastewater discharge.

2.1 Introduction
Pharmaceutical and personal care products (PPCPs) include prescription, over the
counter, and illicit drugs, antimicrobials, fragrances, preservatives, and surfactants (Lara-
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Martín et al. 2014). PPCPs are frequently detected in marine and aquatic environments
worldwide and can enter the environment from multiple sources (Arpin-Pont et al. 2016).
When pharmaceuticals are consumed, they are rarely fully metabolized by the body and
therefore traces of medicines are excreted in human waste (Jjemba 2006). Leftover drugs
are often disposed of by flushing down the sink or toilet (Ruhoy and Daughton 2007).
Personal care products that are applied to the skin and washed off and surfactants in
detergents and cleaners are commonly rinsed down the drain. Current wastewater
treatment plant technologies do not fully remove most PPCPs (Vieno et al. 2007)
resulting in regular discharge to the environment and continuous exposure of organisms
to multiple chemical stressors. Other sources of PPCPs include veterinary facilities,
hospitals, stormwater and industrial discharges, septic leakage, landfill leachate, and
agricultural runoff (Gaw et al. 2014), but wastewater is considered the most prominent
source of pharmaceuticals to aquatic and marine environments (Hughes et al. 2013).
Pharmaceuticals are unique contaminants because they are designed to elicit a
biological or therapeutic response in humans or other mammals at low doses (Fabbri and
Franzellitti 2016). Due to potential biological effects, pharmaceutical presence in the
environment is cause for particular concern. The pathway of a drug in the body, known as
the mode of action, may be similar to humans for some aquatic species containing similar
receptors or symbionts; for example, there are some known overlapping receptors present
in fish (Fent et al. 2006). For other species, particularly invertebrates with very different
physiological functions, potential effects of pharmaceuticals may be less clear (Fent et al.
2006). In general, pharmaceuticals have low risk for acute toxicity to marine organisms,
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but show effects under chronic exposure to low concentrations (Prichard and Granek
2016). For example, caffeine increases production of heat shock proteins, a sign of stress,
in California mussels after 10-30 days of exposure (Rodriguez del Rey et al. 2011).
The US Food and Drug Administration (FDA) regulates environmental
assessment of pharmaceuticals through the approval process of new drugs (US FDA
1998). An environmental assessment based on expected environmental concentrations,
physical and chemical properties and mechanisms of breakdown of the drug is submitted
by the manufacturer with the application (US FDA 1998). Many drugs qualify for an
exclusion, particularly if the expected environmental concentration is below 1 ug/L (US
FDA 1998). Once approved there are no federal water quality criteria or regulations in
place to limit the environmental presence of pharmaceuticals and current policies do not
evaluate or regulate mixtures of drugs entering the environment.
Alkylphenols are used as surfactants in a variety of household and industrial
products, such as cleaners, detergents, soaps, paints, and cosmetics (US EPA 2010). The
primary components of these products, alkylphenol ethoxylates, break down rapidly
during wastewater treatment and biodegradation in the environment (US EPA 2010). The
breakdown products (e.g., nonylphenol and octylphenol) are persistent in the
environment and toxic to aquatic life (US EPA 2010). Unlike most PPCPs, water quality
criteria exist for nonylphenol (NP). For example, the acute and chronic maximum
allowed concentrations for 4-nonylphenol in marine waters is 7 ug/L and 1.7 ug/L,
respectively (US EPA 2010). As a group, alkylphenols act as estrogen mimics and
endocrine disruptors and have adverse effects on exposed organisms, including reduced
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growth, increased stress, and altered reproductive activity (Christensen et al. 1999;
Ashfield et al. 1998; Granmo et al. 1989).
Several factors influence the concentrations of pharmaceuticals and alkylphenols
in the environment, including proximity to wastewater, type of wastewater treatment,
population size and product usage patterns, land use, hydrodynamics and residence time,
wastewater dilution and mixing, and individual chemical properties (Daughton and
Ternes 1999; Gaw et al. 2014; Fabbri and Franzellitti 2016). Since municipal wastewater
is a large source of PPCPs, it is expected that concentrations would be highest near
wastewater discharges. However, previous studies have shown inconsistent results
regarding wastewater proximity as a predictor of pharmaceutical concentration. Dodder
et al. (2014) found that pharmaceutical concentrations in mussels collected from 68
marine sites distributed along the entire California coast showed no variation based on
land use (urban vs. agricultural) or proximity to municipal discharge. Bayen et al. (2013)
had similar results indicating that distance to WWTP did not influence the concentration
of pharmaceuticals and endocrine disruptors in seawater from eight sites with different
flushing patterns surrounding the island of Singapore. Instead, sites with lowest flushing
potential had the highest concentrations, indicating that residence time and
hydrodynamics are more important (Bayen et al. 2013). Conversely, Krogh et al. (2017)
found that in marine waters off the coast of Victoria, British Columbia, pharmaceutical
concentrations in mussel tissues decreased steeply with increasing distance from the
nearest WWTP outfall. Similarly, Biel-Maeso et al. (2018) observed pharmaceutical
concentrations in estuarine water collected downstream from a WWTP in the Gulf of
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Cadiz, Spain were double the concentration of samples collected further away from the
treatment plant, but still within the estuary. With these opposing findings at different
geographic locations, questions remain about variation in occurrence of PPCPs at small
spatial scales.
The likelihood of a compound to accumulate in organism tissues and sediments
can be described using the octanol-water partitioning coefficient (log Kow), or the ratio of
the concentration of a compound in octanol and in water. This measures hydrophobicity,
with higher values indicating greater potential for accumulation. Although most
pharmaceuticals have low log Kow values, they are frequently detected in tissues of
marine organisms (e.g., Dodder et al., 2014; Granek et al., 2016; Meador et al., 2016).
Alkylphenols are more bioaccumulative than pharmaceuticals and have been detected at
concentrations of 66.51 - 1560.0 ng/g wet weight in bivalve shellfish (Gu et al. 2016).
Therefore, bivalves are a suitable option for measuring local contaminant occurrence for
both pharmaceuticals and alkylphenols.
Transplanted bivalves are frequently used to monitor accumulation of
contaminants and compare among sites over a specified time period (Hunt and Slone
2010). This allows for better comparison among sites as resident organisms may be more
adapted to contaminant stress in their home location than at other sites (Smolders et al.
2003). Pacific oysters are an important commercial bivalve species grown using ground
and suspended culture in Oregon and Washington estuaries. Similar to the native
Olympia oysters that have been mostly extirpated, Pacific oysters have the potential to
provide ecosystem services, such as improving water quality and providing habitat for
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other organisms (Dumbauld et al. 2009; Groth and Rumrill 2009). They are suitable for
transplanting because they are sessile filter feeders that can survive a wide range of
environmental conditions (Pauley et al. 1988) and their health or condition can be
assessed using condition indices (Lucas and Beninger 1985).
Previous work has shown that PPCPs are abundant in highly urbanized estuaries
(e.g., (Nilsen et al. 2014; Meador et al. 2016) and in adult native organisms (e.g., Granek
et al., 2016) in the Pacific Northwest. However, few studies have examined PPCP
presence in organisms transplanted close to wastewater sources and in areas with small
human populations. In this study, we examine PPCP accumulation and ecologically
relevant effects in Pacific oysters in areas with low human populations. Additionally, we
investigate small-scale spatial variation in concentrations and organism health near
wastewater treatment plant outfalls using transplanted juvenile oysters collected from a
hatchery. Specifically, we address the following research questions:
1. How do transplanted oyster contaminant types and concentrations vary based on
proximity to wastewater treatment plant outfalls?
2. Does transplanted oyster health (condition index) vary based on proximity to
wastewater treatment plant outfalls?

2.2 Methods
2.2.1 Study Sites
This study was conducted in three estuaries in Oregon and Washington with
significant oyster growing operations and variable pollution inputs: Coos Bay, OR,
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Netarts Bay, OR, and Grays Harbor, WA (Figure 2.1). Sites within these estuaries were
classified as either wastewater sites, areas in close proximity to a WWTP outfall (2451500 meters), or oyster growout sites, areas near oyster aquaculture and at least 7 km
from the nearest WWTP outfall. Specific estuary characteristics are reported in Table 2.1.
Table 2.1 Characteristics of study estuaries in OR and WA. Sources: (1) Lee II and
Brown 2009, (2) Cortright et al. 1987, (3) US Census Bureau 2019, (4) Souder 2016, (5)
Shirzad et al. 1988, (6) Follansbee et al. 1999, (7) WA DOE 2015, (8) Sutherland and
O’Neill 2016, (9) Glanzman et al. 1971, (10) Grays Harbor County 2016, (11) NOAA
NERRS 2020, (12) Barton et al. 2015.

Estuary
Classifications

Area (km2)
Major Freshwater
Input
Residence Time

Water Temp.
(degrees C)
Salinity (ppt)
pH
Major Urban Centers
Approximate
Surrounding
Population
Land Uses

# of WWTPs
Sources

Coos Bay, OR
Tide-dominated;
drowned river
mouth; deep
draft
development
54.9
Coos River

Netarts Bay, OR
Tide-dominated;
well-mixed; bar built

Grays Harbor, WA
Tide-dominated; wellmixed; drowned river mouth

10.43
Small creeks

262.7
Chehalis River

7-16 days (wet
season); 11-48
days (dry season)
6-18

4 days (freshwater
retention time)

Not found

9-18

10-18

5-33
7.7-8.41
Coos Bay, North
Bend
26,180

25-33
7.6-8.12
Netarts

20-33
7.4-8.13
Westport, Aberdeen,
Hoquiam, Cosmopolis
28,600

Forest,
residential,
farmland,
industry
3
1, 2, 3, 4, 8, 11

Forest, rural
residential

Forest, industry, residential

0
1, 5, 6, 9, 12

4
1, 7, 10

744

1

Data from summer 2009 at Valino Island station.
Data from summer 2009 monitoring following acidification event in 2008.
3
Data from summer 2009 monitoring in Westport, WA.
2
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Figure 2.1 Map of estuaries on the OR and WA coast where study sites were set up
(indicated by circles and large labels). Cartographic State Boundaries and Highway lines
retrieved from Census Tiger Geographic Database; Major Washington cities retrieved
from Washington Data Portal; Major Oregon cities retrieved from Oregon Geospatial
Data Library in June 2020.

Coos Bay is the largest estuary in Oregon and is located in the Southern coast
region. While the surrounding population is small for a city center, it is large compared to
other Oregon coast cities and therefore is expected to have moderate PPCP inputs (Table
2.1). Three study sites were chosen within the Coos Estuary: two wastewater sites and
one oyster growout site. Sites were chosen based on presence of an outfall, habitat
suitability for oysters, and accessibility. There are three WWTPs that discharge into the
bay and are located near Empire, North Bend, and the city of Coos Bay. The one closest
to the mouth of the bay in Empire is surrounded by sandy habitat, which is not suitable
25

for Pacific oysters, which are typically grown on muddy tide flats. The other two
treatment plants, in North Bend and the city of Coos Bay, had adjacent accessible mudflat
areas so sites were set up near these two plants. Individual treatment plant characteristics
are presented in Table 2.2. An area of mudflat to the Southeast of Valino Island near
Long Island Point was chosen as an oyster growout site since oyster aquaculture
operations were nearby. This area is located in the South Slough National Estuarine
Research Reserve and is mainly used for environmental monitoring by the reserve staff.
This recreational area with low surrounding population and no direct wastewater inputs
has had historical water quality issues, such as shellfish detections of tributyltin (TBT),
an antifouling compound used in boat paints (Elgethun et al. 2000) and storm driven
increases in bacterial loadings from cattle grazing, failing septic systems, and landfill
leachate (Juza 2000) at several sites throughout the slough. While restoration and
pollution remediation efforts have improved water quality, it is not considered a pristine
area.
Table 2.2 Wastewater treatment plant characteristics at study sites in Coos Bay and North
Bend. Discharges are reported in million gallons per day (mgd). Source: (US FDA 2015).
Location
North Bend

Population
Served
9,800

Coos Bay

11,000

Highest Level of
Treatment
Secondary (activated
sludge and chlorine
disinfection)
Secondary (activated
sludge and chlorine
disinfection)

Discharge
Capacity (mgd)
2.0-5.0

Actual Average
Discharge (mgd)
1.0 (dry season);
2.5 (wet season)

2.0-5.0

1.6 (dry season);
3.2 (wet season)

Netarts Bay is a small estuary located on the Northern Oregon coast with low
freshwater inputs and high ocean exchange (Lee II and Brown 2009) (Table 2.1). For
example, in one tidal cycle, 75% of the water in the bay is renewed, leaving only 25%
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residual water at low tide (McCallum 1977). There is no direct municipal or industrial
sewage input to Netarts Bay, but septic systems from surrounding homes and a
campground south of the bay could be potential sources of wastewater contamination
(Glanzman et al. 1971). The closest wastewater treatment plant outfall is located
approximately 2 km north of the mouth of the estuary off the coast of Oceanside, OR.
The study site was set up at the south end of Netarts Bay in the Oregon Department of
Fish and Wildlife Shellfish Preserve. This site was classified as an oyster growout site
due to nearby oyster aquaculture operations and lack of direct wastewater inputs.
Grays Harbor is located on the southern Washington coast and receives 80% of its
freshwater input from the Chehalis River (WA DOE 2015) (Table 2.1). The cities of
Westport, Aberdeen, Hoquiam and Cosmopolis comprise the populated areas surrounding
Gray’s Harbor and have a combined population similar to the Coos Estuary. With the
exception of Westport, all of these cities are on the east side of the bay, which is the most
heavily populated area and contains heavy industry. Oyster growing takes place mainly in
the sparsely populated areas in the north and south, including in Westport which has a
lower population than other Grays Harbor cities (WA DOE 2015). There are four
wastewater treatment plants with discharges into Gray’s Harbor. Two of these are located
on the populated east side and two are on the west, just inside the mouth of the estuary.
Most of Gray’s Harbor is considered uncontaminated, but TMDLs have been developed
for fecal coliform, temperature, copper, nutrients, and a dioxin (WA DOE 2015). An
oyster growout site was set up in Westport, WA on the property of an oyster grower. The
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closest wastewater treatment plant was approximately 8 km North along the shoreline
towards the mouth of the estuary.

2.2.2 Oyster Transplantation
In July 2016, juvenile Pacific oysters (~1 week old spat) settled on nonliving
oyster shells were collected from Whiskey Creek Shellfish Hatchery in Netarts, OR.
Oyster shells with spat were placed in mesh growout bags that were tied closed on each
end with approximately 20 shells per bag. These juvenile oysters were transplanted to
wastewater and oyster growout sites. At each site, three oyster bags were attached with
zip ties to PVC racks that elevated the oysters about 1 ft above the mudflat at an
approximately -1.0 ft low tide (Figure 2.2). At the sites with WWTP outfalls, racks were
placed along a hypothesized pollution gradient, with one rack as close as possible to the
outfall, and remaining racks at increasing distances downstream (Figure 2.2).
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Wastewater Outfall

245-1500 meters

= Oyster Rack
Figure 2.2 Schematic of field design for sites with a wastewater treatment plant outfall
and picture of oyster racks with bags of juvenile oysters settled on nonliving oyster
shells (inset photo).

The study was designed with the intent of placing four racks per site at a distance of 250
m apart to examine small-scale spatial variation. The number of racks and distances were
adjusted based on accessibility and habitat conditions at each site. In the Coos Bay area,
the shoreline is populated with businesses and industry along a single roadway (Tremont
Ave) that runs parallel to the shore with no area to pull over. There are limited access
points along the road to pull into and park a car. Several sections of the shore are
inaccessible to the public due to the road design and business locations. Additionally, the
mudflat sediment is very unstable, thus it was not feasible to access sites by walking long
distances on the mudflat while carrying equipment. The outfall pipe was located at a
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section of road with no access points and the closest parking area approximately 250
meters upstream of the outfall. The first rack (COOSa) was placed at this site (Figure
2.3). Due to tidal influence and based on a dye study conducted by the Oregon
Department of Agriculture in 2011 showing that effluent is reaching this area (US FDA
2015), we assumed that wastewater would reach these oysters upstream of the effluent
pipe. The second (COOSb) and third (COOSc) racks were placed at the two closest
access points downstream of the outfall, which were 750 and 1,500 meters from the
outfall, respectively (Figure 2.3). We were unable to identify a suitable fourth site in this
area. In North Bend, racks were placed on a section of mudflat that runs parallel to the
airport runway at the Southwest Oregon Regional Airport (Figure 2.3). The WWTP
outfall discharges in the middle of the channel to the north of the mudflat. This site was
accessed via boat and racks were placed along the mudflat approximately 250 meters
apart. Because the outfall was within the channel, the distances from each site to the
outfall were 245 m (NBc), 265 m (NBb), 465 m (NBa), and 480 m (NBd). The sites
closest and furthest from the outfall were on the edge of the accessible mudflat and
therefore represent the outer spatial distribution of that area. The aforementioned dye
study evaluated discharges from the North Bend outfall and reported dye movement both
up- and downstream following discharge, confirming this configuration captures the
theoretical plume (US FDA 2015).
At oyster growout sites, racks were placed at distances ranging from 50-250
meters apart to account for environmental variability. Three racks were placed 25 meters
apart on a mudflat to the Southeast of Valino Island (VALa, VALb, VALc) (Figure 2.3).
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While there was additional mudflat area available, staff at the South Slough National
Estuarine Research Reserve requested that we only use a small space to minimize
disturbance of the area due to previous restoration and ongoing monitoring activities.
Oyster growing activities were taking place in close proximity to this area on nearby
mudflat.
In Netarts Bay, racks were set up at the South end of the bay, in the Oregon
Department of Fish and Wildlife designated shellfish preserve. There was ample space
and sites were easily accessible so racks were placed 250 meters apart with NETa, NETb,
and NETc placed South to North (Figure 2.3). NETa was directly adjacent to an oyster
grower. There were originally five sites placed in Netarts, but the two sites north of NETc
were missing at the first sampling. In Westport, WA, two racks were placed 25 meters
apart on a mudflat on the property of an oyster grower (WESTa, WESTb) (Figure 2.3).
The space was very limited so only two racks would fit with a short distance between
them.
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Figure 2.3 Map of study sites and set up of oyster racks at each wastewater and oyster
growout site (inset panels): Coos (wastewater site), North Bend (wastewater site), Valino
Island (oyster growout site), Netarts (oyster growout site) and Westport, WA (oyster
growout site). Imagery provided by National Agricultural Imagery Program (NAIP) under
contract for the United States Department of Agriculture (USDA), for the Farm Service
Agency’s (FSA) Oregon Imagery Framework Implementation Team.
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2.2.3 Oyster Measurements
Oysters were collected from each rack in April 2017 (9-month spring sample) and
July 2017 (12-month summer sample). Oysters were brought to the Applied Coastal
Ecology lab at Portland State University in bags to be counted and measured. In the April
sample, one oyster bag was collected from each rack. At this sampling, oysters were
small and tightly clumped together, and it was not possible to separate them without
breaking the shells of the oysters. Therefore, oysters were kept in clumps for
measurements. Oyster dimensions were recorded based on the methods of (Galtsoff
1964) where the height is described as the distance between the umbo and the top of the
shell and the length is the maximum distance across the shell parallel to the hinge. Total
abundance was counted, and length and height were measured in millimeters for 50% of
the oysters in the bag. A sample of eight oysters from each rack was shucked and frozen
for contaminant analysis.
In the July sample, the remaining two oyster bags from each rack were collected
and transported to the lab. The furthest Coos Bay site (COOSc) was missing when July
samples were collected, but all others were undisturbed. Oysters were counted and
clumps in each bag were broken apart as much as possible. Oyster mass, length, width,
and height were measured for 50% of the oysters, or 100 oysters if the total count was
above 200. A sample of ten oysters from each rack was shucked and frozen for
contaminant analysis. Samples of 32 oysters per site (16 per bag) were frozen for analysis
of condition index (CI), the ratio of dry tissue weight to dry shell weight (Rainer and
Mann 1992). This index examines the physiological state of a bivalve with lower values
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indicating stress from unfavorable environmental conditions and is recommended
because it is easily standardized and removes bias from moisture content in wet tissue
weight measurements (Lucas and Beninger 1985).
Equation 1: CI = dry tissue weight x 100/dry shell weight
In summer of 2019, these oysters were thawed, shucked and weighed (tissue weight).
Individual oyster tissues were placed in porcelain crucibles and dried for 48-96 hours to
constant weight at 105o C (Mo and Neilson 1994). Shells were air dried for 24 hours. Dry
tissue and shell weights were used to calculate condition index in Microsoft Excel.

2.2.4 Contaminant Analysis
In June 2017, ten April samples were sent to AXYS Analytical in British
Columbia to be analyzed for 46 pharmaceuticals (Figure D1): all three racks at Coos Bay
(WWTP outfall sites), all four racks at North Bend (WWTP outfall sites), and one rack
from Valino Island, Netarts Bay, and Westport, WA (oyster growout sites). Funding was
inadequate to analyze all racks and therefore we prioritized racks near wastewater to
examine small scale spatial variation. July samples were analyzed for a different set of 12
pharmaceuticals (Figure D2), and four alkylphenols at AXYS. The change in analyzed
compounds was due to the low detection rate of pharmaceuticals in the April sample and
funding constraints. The alkylphenols were broken into two groups: two nonylphenol
ethoxylates (NPEs), nonylphenolmonoethoxylate (NP1EO) and nonylphenoldiethoxylate
(NP2EO), and two breakdown products, 4-nonylphenol (4-NP) and 4-n-octylphenol (4-n-
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OP). Since we did not see a strong pattern based on proximity to wastewater, one rack per
site was chosen for analysis (five samples total) in August 2017.
At AXYS Analytical, pharmaceuticals and alkylphenols were analyzed using
liquid chromatography tandem mass spectrometry (LC-MS/MS). Before analysis,
pharmaceutical samples were adjusted to a pH of 2, spiked with surrogate standards, and
extracted by sonication with aqueous buffered and pure acetonitrile. They were then
cleaned up using solid phase extraction and analyzed for concentrations using LCMS/MS with electrospray ionization (LC/ESI-MS/MS) in positive ionization mode.
Alkylphenol samples were prepared by dispersion in water and addition of labeled
surrogate standards and extracted into isooctane by steam distillation. Samples were
cleaned up with solid phase extraction and analyzed with LC/ESI-MS/MS in negative ion
model for 4-NP and 4-n-OP and positive ion mode for NP1EO and NP2EO. Reporting
limits are included in Tables 3 and 4.

2.2.5 Data Analysis
Oysters were sampled at different seasons to look at seasonal variation in oyster
growth and contaminants, but due to budget constraints and inability to extract whole
oysters in the April sample, we were not able to make this comparison. Therefore, April
and July sample results were analyzed and summarized separately. The mean and
standard deviation were calculated at each rack for oyster height and length in April
samples and for all oyster dimensions (height, length, width, and whole oyster mass) in
July samples. Due to the variable nature of oyster shape, shell dimensions may yield
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misleading results regarding oyster growth. Instead, condition index was used to compare
oyster growth and fitness across racks and sites. Within each site (Coos Bay, North Bend,
Valino Island, Netarts, Westport), condition index was compared at each rack,
representing distance, using a one-way ANOVA or a two sample T-test with rack and
condition index as factors. Tukey’s Honestly Significant Difference post-hoc test was
used to determine which racks were different among each site. To compare oyster
condition at wastewater (Coos, North Bend) and aquaculture (Valino Island, Netarts,
Westport) sites overall, a sample of 50 oysters was randomly selected from all of the
racks at each site. With sample sizes ranging from 64 to 128, this number was chosen to
ensure a robust even sample size without sampling more than 80% of the oysters from a
given site. Combining oysters from racks at different distances could potentially violate
the independence assumption of parametric statistics. However, due to the substantial
distance between sites (9-400 km) compared to the distance between racks (25-1500
meters), we assumed that any differences between racks would be negligible in
comparison to differences at an estuary scale. Therefore, we proceeded with a parametric
ANOVA. All other assumptions of ANOVA were met (residual normality and equal
variance). We ran a post hoc power analysis to determine if this sample size was adequate
with the following parameters: effect size calculated as Cohen’s f value from the
ANOVA output (Ialongo 2016), alpha of 0.05, and power of 0.80. All analyses were
performed in R version 3.4.1.
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2.3 Results
2.3.1 PPCP Concentrations
In the April sample, two out of 46 pharmaceuticals were detected in oyster
tissues: virginiamycin M1 and miconazole (Table 2.3). Virginiamycin was detected at all
wastewater sites, and one oyster growout site (Westport, WA) at an overall range of 1.93.83 ng/g wet weight. The highest concentration (3.98 ng/g) was at the North Bend rack
placed 265 meters from the outfall (NBb) and the lowest concentration was at the Coos
Bay rack placed 1,500 meters from the outfall (COOSc). At North Bend, concentrations
of virginiamycin at each rack are very similar (difference of less than 1 ng/g) but do show
slight variation based on distance from the outfall. Concentrations were higher at racks
that were in mid-range distances from the outfall, and lowest at the closest and furthest
racks, with the furthest rack (NBd, 480 m) having the lowest concentration. A similar
pattern is evident at the Coos Bay racks with the highest concentration at the middle rack
(COOSb, 750 m) and the lowest concentration at the furthest rack (COOSc, 1,500 m), but
these differences are within 0.50 ng/g of each other. The concentration at Westport, WA
was 2.77 ng/g, intermediate between the concentrations at Coos Bay and North Bend.
Miconazole was only detected in oysters at the Coos Bay site at concentrations of 0.87
and 0.63 ng/g at racks 250 (COOSa) and 1,500 (COOSc) meters from the outfall,
respectively. The concentration was higher closer to the outfall, but it is important to
note that these concentrations are very low and close to the detection limit.
Table 2.3 Concentrations of pharmaceuticals detected in April 2017 oyster tissues at
wastewater sites (Coos, North Bend) and oyster growout sites (Westport, Netarts, Valino
Island) reported in nanograms/gram (ng/g) wet weight. Distance from the nearest
wastewater treatment plant outfall is listed in meters (m) for each oyster rack at the
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wastewater sites. For the oyster growout sites, there were no WWTPs in close proximity.
The shoreline distance to the nearest outfall was 7,500 meters or greater at each oyster
growout site. Westport, WA has two upstream wastewater treatment plants >18 km away.
Each sample is a composite of 8 oysters. ^ denotes concentration less than 2x lab blank
or reporting limit. ND = not detected. RL = reporting limit.
Site
Coos Bay
Coos Bay
Coos Bay
North Bend
North Bend
North Bend
North Bend

Rack
COOSa
COOSb
COOSc
NBc
NBb
Nba
NBd

Valino Island

VALa

Netarts Bay

NETc

Westport

WESTa

Site Type
Wastewater
Wastewater
Wastewater
Wastewater
Wastewater
Wastewater
Wastewater
Oyster
Growout
Oyster
Growout
Oyster
Growout

Distance to
nearest WWTP
Outfall
250 m
750 m
1,500 m
245 m
265 m
465 m
480 m

Virginiamycin
M1 (RL)
2.22^ (1.20)
2.38^ (1.21)
1.9^ (1.24)
3.83 (1.21)
3.98 (1.21)
3.84 (1.20)
3.28 (1.20)

Miconazole
(RL)
0.87^ (0.60)
ND
0.63^ (.59)
ND
ND
ND
ND

N/A

ND

ND

N/A

ND

ND

N/A

2.77 (1.22)

ND

All four alkylphenols were detected in oyster tissues in July 2017 (Table 2.4), but
none of the 12 pharmaceuticals were present. NP1EO was detected at Coos Bay and
Westport at concentrations of 4.24 and 15.4 ng/g, respectively. NP2EO was detected at
all sites, at a range of 0.61-1.92 ng/g, with the highest concentration at Westport, WA.
Nonylphenol (4-NP) was detected at all sites, and had the highest overall concentration
compared to other alkylphenols ranging from 12.2-43.8 ng/g, with the highest
concentration at Westport, WA. Octylphenol (4n-OP) was found at all sites except for
Netarts, at a range of 1.61-3.94 ng/g, with the highest concentration at Valino Island.
Overall, alkylphenols were widespread throughout the sites, regardless of distance to
wastewater, except Netarts Bay which had fewer detections and lower concentrations
(Table 2.4).
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Table 2.4 Concentration of alkylphenols detected in July 2017 oyster tissues at all sites
sampled: wastewater (Coos, North Bend) and oyster growout (Westport, Netarts, Valino
Island) reported in nanograms/gram (ng/g) wet weight. Distance from the nearest
wastewater treatment plant outfall is listed in meters (m) for each oyster rack. Each
sample is a composite of 10 oysters. ^ denotes concentration less than 2x lab blank or
reporting limit. ND = not detected. RL = reporting limit.

Site

Rack

Site Type

Distance to
WWTP
Outfall

Coos Bay

COOSa

Wastewater

250 m

NP1EO
(RL)
4.24
(1.87)

North Bend
Valino
Island

NBb

Wastewater

265 m

ND

VALc

Oyster Growout

10,000 m

ND

Netarts Bay

NETc

Oyster Growout

8,900 m

Westport

WESTa

Oyster Growout

8,110 m

ND
15.4
(1.0)

NP2EO
(RL)
1.47
(0.47)
1.35
(0.48)
1.15
(0.47)
0.61^
(0.50)
1.92
(.47)

4-NP
(RL)
15.9
(0.76)
14.7
(0.48)
14.4
(.67)
12.2
(0.71)
43.8
(0.53)

4n-OP
(RL)
1.61
(0.52)
2.38
(0.61)
3.94
(0.98)
ND
1.95
(0.52)

2.3.2 Oyster Size and Condition
Oyster size was highly variable among sites and racks. The mean (and standard
deviation) of shell height for oysters at all sites was 35.24 (11.26) mm among April
samples (Table A1) and 44.54 (13.38) among July samples, and the mean whole oyster
weight was 11.98 (7.33) g among July samples (Table A2). The number of oysters per
bag ranged from 55-402 in April samples and 47-578 in July samples. In April, oysters at
Valino Island were larger, but this pattern was not evident in July. A summary of oyster
dimensions and abundance for each rack, as well as fouling organisms within oyster bags,
is provided in the Appendix (Table A1, A2, and A3).
Oyster condition index was relatively similar across four sites (Coos Bay, North
Bend, Netarts Bay, Westport), but significantly higher at Valino Island (Table 2.5, Figure
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2.4A)(One-Way ANOVA: p<.001, F4,245=28.017). The power analysis showed that a
sample size of six oysters would be adequate, therefore we conclude that our sample size
of 50 per site here was enough to detect significant differences among sites. When
comparing rack distance at individual sites, differences in oyster condition were only
observed at oyster growout sites with racks spaced along an environmental gradient
(Table 2.6, Figure 2.4). At wastewater sites, mean condition index did not differ between
racks placed at varying distances from a wastewater outfall (Coos Bay: two sample t-test:
p=.68, t61=.41, Figure 2.4B; North Bend: one-way ANOVA: p=.26, F3,123=1.35, Figure
2.4C). At Valino Island, condition index at the most downstream site, VALa, was
significantly higher than VALb, but not VALc, the upstream site (one-way ANOVA:
p=.02, F2,93=3.91, Figure 2.4D). At Netarts Bay, the most downstream site, NETc had
significantly lower condition index than the other two upstream Netarts Bay racks (NETa
and NETb) (one-way ANOVA: p<.001, F2,93=19.84, Figure 2.4D). At Westport,
condition index was similar between both racks, WESTa and WESTb (two sample t-test:
p=.17, T62=1.38, Figure 2.4F).
Table 2.5 Summary of condition index and oyster dimensions for 50 randomly selected
oysters from all racks within each site. Avg = average, SD = standard deviation, g =
grams, mm = millimeters.
Site
Coos Bay
North Bend
Valino Island
Netarts Bay
Westport

Avg Condition
Index (SD)
6.71 (1.71)
6.27 (2.1)
10.63 (2.66)
7.34 (2.36)
7.34 (2.57)

Avg Wet
Tissue Weight
(g) (SD)
3.42 (1.47)
2.14 (1.66)
5.19 (1.97)
3.33 (1.62)
3.3 (1.66)

Avg Shell
Height (mm)
(SD)
52.82 (10.83)
45.77 (10.28)
56.66 (10.07)
50.07 (10.41)
51.16 (11.98)

Avg Shell
Length (mm)
(SD)
36.64 (7.1)
32.26 (9.54)
36.84 (8.69)
34.39 (5.97)
34.97 (10.05)

Avg Shell
Width (mm)
(SD)
14.37 (4)
11.74 (2.73)
15.03 (3.94)
13.05 (3.54)
12.4 (3.42)
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Table 2.6 Summary of condition index and oyster dimensions for one-year transplanted
Pacific oysters collected in July 2017. Samples of 32 oysters were randomly chosen from
each rack; Avg = average, SD = standard devation, g = grams, mm = millimeters.

Site

Rack

Distance
to
WWTP
Outfall
(m)

Coos Bay

COOSa

250

Coos Bay

COOSb

750

North Bend

NBc

245

North Bend

NBb

265

North Bend

Nba

465

North Bend

NBd

480

Valino Island

VALa

N/A

Valino Island

VALb

N/A

Valino Island

VALc

N/A

Netarts Bay

NETa

N/A

Netarts Bay

NETb

N/A

Netarts Bay

NETc

N/A

Westport

WESTa

N/A

Westport

WESTb

N/A

Avg
Condition
Index
(SD)
6.98
(1.64)
6.79
(1.82)
7.00
(2.60)
5.83
(2.76)
6.06
(2.62)
6.11
(1.87)
11.30
(2.69)
9.17
(2.92)
10.30
(3.43)
7.32
(2.41)
8.39
(2.21)
5.14
(1.63)
7.54
(2.35)
6.70
(2.49)

Avg Wet
Tissue
Weight
(g) (SD)
3.31
(1.52)
3.50
(1.25)
2.47
(2.10)
1.43
(0.75)
2.11
(1.43)
2.35
(1.70)
5.63
(2.41)
4.54
(2.85)
5.05
(1.86)
2.93
(1.53)
4.10
(1.72)
2.21
(1.11)
3.18
(1.45)
3.30
(1.54)

Avg Shell
Height
(mm) (SD)
51.98
(12.75)
53.54
(7.79)
41.17
(13.15)
40.12
(10.32)
45.39
(10.98)
48.74
(9.96)
57.56
(8.82)
56.78
(12.24)
58.80
(12.70)
50.27
(6.89)
51.86
(10.10)
45.99
(11.36)
49.96
(14.71)
53.38
(9.21)

Avg Shell
Length
(mm) (SD)
36.42
(6.65)
36.64
(6.88)
36.37
(13.05)
32.14
(8.92)
32.64
(9.18)
34.32
(7.76)
38.02
(8.13)
36.64
(9.90)
37.08
(8.25)
33.34
(5.58)
33.67
(6.31)
33.21
(6.26)
37.15
(10.02)
32.58
(8.99)

Avg Shell
Width
(mm)
(SD)
13.98
(4.25)
14.73
(3.29)
12.21
(2.64)
11.93
(2.76)
12.39
(3.33)
11.08
(2.44)
14.24
(3.63)
13.54
(3.75)
14.23
(3.80)
12.52
(3.63)
15.09
(4.35)
11.66
(2.65)
12.75
(3.37)
11.88
(2.91)
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Figure 2.4 Condition index of one-year transplanted Pacific oysters collected in July 2017
compared at all sites (A), and at racks within each site for Coos Bay (B), North Bend (C),
Valino Island (D), Netarts Bay (E), and Westport, WA (F). Coos Bay and North Bend are
wastewater sites and racks are listed based on proximity to wastewater from left to right.
P-values and letters above bars based on results of one-way ANOVA and two-sample ttests comparing condition index at each site and rack. Gray dots represent the mean for
each group.

2.4 Discussion
Pharmaceuticals were detected in oyster tissues in OR and WA at the two
wastewater sites, Coos Bay and North Bend, and one oyster growout site, Westport.
Virginiamycin and miconazole were the only pharmaceuticals found out of the 58
examined in this study, indicating that risk of exposure could be lower in low population
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areas. Virginiamycin is an antibiotic used to reduce microbial contamination in ethanol
production (Hynes et al. 1997) and as a growth promoter in livestock farming in the
United States (Dumonceaux et al. 2006; Dzhavakhiya et al. 2016). Miconazole is a
human over the counter drug for treating fungal infections such as athlete’s foot (e.g.,
Lotrimin powder). The concentrations reported in this study are low for virginiamycin
and within a comparable range for miconazole relative to other reported concentrations in
marine animal tissues (Table 2.7). For example, higher concentrations of virginiamycin
were detected in fish in Puget Sound, WA (Meador et al. 2016) and Atlantic salmon
advertised as “antibiotic free” in the southwestern US (Done and Halden 2015), and
similar concentration were found in oysters in Netarts Bay, Oregon (Granek et al. 2016).
Four alkylphenols targeted in this study (4-NP, 4-n-OP, NP1E0, and NP2EO)
were detected in oyster tissues with at least one compound detected at every site. These
compounds have been detected in marine animal tissues in several other studies (e.g.,
Maruya et al., 2012; Klosterhaus et al., 2013; Dodder et al., 2014; Gu et al., 2016; Granek
et al., 2016; Meador et al., 2016). The concentrations reported in this study are similar to
detections in marine animal tissue the Pacific Northwest (Granek et al. 2016; Meador et
al. 2016), slightly lower than urban areas of the U.S. west coast (Maruya et al. 2012;
Klosterhaus et al. 2013), and notably lower than those reported in a heavily populated
area in China (Gu et al. 2016) (Table 2.7). For NP1EO and NP2EO, our concentrations
are similar to the low ranges reported in Puget Sound fish tissues (Meador et al. 2016),
but were approximately 2-12 ng/g higher for NP1EO and ~1 ng/g higher for NP2EO than
Olympia Oysters in Netarts Bay and Coos Bay (Granek et al. 2016). For nonylphenol (4-
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NP), concentrations were relatively similar to Pacific Northwest studies, but the Westport
site concentration was higher than in both Netarts and Coos Bay in Granek et al. (2016).
Concentrations of 4-NP were lower than some reports in flatfish in Southern California
(Maruya et al. 2012) and mussels in the San Francisco Bay (Klosterhaus et al. 2013). One
study in China detected much higher concentrations of 4-nonylphenol in marine mollusks
(Gu et al. 2016). Only one other study (Granek et al. 2016) reported concentrations of 4n-OP in marine animal tissues and the concentrations were similar to those in this study.
Table 2.7 Concentrations of pharmaceuticals and alklyphenols in marine organism tissues
reported in recent literature in nanograms per gram on a wet weight basis (ng/g ww).
Ehrhart and Granek 2020 refers to this study.
Compound
Virginiamycin

Miconazole

Concentration
(ng/g ww)
1.9-3.98

Organism

Location

Source

Pacific oyster
(Crassostrea gigas)

Ehrhart and Granek
(2020)

8-34

Pacific staghorn
sculpin (Leptocottus
armatus)

Coos Bay, OR;
Grays Harbor,
WA
Puget Sound,
WA

5.2

Atlantic salmon
(Salmo salar)

(Done and Halden
2015)

3.94

Olympia oysters
(Ostrea lurida)
Pacific oyster
(Crassostrea gigas)

Farmed seafood
purchased in US
originating from
Scotland
Netarts Bay, OR
Coos Bay, OR

Ehrhart and Granek
(2020)

Puget Sound,
WA

Meador et al. (2016)

Coos Bay, OR;
Grays Harbor,
WA
Puget Sound,
WA

Ehrhart and Granek
(2020)

Puget Sound,
WA

Meador et al. (2016)

Coos Bay, OR

Granek et al. (2016)

0.63-0.87

1.8

NP1E0

4.24-15.4

1.3-60

3-4.9

2.22-2.50

Chinook salmon
(Oncorhynchus
tshawytscha)
Pacific oyster
(Crassostrea gigas)
Chinook salmon
(Oncorhynchus
tshawytscha)
Pacific staghorn
sculpin (Leptocottus
armatus)
Olympia oysters
(Ostrea lurida)

Meador et al. (2016)

(Granek et al. 2016)

Meador et al. (2016)
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NP2EO

41.2

Ribbed horsemussel
– (Geukensia
demissa)

San Francisco
Bay, CA

Klosterhaus et al.
(2013)

0.61-1.92

Pacific oyster
(Crassostrea gigas)

Ehrhart and Granek
(2020)

1.4-51

Chinook salmon
(Oncorhynchus
tshawytscha)
Pacific staghorn
sculpin (Leptocottus
armatus)

Coos Bay, OR;
Netarts Bay, OR;
Grays Harbor,
WA
Puget Sound,
WA
Puget Sound,
WA

Meador et al. (2016)

Olympia oysters
(Ostrea lurida)
Olympia oysters
(Ostrea lurida)
Ribbed horsemussel
– (Geukensia
demissa)

Netarts Bay, OR

Granek et al. (2016)

Coos Bay, OR

Granek et al. (2016)

San Francisco
Bay, CA

Klosterhaus et al.
(2013)

12.2-43.8

Pacific oyster
(Crassostrea gigas)

Ehrhart and Granek
(2020)

30-76

Chinook salmon
(Oncorhynchus
tshawytscha)
Pacific staghorn
sculpin (Leptocottus
armatus)

Coos Bay, OR;
Netarts Bay, OR;
Grays Harbor,
WA
Puget Sound,
WA
Puget Sound,
WA

Meador et al. (2016)

Olympia oysters
(Ostrea lurida)
Olympia oysters
(Ostrea lurida)
Hornyhead turbot
(Pleuronichthys
verticalis)
Ribbed horsemussel
– (Geukensia
demissa)

Netarts Bay, OR

Granek et al. (2016)

Coos Bay, OR

Granek et al. (2016)

Southern CA

(Maruya et al. 2012)

San Francisco
Bay, CA

Klosterhaus et al.
(2013)

Marine molluscs
(Bullacta exarata,
Cyclinas inensis,
Sinonovacula sp.)
Pacific oyster
(Crassostrea gigas)

Yangtze River
Delta, China

(Gu et al. 2016)

Coos Bay, OR;
Grays Harbor,
WA

Ehrhart and Granek
(2020)

1.9-17

0.533-0.879
0.861-0.935
192

4-NP

7.7-35

31.6
19.5-20.0
25-290

94.5

66.51-1560.0

4-n-OP

1.61-3.94

Meador et al. (2016)

Meador et al. (2016)
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1.38-1.93
1.94-2.35

Olympia oysters
(Ostrea lurida)
Olympia oysters
(Ostrea lurida)

Netarts Bay, OR

Granek et al. (2016)

Coos Bay, OR

Granek et al. (2016)

Pharmaceutical occurrence was more frequent at wastewater sites with Westport,
WA being the only oyster growout site with detections. However, there was little
variation in pharmaceutical concentration within these sites based on proximity to
wastewater outfalls. Though racks were spaced to examine small scale variation in
concentration, no prominent pattern was observed among racks within the site pollution
gradient for Coos Bay and North Bend. Concentrations across racks were very similar
and close to the detection limit. Trends in concentrations and detections, or lack thereof,
could be due to various factors, including local hydrodynamics and individual chemical
properties. A study in Coos Bay evaluated hydrodynamics of effluent plumes in the
winter from both WWTPs by tracking dye released from the treatment plants over 12-19
hours (US FDA 2015). Results from this study show that under high flow conditions, the
effluent plume in North Bend would travel across our entire study area in approximately
30 min. Therefore, effluent exposure can be considered ubiquitous around the racks
which could explain the lack of variability in virginiamycin concentration in North Bend.
A similar pattern was observed for Coos Bay. The dye study also found that dilution did
not increase linearly with distance from the outfalls, which could explain the slightly
higher concentration of virginiamycin at the COOSb rack that was in the middle of the
closest and furthest racks from the outfall. Miconazole and virginiamycin have log Kow
coefficients of 6.1 and 1.52, respectively, indicating that miconazole would be more
likely to accumulate than virginiamycin. Yet we found virginiamycin at more sites and at
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higher concentrations, emphasizing that log Kow is only one of many factors that affect
bioaccumulation.
Virginiamycin was detected at an oyster growout site (Westport, WA), despite the
increased distance from wastewater influences. To our knowledge, no ethanol production
takes place in Grays Harbor and livestock rearing operations were not identified in close
proximity to the site. The closest farms are upstream along the Chehalis River, which are
likely too far away to be the major source of this compound in Westport. The surrounding
area is mainly residential. Several studies have identified traces of virginiamycin and
other antibiotics in a byproduct of fuel ethanol production called distiller grains, which
are commonly used in animal feeds, including pet food (Olendorff et al. in press,
Bischoff et al. 2016, Compart et al. 2013). Therefore, farm and household animal feeding
could constitute a more widespread source of this antibiotic. Additionally, ethanol is
added to all gasoline in OR and WA and if traces of antibiotics are present in the final
ethanol product, surface runoff and boat motors could be other potential sources.
However, only one study tested ethanol for virginiamycin and it was not detected
(Hamdy et al. 1996). This study was conducted prior to analytical advances that would
allow for detections at the ng/L and ug/L level and therefore could underestimate
presence in ethanol. More research is needed to identify antibiotics in ethanol given the
widespread use in ethanol production, presence in byproducts, and environmental
occurrence.
Other studies have identified virginiamycin detections in animal tissues without a
known or suspected source. In two recent studies, virginiamycin was found in marine
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animals in close proximity to a wastewater outfall, but was not detected in the effluent or
surrounding water (Meador et al. 2016; Krogh et al. 2017). Krogh et al. (2017) found an
increase in virginiamycin concentrations in marine mussels with distance to a wastewater
outfall and reported concentrations of 67.4, 70.1, and 87.1 ng/g dry weight next to the
outfall, 200 m from the outfall, and at a reference site greater than 5000 m from the
outfall, respectively (Krogh et al. 2017). Similarly, James et al. (2020) found
virginiamycin in mussels at a reference site in Puget Sound and suggest that it may be
from a naturally occurring source, such as bacteria in marine sediments. Bacterial isolates
with gene sequences closely related to Streptomyces virginiae, the bacteria that produces
virginiamycin, have been identified in marine sediments in the Bahamas indicating the
potential for natural synthesis (Hodges et al. 2012). Detections at the Westport site
provide some evidence for naturally occurring sources of this antibiotic in the marine
environment.
Alkylphenol detections were widespread throughout the sites and did not have a
strong pattern with proximity to wastewater. Four of the sites contained at least three of
the four alkylphenols (Coos Bay, North Bend, Valino Island, and Westport) and
concentrations were relatively similar across sites, except for Westport which had notably
higher concentrations of NP1EO, and 4-NP. Widespread concentrations could be due to
multiple sources, high usage of products in both household and industrial settings, and
the bioaccumulative nature of the compounds. Septic systems, stormwater discharge and
industrial activities can be significant sources of alkylphenols and at least one is present
near each of these sites. Alkylphenols have higher log Kow values (e.g., 5.76 for 4-NP)
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than most pharmaceuticals and are therefore very likely to accumulate in tissues over
time. The high detections and concentrations at Westport specifically could be due to
higher inputs of compounds from upstream industrial activities and multiple wastewater
treatment plants. The city of Hoquiam which is located approximately 19 km upstream of
Westport supports several types of industrial production. There are also four wastewater
treatment plants that discharge into the estuary and the Chehalis River. One of these is
located just inside the mouth of the bay to the North of the study site. Grays Harbor has
high tidal influence, especially near the mouth, which could be pushing effluent towards
the site. There are also roads in close proximity to the site that could increase exposure to
stormwater runoff. These factors could contribute overall to higher contamination in this
estuary, but a specific source for the high concentration of 4-NP could not be easily
identified.
The other two growout sites had lower levels of alkylphenols. Despite the lack of
wastewater inputs at Valino Island, concentrations of NP2EO, 4-NP, and 4N-OP were
comparable to those at wastewater sites (North Bend and Coos Bay). Residences with
septic systems and low flushing rate could be reasons for similar detections. One growout
site, Netarts Bay, had only two alkylphenol detections (NP2EO and 4-NP) and the lowest
concentrations among all of the sites (Table 2.4). Netarts Bay is mainly surrounded by
forestland, has a small surrounding population, a high flushing rate, and lacks a dominant
freshwater input. These factors likely contribute to lower contamination at the Netarts
site.
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In this study, we found that oyster condition did not vary based on wastewater
proximity on a small spatial scale. At the two wastewater sites (North Bend and Coos
Bay), there was no significant difference in oyster condition index across the racks placed
at different distances from a wastewater outfall. However, at two oyster growout sites
(Valino Island and Netarts) with racks spaced to account for environmental variability,
we detected significant differences in oyster condition. This indicates that variability in
environmental factors (e.g., nutrient availability, flow, sedimentation) at a small spatial
scale could be a significant driver at these sites. Since differences in condition index were
not apparent within wastewater sites, we hypothesize that effluent could be spanning a
broader spatial scale than expected and affecting oysters within the range of the plume.
This is further emphasized by results of condition index at the site level (Coos, North
Bend, Valino Island, Netarts, Westport), where we found that wastewater sites had lower
condition index than growout sites (Figure 2.4A). However, the weak pattern at
wastewater exposed sites indicates that oysters may not show strong negative effects at
the organism level when exposed to wastewater. Pacific oysters can thrive in variable
environmental conditions (Pauley et al., 1988) and therefore may be able to adapt to poor
conditions, including pollution exposure. This has implications for aquaculture since
oyster condition is commonly used to determine oyster quality for consumption, and
oysters may appear to be in good condition despite ambient pollution exposure.
Additionally, suspended culture may reduce exposure to contaminants bound to
sediments, which can be a secondary source of pharmaceuticals and alkylphenols,
especially those with higher log Kow values (Gaw et al. 2014). When the sediment is
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disrupted, compounds bound to the sediments can be released in the surrounding water.
Therefore, oysters suspended above the ground would have less exposure to these
resuspended compounds.
While we did not see strong effects on oysters in this study, PPCP effects on
organisms have been documented in other research. Though previous research has not
focused specifically on virginiamycin or miconazole, other antibiotics have been the
focus of some experiments. For example, Teixeira and Granek (2017) showed that the
antibiotic agents sulfamethoxazole and trimethoprim reduce marine microalgal growth in
three weeks. Alkylphenols are endocrine disruptors and several studies have
demonstrated their negative effects on aquatic and marine organisms. Nonylphenol,
octylphenol and NP1EO can reduce body weight and length of juvenile female Rainbow
trout (Oncorhynchus mykiss) when exposed to environmentally relevant concentrations of
each compound individually (Ashfield et al. 1998). Other effects include feminization
and decreased liver protein in adult male flounders (Platichthys flesus) (Christensen et al.
1999) and reduced byssus thread strength in Bay mussels (Mytilus edulis) (Granmo et al.
1989).
There may be concerns among the public about human health effects of
consuming trace amounts of PPCPs in oysters. Generally, the amounts found in seafood
are orders of magnitude lower than prescribed doses, thus therapeutic and/or associated
side effects are unlikely to occur. The US FDA and Department of Agriculture (USDA)
place strict regulations on the use of veterinary antibiotics in livestock farming and have
set allowable levels of antibiotics in edible tissue, which are typically 100- to 1000-fold
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lower than no effect concentrations (Donoghue 2003). The levels reported here are
significantly lower than the safe consumption level (250 mg/kg of body weight) and
allowable level in meat (100 ng/g) (US FDA 2019), indicating that consumption of
oysters with trace amounts of antibiotics does not pose a health risk. Additionally,
nonylphenol concentrations in this study were well below the no effect levels for humans
which range from 13-100 mg/kg of body weight per day (EPA 2010), again suggesting
consumption of oysters with trace chemical levels is safe. Lastly, although these
compounds were found in oysters near aquaculture sites, they originate from land-based
sources, primarily household use, and are not associated with the oyster aquaculture
industry. Therefore, these data to not indicate that consumption of farmed seafood is
harmful to humans based on the contamination levels reported here.
This study had several limitations that should be considered for interpretation of
results and future work. First of all, replication at the site level (wastewater vs. oyster
growout) was low and uneven, with two wastewater sites and three oyster growout sites.
Secondly, distances separating racks at both site types were inconsistent among sites and
a lack of data pertaining to environmental variables at each rack limited conclusions
about effects on oyster health. Lastly, due to funding limitations, PPCP analysis was
limited to only a few samples and compounds, and was inconsistent among seasons
(spring and summer). A better resourced research setup could focus on higher replication
at the site level by identifying all possible wastewater exposed and aquaculture sites in
OR and WA, and randomly choosing an even number of each type to compare, with
higher replication than this study. We found that wastewater sites had slightly lower
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oyster condition and more pharmaceutical detections than oyster growout sites, therefore
more replication of those site types could elucidate a stronger pattern, if it exists. To
examine differences in contaminants and oyster health along a pollution gradient, we
recommend placing oyster racks at consistent distances from wastewater outfalls among
sites, and measuring covariates to account for environmental variability at all site types.
We found that environmental variability was likely important at individual sites, but were
unable to describe the specific drivers of these differences. Lastly, analyzing samples
collected at different seasons for the same contaminants would be helpful in determining
seasonal differences. We detected few compounds in the spring samples, but more may
have been present in the summer when rain events were rare and PPCP inputs likely
higher due to a heavy tourist season on the OR and WA coasts. Many of these challenges
were driven by limited funding and resources, therefore increased funding to support
larger scale studies is needed. Despite these limitations, this study reports useful data on
PPCP occurrence and organism effects near wastewater at small spatial scales, with
recommendations to inform future work.

2.5 Conclusion
Pacific oysters accumulated PPCPs in areas near wastewater and commercial
production, with more detections and higher concentrations near wastewater sources.
Concentrations were relatively low, and well below concerning levels for human
consumption, indicating low PPCP occurrence in OR and WA estuaries with small
human populations. We found that oyster condition was slightly lower at wastewater sites
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compared to oyster growout sites, thus pollution exposure may affect organism health.
However, at a small spatial scale (among racks), oyster condition showed more variation
at sites without wastewater influence, emphasizing the importance of environmental
variability. We recommend that future studies expanding on this work increase
replication at the site level, measure environmental covariates to more specifically
characterize the role of environmental variability in PPCP occurrence and oyster health,
and analyze multiple matrices (tissue, water, sediment) for more analytes.
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Chapter 3: PPCPs in coastal wastewater treatment plant effluent and effects on
Pacific oysters

Abstract
Municipal wastewater treatment plant (WWTP) effluent is a primary source of
pharmaceutical and personal care products (PPCPs) to the marine environment as most of
these compounds are not fully removed during the treatment process. Continual discharge
from WWTPs into coastal areas may act as a stressor by continually exposing organisms
to a suite of PPCPs. To quantify effects of PPCP mixtures on wildlife, we conducted a lab
experiment that exposed Pacific oysters to effluent from two Oregon coastal WWTPs of
different discharge capacities (<1 million gallons/day and >1 million gallons/day).
Oysters were distributed across six treatments: 10% and 25% composite effluent from
each treatment plant, 50% grab effluent from one treatment plant, and a seawater control
(0% effluent). At 6 and 12 weeks, various organismal endpoints were examined. Effluent
was collected weekly during the study and analyzed for PPCPs. A subset of oysters from
week 12 were freeze-dried and analyzed for PPCPs. Though few effects on oysters were
measured during the 12 weeks of exposure, 30 PPCPs and three alkylphenols were
detected in effluent and 13 PPCPs and four alkylphenols were detected in oyster tissue.
Although PPCPs were abundant in effluent and accumulated in oyster tissue over three
months, concentration had little effect on growth, feeding rates, and condition. This
finding may point to acclimation of oysters to these persistent stressors or limited
detection due to overall lower fitness following the experimental period.
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3.1 Introduction
Municipal wastewater treatment plant (WWTP) effluent is a primary source of
emerging contaminants to the marine environment. Treated effluent contains a mixture of
compounds including pesticides, steroid hormones, and pharmaceutical and personal care
products (PPCPs; drugs, supplements, antimicrobials, preservatives, fragrances,
surfactants) (Vidal-Dorsch et al. 2012). Many PPCPs persist after use, excretion, and
household disposal and are not fully removed during the wastewater treatment process
(Vieno et al. 2007). Consequently, PPCPs are frequently detected in effluent (e.g., LaraMartín et al. 2014; Meador et al. 2016; Biel-Maeso et al. 2018), as well as marine water,
organism tissue, and sediment (Arpin-Pont et al. 2016). Approximately 20,000
prescription drugs are currently approved for market use by the United States (US) Food
and Drug Administration (FDA 2019) and in the US 48% of people report using at least
one prescription drug in the last 30 days (CDC 2020). A handful of drugs, such as
diclofenac, ibuprofen, and sulfamethoxazole, have been identified as concerning
environmental pollutants due to toxicity, detection frequency, and/or concentration levels
(Guruge et al. 2019; Papageorgiou et al. 2016; Rivera-Jaimes et al. 2018). These
represent only a small fraction of currently used drugs and further research is needed to
identify pharmaceuticals in marine environmental matrices and their subsequent risks.
Alkylphenols, which constitute a variety of surfactants used in household and industrial
products, are commonly detected in effluent and organism tissues, and are more
bioaccumulative and toxic than most pharmaceuticals. Many studies have identified
endocrine disruptive effects of alkylphenols on various species (Acir and Guenther 2018).
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Alkylphenols are classified into two categories: alkylphenol ethoxylates (APEOs) surfactants found in detergents, cleaners, cosmetics, paints, indoor pesticides and other
products, and metabolites used in the production of APEOs such as nonylphenol (NP)
and octylphenol (OP) (US EPA 2010). Following wastewater treatment and
environmental degradation, APEOs break down into their associated metabolites, many
of which are more persistent and toxic (US EPA 2010).
Concentrations and removal rates of PPCPs in WWTPs vary based on effluent
flow rates, size of the source population and the type of wastewater treatment (Daughton
and Ternes 1999; Gaw et al. 2014). When flows are higher, (e.g., during heavy rain
events), removal efficiency is lower because PPCPs spend less time going through the
breakdown process at the plant (Gaw et al. 2014). For example, Ternes (1998) found that
removal rates of some drugs decreased from 60% to under 5% with heavy winter runoff.
Most WWTPs in the United States employ primary and secondary treatment. Tertiary
treatments such as ozonation are more effective in removing pharmaceuticals than
secondary treatment, but are rarely implemented due to their cost (Castiglioni et al. 2006;
Ternes et al. 2003). In general, removal rates for pharmaceuticals range from less than
10% to 100% (Gaw et al. 2014). For example, Lara-Martín et al. (2014) found that drugs
were removed at varying percentages from a WWTP in New York City, NY with the
antiepileptic drug, carbamazepine, removed at a rate of 42%, the antihypertensive,
propranolol, at 35%, and the antibiotic, clarithromycin, at 15%. In a study in Spain, only
25% of targeted pharmaceuticals in WWTP influent were efficiently removed during
treatment (85% or greater removal) (Biel-Maeso et al. 2018). Alkylphenols, which have
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higher octanol-water partitioning coefficients (log Kow) than pharmaceuticals, are more
likely to bind to sediment during wastewater treatment and be eliminated (Priac et al.
2017).
In populated coastal areas, WWTPs outfalls are commonly located near rocky
shorelines and in bays and rivers that drain into the ocean. Continual discharge from
WWTPs exposes organisms to mixtures of PPCPs, which may have negative effects on
their health. Studies on individual PPCPs have shown that chronic exposure leads to
various organismal effects (Fent et al. 2006; Peters and Granek 2016), but questions
remain about exposure to multiple compounds simultaneously. Studies on whole effluent
mixture effects are rare, though when conducted typically use high concentrations that
elicit significant sub-lethal effects (e.g., Aerni et al. 2004; Wehmas et al. 2011; Vajda et
al. 2015; Harding et al. 2016; Freitas et al. 2017). For example, Vajda et al. (2015) saw a
reduction in testes stage in fish exposed to 50% and 100% effluent after 28 days. Most
studies to date take place on short timelines (3-28 days) and focus on fish (e.g., Aerni et
al. 2004; Wehmas et al. 2011; Minarik et al. 2014; Vajda et al. 2015; Cavallin et al. 2016;
Harding et al. 2016), though a few studies have examined short-term effects on marine
bivalves with resulting effects at molecular and cellular levels (Díaz-Garduño et al. 2018;
Dumas et al. 2020; Flores-Nunes et al. 2015; Medeiros et al. 2008). A study that
compared Pacific oyster exposure to whole effluent and a single contaminant in effluent
(linear alkylbenzene), found that after 36 hours there were different responses in several
endpoints (Flores-Nunes et al. 2015). This indicates potential synergistic and/or
antagonistic effects and emphasizes the importance of examining toxic effects of
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contaminant mixtures. Further investigation is needed regarding effects of long-term
exposure (>30 days) on sessile marine bivalves, which may be more susceptible to
pollution than mobile organisms.
Pacific oysters (Crassostrea gigas) are a prominent aquaculture species on the US
west coast, comprising 89% of shellfish aquaculture production in this area (Dumbauld et
al. 2009). They are commonly grown in Oregon and Washington estuaries using ground
culture, among other methods (Dumbauld et al. 2009) and provide important food and
economic resources. As sessile, filter-feeding bivalves, they are susceptible to pollutant
exposure. Additionally, prior research has shown that oysters are suitable for
environmental toxicity determination (Palmer et al. 2015) and accumulate contaminants
from the surrounding environment in their tissues. Understanding uptake of PPCPs in
effluent and their effects on oysters is important for informing policies relating to safe
aquaculture, ecological functions provided by oysters, and human health.
In Oregon, coastal cities are considerably smaller than many populated coastlines
in the United States ranging from approximately 300 (Nehalem) to 16,000 (Coos Bay)
people. Along the Oregon coast, there are 17 sewage treatment plants that discharge
directly to an estuary or the ocean with discharge rates ranging from less than one million
gallons per day (mgd) to five mgd (Oregon Department of Environmental Quality
personal communication 2015).
In this experiment, we examine PPCP uptake and effects in Pacific oysters
following exposure to effluent from Oregon coastal WWTPs. Our research objectives
were to:
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1) Determine PPCP types and concentrations in effluent from the Oregon coast
2) Examine uptake of PPCPs by Pacific oysters following exposure to WWTP
effluent
3) Identify organism level effects (growth, condition index, feeding rate) of chronic
effluent exposure on Pacific oysters
4) Compare PPCP concentrations, uptake, and effects from effluent at two Oregon
coastal WWTPs with different discharge capacities

3.2 Methods
3.2.1 Source Wastewater Treatment Plants
In a lab experiment conducted at Portland State University (PSU), adult Pacific
oysters were exposed to different dilutions of effluent from WWTPs located on the
northern Oregon coast. WWTP identities are anonymous per agreements with the
operators who supplied effluent. The flow information was obtained from the associated
National Pollutant Discharge Elimination System (NPDES) permits (not cited to maintain
anonymity). The first treatment plant (WWTP1) processes <1 mgd and uses secondary
treatment, specifically activated sludge and ultraviolet disinfection. The average flow
from May to October is 0.18 mgd and the surrounding population is around 1,300 people.
The second treatment plant (WWTP2) is permitted to process >1 mgd, but <2 mgd with
secondary treatment of activated sludge and chlorine disinfection. The actual average
flow of WWTP2 is 0.71 mgd from May to October and the surrounding population is
approximately 8,000 people. On week three of the experiment, the operator of WWTP2
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refused to continue providing effluent, after agreeing initially to participate in the 12week study. At this point, we secured agreement from another coastal WWTP with the
same permitted discharge capacity as a replacement. The average flow from May to
October is 1.08 mgd, slightly higher than the initial WWTP, but within the discharge
range we were targeting. This plant utilizes activated sludge and ultraviolet disinfection
as secondary treatment and has a surrounding population of approximately 6,700 people.

3.2.2 Experimental Design and Animal Care
On May 2, 2018, donated adult Pacific oysters were picked up from an oyster
grower in Netarts Bay, OR. This estuary was chosen because it is considered relatively
pristine due to low surrounding population, lack of dominant freshwater input, and heavy
marine influence (high flushing rate). The oysters were kept in a clean holding tank for
two weeks and then nine oysters were added to each of 24 individual experimental tanks
(2.5 gallons), with artificial seawater made from Instant Ocean at a salinity of 25 ppt.
Oysters acclimated in the tanks for six weeks before the experiment began. Tanks were
randomly assigned one of six treatments, with four tanks per treatment: 10% and 25%
composite effluent dilutions for each WWTP, a 0% effluent control, and a 50% grab
effluent dilution from WWTP2 (Figure 3.1). The composite concentrations were chosen
to represent environmentally relevant concentrations of exposure within the limits of
available composite effluent samples. Each WWTP was able to provide a 24-hour
composite sample of a maximum of 10 L. Since composite samples were limited, we
used a grab sample as a 50% exposure for comparison to other studies that found
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significant negative effects at this concentration. Due to a limited number of tanks in our
lab (24), we were only able to examine this exposure for one treatment plant.
Three times per week, oysters were fed Shellfish Diet 1800 from Reed
Mariculture, Inc., a refrigerated mixture of five microalgal species commonly used to
feed cultured bivalves. The amount fed was based on manufacturer recommendations and
was adjusted as oysters were removed from tanks for analysis. A 25% water change was
performed on every tank weekly on the day before dosing occurred, to minimize dilution
of effluent from the previous week.

Figure 3.1 Schematic of experimental design for effluent exposure lab study where
oysters were exposed to composite (c) and grab (g) samples of effluent at concentrations
of 10, 25, and 50% effluent. Oysters were sampled at two time periods - 6 and 12 weeks.
3.2.3 Effluent Collection, Transport, and Dosing
The experiment began on June 27, 2018 and ran for 12 weeks. We collected 24hour composited effluent samples weekly on Thursdays from both treatment plants and a
grab sample from the larger treatment plant. In weeks 9 and 10, WWTP1 was not able to
provide composite effluent and in week 2, WWTP2 was not able to provide composite
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effluent, so corresponding tanks were left untreated at those dosing periods. Effluent was
transported in 5-gallon buckets to Portland State University. Upon arrival, salt was added
to bring the salinity to the ambient salinity in the experimental tanks (25 ppt) to reduce
stress caused by salinity fluctuations. The appropriate amount of tank water was then
removed from each tank and replaced with effluent. To mimic the dosing procedure, a
25% water change was performed on control tanks using the same methods. Gloves and
lab coats were worn at all times during dosing and care was taken to prevent crosscontamination among treatments and controls by changing gloves and using designated
tools for each treatment.

3.2.4 Biological Measurements
At 0, 6 and 12 weeks, oyster shell dimensions (length, width, height) and whole
wet weight were measured for all oysters. Three oysters from each tank were sacrificed
on each sampling date to measure wet tissue weight, dry tissue weight, and dry shell
weight. The weighed wet tissues were frozen in pre-cleaned glass jars with PTFE lined
caps at -20 degrees F. All oysters were dried to be analyzed for condition index, a proxy
for oyster health expressed as the ratio of dry tissue weight to dry shell weight (Lucas and
Beninger 1985).
Equation 1: CI = dry tissue weight x 100/dry shell weight
All shells were air dried for 24 hours and weighed. Following the methods of Mo and
Neilson (1994), oyster tissues from weeks 0 and 6 were thawed and dried in porcelain
crucibles in a drying oven at 105 degrees C to constant weight (48-96 hours). To preserve
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samples from week 12 for PPCP analysis, oyster tissues were freeze dried in a Harvest
Right freeze dryer for a 24-hour automatic cycle. Limited access to a freeze drier and
partial funding for PPCP tissue analysis only allowed for using this method for the last
sampling point. To determine if freeze- and oven-dried tissue weights could be compared
across sample weeks, we selected a subset of oysters from each group (freeze- and ovendried) with similar wet tissue weights and graphed the dry weights against the wet
weights (Figure A1). This comparison showed that both drying methods yielded similar
dry weights with no consistent pattern of one weighing less or more. Therefore, condition
index was compared across samples dates with different tissue drying methods.
To measure feeding rate (algal clearance rate), we took 10 mL samples of tank
water within 20 minutes of feeding, diluted them in filtered seawater by a factor of 100
(100 uL of tank water in 10 mL of diluent), and used a Beckman Coulter Counter to
count the number of algal cells in three to five 0.5 mL aliquots. Sampling and cells counts
were repeated 3-5 hours after feeding. To account for settling of algae on tank surfaces,
we set up four tanks without oysters and performed the same sampling methods. Algal
clearance rate was calculated using the following equation (Coughlan 1969):
Equation 2: CR = (V/n) [ln(C0/Ct)/t] – [ln(C0’/Ct’)/t]
In the equation, CR = clearance rate (mL/min), V= tank volume (mL), n=number of
oysters per tank, t=time (min), C0 = initial algal concentration (cells/mL), Ct = algal
concentration at the end of the test period (cells/mL), C0’ = initial algal concentration of
tank without oysters (cells/mL), and Ct’ = algal concentration at the end of the test period
in tank without oysters (cells/mL). Feeding rate was measured in weeks 6, 7, 10, and 12.
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3.2.5 Effluent and Tissue Analysis for PPCPs
In addition to effluent for dosing, we collected a 500 mL effluent sample each
week in an I-Chem certified clean amber glass jar with a PTFE lined cap for PPCP
analysis. These samples were transported in a cooler to PSU and immediately frozen at 20 degrees F upon arrival. Due to funding constraints, the weekly effluent samples were
composited into one sample for each WWTP by adding an even volume (~100 mL) of
each sample to two 1-liter containers, one for PPCPs and one for alkylphenols. Many of
the bottles containing frozen effluent were broken upon inspection. To obtain these
samples, effluent was thawed long enough to release from the glass, and then the frozen
portion was moved to a methanol rinsed foil tray to thaw. Samples were put in clean,
methanol rinsed amber glass jars and refrigerated until composited. Freeze-dried oyster
tissues from week 12 exposed to 25% effluent from each treatment plant and controls
were prepared for analysis. Three oysters from each tank were homogenized in a blender,
split in half, then composited so that each sample consisted of three half oysters, with
three composite samples per treatment plant and two controls. With limited funding, we
chose to replicate analysis of the higher exposure rather than run few replicates of both
exposure levels, as this would be expensive and redundant. The additional half oysters
were set aside for a supplementary project that examined PPCP and microplastic analysis
and co-occurrence of these contaminants.
In September 2020, composite effluent and tissue samples were analyzed for
PPCPs and alkylphenols at SGS AXYS Analytical Services in Sydney, British Columbia.
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Each sample was analyzed for 58 PPCPs (Figure D1 and D2) and 4 alkylphenols: two
nonylphenol ethoxylates (NPEOs), 4-nonylphenol monoethoxylate (4-NP1EO) and 4nonylphenol diethoxylate (4-NP2EO), and two breakdown products, 4-nonylphenol (4NP) and 4-n-octylphenol (4-n-OP). The following is a brief summary of standard
protocols and methods provided by SGS AXYS Analytical for PPCP and alkylphenol
target analysis. PPCP samples in effluent and tissues were adjusted to a pH of two prior
to extraction. Tissue samples were extracted using sonication with aqueous buffered and
pure acetonitrile, and aqueous samples were filtered. Tissue extracts and the aqueous
portion of effluent samples were cleaned up using solid phase extraction (SPE) and
analyzed with high performance liquid chromatography electrospray ionization tandem
mass spectrometry (LC/ESI-MS/MS). Alkylphenol tissue samples were mixed with water
and extracted by steam distillation into isooctane. Samples were cleaned up with SPE,
prepared in methanol and analyzed by LC/ESI-MS/MS in two runs, one in ESI positive
mode and one is ESI negative mode. Alkylphenol effluent samples were extracted with
hexane and derivatized by non-aqueous acetylation. Samples were cleaned up by
chromatography on a 28% deactivated silica column and analyzed with gas
chromatography mass spectrometry (GC-MS). All samples were spiked with surrogate
standards prior to extraction and spiked with recovery standards prior to analysis.

3.2.6 Data Analysis
All analyses were performed in Microsoft Excel and R version 3.4.1. Summary
statistics (mean and standard deviation) of oyster growth dimensions (shell height, length,
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width, whole weight, wet tissue weight, condition index) were calculated for each tank at
the three sampling points. Change in growth was determined for shell height (distance
between the umbo and ventral valve) and whole weight (mass) through the following
equation: Dimensiont – Dimenstion0. Analyses for change in mass and shell height were
performed on within-tank means of six oysters at week 6 and three oysters at weeks 12.
For condition index and wet tissue weight, analyses were performed on within-tank
means of three sacrificed oysters at each sampling date (0, 6, 12). We used a two-way
mixed ANOVA, an extension of repeated measures ANOVA, to determine statistical
significance of change in mass, change in height, wet tissue weight and condition index
for each treatment (effluent dose) and sample week. Exposures from each treatment plant
were analyzed separately, as well as the grab samples from WWTP 2. For the ANOVA,
treatment was considered a between-group factor and sample week was considered a
within-group factor. Assumptions were assessed using quantile-quantile plots and
Shapiro-Wilk tests for normality, Levene’s test for equal variance, Box’s M-test for
homogeneity of covariances, and the Mauchly’s test for sphericity. For mass, height, and
condition index, all data met the assumptions for parametric mixed ANOVA. For wet
tissue weight, the WWTP2 grab samples did not meet the equal variance assumption even
with transformation, so a robust ANOVA, which does not assume equal variance (Mair
and Wilcox 2019), was used instead. Post-hoc comparisons were made with pairwise ttests and a Bonferroni correction where applicable.
Feeding rates were calculated for each tank at each sampling point on weeks 6, 7,
10, and 12. Approximately 50% of measurements from the empty control tanks (Ct’/C0’)
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resulted in values that were not representative of settling. Specifically, Ct’ was lower than
C0’ or the difference between Ct’ and C0’, was larger than the difference between Ct and
C0. Both of these conditions resulted in a negative feeding rate. Therefore, the settling
term, [ln(C0’/Ct’)/t], was omitted from the feeding rate equation. Over the course of all
feeding trials, 14 calculations resulted in negative feeding rates due to Ct values being
higher than C0 values in individual tanks. These tanks were removed for graphical and
statistical analysis of clearance rates. If more than one tank was removed from each
treatment, leaving less than three replicates, the treatment was excluded from statistical
analysis. Due to a loss of two control tanks (0% effluent) during week 10 feeding trials,
all week 10 samples were excluded from analysis. To achieve even sample sizes for
ANOVA, at each sampling week, remaining treatments with four tanks were reduced to
three tanks using a random number generator to remove one tank. Since different tanks
were removed at each sampling point, repeated measures ANOVA was deemed
inappropriate for analysis (some tanks were not repeatedly measured). Instead, one-way
ANOVA was used to analyze differences in feeding rate among treatments at each
sample week. Post-hoc comparisons were made with Tukey’s HSD test. Data met all
assumptions prior to analysis.
Combined total contaminant concentrations in effluent from the two treatment
plants were compared using a t-test. Data were log transformed to meet assumptions of
normality and equal variance.
Bioaccumulation factors (BAFs) were calculated for each tissue sample using the
following equation:
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Equation 3: BAF = Tissue Concentration/Water Concentration
To determine the approximate water concentration, effluent concentrations were
multiplied by 0.25, to account for 25% dilution in the tanks.
We ran a post hoc power analysis on the observed effect sizes from the
experiment to examine recommended sample sizes. Since practical methods are not
available for a mixed ANOVA, we ran one-way ANOVAs on the 12-week results for
each response variable. Therefore, the results do not address effects over time. We used
Cohen’s f as a measure of effect size (Ialonga 2016), set alpha at 0.05 and power at 0.80,
and calculated sample size using the R package, pwr.

3.3 Results
3.3.1 Oyster Size, Condition and Feeding Rate
Throughout the experiment, mortality was low (1.3%) and deaths were dispersed
among treatments, indicating that tank environments were suitable for oyster survival and
effluent did not induce mortality in any concentration. Summary statistics of oyster
dimensions, condition index, and change in growth are reported in Tables 3.1 and 3.2.
Over the course of the experiment, a small amount of shell growth occurred, with
increase in shell height ranging from 0-5.62 mm from week 0-6 and 0-6.28 mm from
week 0-12. The mean change in shell height was 0.51 mm for week 0-6 and 0.96 for
weeks 0-12, suggesting that most oysters experienced minimal shell growth. Control
oysters had a significant increase in shell height from week 6 to 12 (Paired t-test: p=.031)
as did oysters in WWTP2 (composite: ANOVA: F1,9=11.640, p=.008; grab: ANOVA:
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F1,6=13.304, P=.011), while treatments with WWTP1 effluent did not (10%: paired t-test:
p=.406; 25%: paired t-test: p= .077), though the increase in the 25% treatment was
marginally significant (Figure 3.2, Table 3.3). In WWTP2, there was a marginally
significant difference in shell height between treatments at week 6 (ANOVA: F2,9=3.833,
p=.070), with the 10% effluent treatment having lower change in shell height compared
to the 25% treatment (paired t-test: p=.099).
Oyster mass was similar among treatments at each sampling point, with an overall
decrease from week 0 to 6 in all treatments (Figure 3.2). From week 6 to 12, oysters
regained some weight, but did not reach or surpass their original mass. The increase in
mass from week 6 to 12 was marginal for both WWTP1 (ANOVA: F1,9=3.993, p=.077)
and WWTP2 (ANOVA: F1,9=4.942, P=.053). In both WWTPs, wet tissue weight was
relatively similar across sample weeks. In WWTP2, wet tissue weight decreased
marginally over time (ANOVA: F2,18=2.727, p=.092 (Figure 3.3, Table 3.3).
Condition index decreased over time in all treatments from both WWTPs
(ANOVA: WWTP1: F2,18=11.578, p<.001; WWTP2: F2,18=27.409, p<.001;
WWTP2(grab): F2,12=9.371, p=.004) and did not vary by effluent concentration (Figure
3.3, Table 3.3). Specifically, condition index was significantly lower at week 6 and week
12 compared to week 0 (Paired t-test: WWTP1: 0-6: p=.02, 0-12: p=.001; WWTP2: 0-6:
p=.001, 0-12: p<.001; WWTP2(grab): 0-6: p=.05, 0-12: p=.005) (Figure 3.3, Table 3.3).
Over the three sampling weeks, only one significant difference was identified in
feeding rate (Figure 3.4, Table 3.4). In the week 6 trial, the 10% effluent treatment from
WWTP1 had significantly higher algal clearance than the control and 25% treatment
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(ANOVA: F2,6=10.269, p=.01) (Figure 3.4, Table 3.4). Also, oysters in the 50% grab
treatment had marginally higher clearance rates than the the control (t-test: t4=-2.325,
p=.081). Overall, feeding rates showed an increase over time with high variation and no
further significant differences.
The power analysis resulted in recommended sample sizes ranging from 2-322
replicates with most of the values within the range of 6-30 replicates (Table 3.7). This
shows that for most of the responses measured, a higher sample size may have been
necessary to identify significant effects.
Table 3.1 Summary statistics (mean and standard deviation) of oyster dimensions for
each treatment at three sampling dates. Oysters were exposed to composite effluent from
two treatment plants at 10% and 25% concentrations, and 50% grab effluent from
WWTP2. Summaries represent the average of three oysters sampled per tank and
averaged for each treatment (n=4 tanks per treatment) at each sampling week.

Mass (g)

Height
(mm)

Length
(mm)

Width
(mm)

Wet
Tissue
Weight
(g)

38.74
(2.71)
43.15
(4.78)
37.73
(3.9)

82.2
(4.56)
86.32
(5.36)
78.36
(6.55)

46.06
(1.39)
52.76
(5.19)
55.04
(2.92)

20.82
(3.16)
19.76
(1.17)
19.71
(0.85)

7.92
(1.03)
8.95
(0.39)
7.47
(1.03)

5.04
(0.55)
4.02
(0.92)
3.76
(0.76)

79.76
(3.55)
79.48
(8.11)
74.87
(6.43)
78.16
(2.89)
78.17
(4.58)
83.94
(4.93)

50.5
(3.78)
49.32
(7.84)
51.38
(2.17)
51.16
(2)
49.79
(3.35)
53.27
(5.81)

20.75
(2.69)
17.78
(2.31)
19.19
(1.53)
18.84
(1.76)
19.95
(2.01)
18.75
(2.48)

8.21
(1)
7.14
(1.9)
7.04
(1.03)
8.26
(1.09)
8.13
(1.43)
7.94
(1.46)

5.08
(0.87)
3.84
(0.82)
3.76
(0.46)

12

40.93
(8.68)
33.04
(11.5)
33.87
(6.28)
37.13
(4.24)
37.66
(2.24)
37.6
(6.86)

0

38.37
(7.79)

77.87
(6.92)

49.31
(5.81)

18.65
(3.05)

7.99
(2.05)

5.23
(0.36)

Effluent
Concentration
Control

Sample
Week

0%

0

0%

6

0%
WWTP1

12

10%

0

10%

6

10%

12

25%

0

25%

6

25%
WWTP2
10%

Condition
Index

4.84 (0.4)
3.84
(0.41)
3.32
(0.67)
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10%

6

10%

12

25%

0

25%

6

25%
12
WWTP2: Grab
50%

0

50%

6

50%

12

37.91
(6.29)
39.95
(4.18)
40.13
(6.29)
42.78
(7.66)
33.06
(5.7)

82.36
(2.38)
80.28
(3.98)
78.61
(8.63)
81.62
(4.8)
77.6
(2.75)

52.2
(2.56)
55.17
(1.74)
48.75
(3.38)
55.27
(4.19)
49.49
(0.85)

19.67
(2.35)
20.25
(0.96)
21.16
(2.03)
21.97
(1.44)
19.3
(2.47)

8.3
(1.39)
8.35
(1.17)
9.29
(2)
10.25
(3.55)
6.88
(1.14)

3.78
(0.39)
3.85
(0.52)
5.53
(0.52)
3.85
(0.56)
3.34
(0.37)

35.45
(9.42)
40.05
(6.37)
32.08
(5.5)

78.75
(8.97)
81.3
(4.24)
79.42
(3.39)

47.26
(2.73)
56.58
(4.08)
47.53
(3.28)

18.14
(1.02)
19.24
(1.94)
17.98
(1.38)

7.35
(2.34)
8.84
(1.99)
7.07
(1.5)

4.97
(0.57)
3.62
(0.65)
3.42
(0.52)

Table 3.2 Summary statistics (mean and standard deviation) for change in oyster mass
and height from week 0-6 and week 0-12. Oysters were exposed to composite effluent
from two treatment plants at 10% and 25% concentrations, and 50% grab effluent from
WWTP2. Summaries represent the average of within-tank means of six oysters at week 6
and three oysters at weeks 12 for each treatment (n=4 tanks per treatment).
Effluent Concentration
Control
0%
0%
WWTP1
10%
10%
25%
25%
WWTP2
10%
10%
25%
25%
WWTP2: Grab
50%
50%

Sample Week

Change in mass (g)

Change in height (mm)

6
12

-1.11 (0.28)
-0.88 (0.09)

0.46 (0.31)
1.15 (0.45)

6
12
6
12

-1 (0.55)
-0.81 (0.72)
-0.94 (0.17)
-0.9 (0.29)

0.77 (1.31)
0.9 (1.5)
0.41 (0.21)
0.56 (0.12)

6
12
6
12

-1.16 (0.21)
-1.18 (0.55)
-1.26 (0.23)
-0.8 (0.29)

0.25 (0.09)
0.36 (0.48)
0.63 (0.18)
1.08 (0.55)

6
12

-0.91 (0.12)
-0.63 (0.52)

0.53 (0.25)
0.76 (0.39)

Table 3.3 Statitistical summary for two-way mixed ANOVA on oyster growth, wet tissue
weight, and condition index. Treatment refers to effluent concentration. Significant pvalues (p<.05) are bolded and marginally significant p-values (p<.10) are italicized. Wet
tissue weight results from WWTP2: Grab are from robust (nonparametric) ANOVA.
Dependent Variable
WWTP1
Change in Mass

Factor

Df

F

P

Treatment
Sample Week

2
1

0.058
3.993

0.944
0.077
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Change in shell height

Wet tissue weight

Condtion Index

WWTP2
Change in Mass

Change in shell height

Wet tissue weight

Condtion Index

WWTP2: Grab
Change in Mass

Change in shell height

Wet tissue weight

Condtion Index

Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week

2
2
1
2
2
2
4
2
2
4

0.523
0.216
17.434
5.375
0.897
1.194
0.991
0.877
11.578
0.098

0.609
0.810
0.002
0.029
0.441
0.326
0.437
0.449
0.00059
0.982

Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week

2
1
2
2
1
2
2
2
4
2
2
4

0.516
4.942
1.792
3.633
11.640
1.896
0.467
2.727
1.213
0.020
27.409
0.888

0.614
0.053
0.221
0.070
0.008
0.205
0.641
0.092
0.340
0.980
0.000003
0.491

Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week
Treatment
Sample Week
Treatment*Sample Week

1
1
1
1
1
1
1
2
2
1
2
2

1.759
3.773
0.040
0.542
13.304
3.474
0.2640
1.935
0.043
1.113
9.371
0.128

0.233
0.100
0.849
0.489
0.011
0.112
0.634
0.259
0.959
0.332
0.004
0.881

Table 3.4 Statistical summary for one-way ANOVA and t-tests on oyster feeding rate at
each sampling week among treatments (control, 10%, 25%, 50% (grab) effluent).
Analysis was performed separately for each WWTP.
WWTP1

WWTP2

WWTP2: Grab

Sample Week
6
7
12
6
7
12
6
7
12

Analysis
ANOVA
ANOVA
ANOVA
ANOVA
ANOVA
t-test
t-test
t-test
t-test

Df
2
2
2
2
2
4
4
4
4

F/T
10.269
1.545
0.274
1.088
0.120
0.622
-2.325
-0.800
-0.602

P
0.012
0.288
0.770
0.395
0.889
0.568
0.081
0.454
0.580
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*

Figure 3.2 Boxplots of change in oyster mass and shell height after exposure to effluent
(10%, 25%, 50%) from two wastewater treatment plants and a seawater control (0%)
from 0-6 weeks and 0-12 weeks. The mean change in growth per tank was calculated for
6 oysters at week 6 and 3 oysters at week 12. Asterisks indicate significant differences
(p<.05) from mixed ANOVA.
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Figure 3.3 Boxplots of oyster wet tissue weight and condition index after exposure to
effluent from two wastewater treatment plants and a seawater control (0%), sampled
at three time points (0, 6, and 12 weeks). Significant differences in oyster condition at
sample weeks are indicated by asterisks. No significant differences were observed
based on treatment (p>.05).
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Figure 3.4 Boxplots of oyster feeding rates (measured as algal clearance) after
exposure to effluent from two wastewater treatment plants and a seawater control
(0%), sampled at three time points (6, 7 and 12 weeks). A significant difference in
feeding rate during week 6 in WWTP1 is indicated by an asterisk (One-way
ANOVA: p=.01).
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3.3.2 PPCPs in Effluent and Tissue
In the effluent, 30 of the 58 analyzed PPCPs and their metabolites were detected,
with 27 compounds detected in each WWTP (Table 3.5). Miconazole, roxithromycin, and
sulfamethazine were detected in WWTP1, but not WWTP2 effluent. Caffeine,
dehydronifedipine, and glyburide were detected in WWTP2, but not WWTP1 effluent.
Concentrations ranged from 0.734-1869 ng/L with roxithromycin, glyburide, and
miconazole having the lowest concentrations and hydrochlorothiazide, furosemide, and
2-Hydroxy-ibuprofen having the highest concentrations (Table 3.5). The total combined
concentrations of PPCPs in the two treatment plants were similar, with a mean and
standard deviation of 239 (409) for WWTP1 and 241 (351) for WWTP2. A t-test on log
transformed data revealed no significant difference in concentration between the two
WWTPs (t-test: t58 = -0.46, p=.64). Three of the four analyzed alkylphenols were
detected in effluent with 4-NP and 4-NP2EO in both treatment plants, and 4-NP1EO only
in WWTP1 (Table 3.5). Nonylphenol was found at the highest concentrations with 197
and 166 ng/L in WWTP1 and WWTP2, respectively. Both nonylphenol ethoxylates had
concentrations less than two times the lab blank. We detected a total of 13 PPCPs in
oyster tissues, with 12 PPCPs in WWTP1 oysters and 11 PPCPs in WWTP2 oysters
(Table 3.6). Six PPCPs were detected in every sample, regardless of WWTP
(carbamazepine, diphenhydramine, diltiazam, fluoxetine, thiabendazole, trimethoprim)
and diphenhydramine had the highest concentrations overall. Triclocarban and 2hydroxy-ibuprofen were detected in WWTP1, but not in WWT2 exposed oysters.
Clarithromycin was detected in WWTP2, but not WWTP1 exposed oysters. Control
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oysters had few detections in comparison to wastewater exposed oysters, with only three
PPCPs found (2-Hydroxy-ibuprofen, sulfamethoxazole, thiabendazole). With the
exception of 2-Hydroxy-ibuprofen, control concentrations were just above the detection
limit. Four alkylphenols (NP1EO, NP2EO, 4-NP, 4n-OP) were detected in oysters
exposed to both treatments and the controls. Three alkylphenols (NP1EO, NP2EO, 4-NP)
were detected in lab blanks above the reporting limit, with the lab blank concentraions for
4-NP higher than all sample detections. Therefore, most of the tissue alkylphenol
concentrations were lower than or very close to the lab blank. All of the compounds
detected in oyster tissues were found in the effluent except for 4n-OP. Bioaccumulation
factors ranged from 0.03 to 10.8 with 4-NP2EO, 4-NP, and fluoxetine having the highest
values.

Table 3.5 Concentrations of PPCPs and alkylphenols detected in composite wastewater
treatment plant effluent. Each sample is a composite of approximately 100 mL from each
weekly 24-hour composite sample from each treatment plant. Concentrations are reported
in nanograms per liter (ng/L) with higher concentration of each analyte among the two
WWTPs bolded. log Kow values calculated using XLogP3 were obtained from PubChem.
Concentration ranges in single samples of effluent from Meador et al. (2016) are included
for comparison. Reporting limit for each compound is reported in parentheses. Codes:
ND=not detected; ^=less than 2x lab blank or reporting limit; NF=not found.
Analyte
PPCPs
Azithromycin
Bisphenol A
Caffeine
Carbamazepine
Ciprofloxacin
Clarithromycin
Dehydronifedipine
1,7-Dimethylxanthine
Diphenhydramine
Diltiazem
Erythromycin-H2O

Use

log
Kow

WWTP1

WWTP2

Meador et
al. (2016)

Antibiotic
Product additive
Stimulant
Anticonvulsant
Antibiotic
Antibiotic
Drug metabolite
(nifedipine)
Drug metabolite
(caffeine)
Antihistamine
Antihypertensive
Antibiotic

4.0
3.3
-0.1
2.5
-1.1
3.16
2.8

500 (2.76)
25.8^ (13.4)
ND
732 (1.48)
43.2 (12.9)
69.2 (1.48)
ND

344 (1.69)
13.3^ (7.00)
115 (14.7)
253 (1.47)
113 (8.93)
111 (1.47)
2.62 (0.589)

261-629
350-4290
152-1170
510-735
158-192
52-181
13-15

NF

114^ (59.1)

270 (58.9)

873-2060

3.3
3.1
2.7

280 (0.591)
79.1 (0.296)
11 (2.27)

554 (0.589)
78.8 (0.437)
75.6 (2.26)

1030-1240
390-425
87-138
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Fluoxetine
Furosemide
Gemfibrozil
Glipizide
Glyburide

Antidepressant
Diuretic
Lipid-regulator
Antidiabetic
Antidiabetic

4.0
2.0
3.8
1.9
4.8

49.6 (4.44)
939 (3.94)
254 (0.788)
6.04 (0.788)
ND

Hydrochlorothiazide
2-Hydroxy-ibuprofen

Diuretic
Drug metabolite
(ibuprofen)
Non-steroidal antiinflammatory drug
Antifungal
Non-steroidal antiinflammatory drug
Antibiotic
Antibiotic

-0.1
2.1

Antibiotic
Antibiotic
Antihelmintic
Antimicrobial
Antimicrobial
Antibiotic
Anticoagulant
Surfactant
Surfactant
Surfactant metabolite

Ibuprofen
Miconazole
Naproxen
Ofloxacin
Roxithromycin
Sulfamethazine
Sulfamethoxazole
Thiabendazole
Triclocarban
Triclosan
Trimethoprim
Warfarin
Alkylphenols
4-NP1EO
4-NP2EO
4-NP

57-60
994-1290
1360-1640
22-23
7.1-11

1860 (8.67)
620 (6.66)

24.9 (1.47)
453 (3.93)
314 (0.785)
3.35 (0.785)
1.54^
(0.785)
1750 (8.64)
471 (7.24)

3.5

167 (3.94)

227 (3.93)

116-1060

5.3
3.3

1.79^ (1.48)
79.5 (3.40)

ND
220 (2.66)

4.9
106-701

-0.4
3.1

85.6 (2.52)
ND

108-387
3.8

0.3
0.9
2.5
5.3
5.0
0.9
2.7

14.5 (3.44)
0.734^
(0.640)
8.22 (3.32)
408 (2.33)
16.8 (16.8)
4.75 (0.394)
98.1 (5.91)
59.6 (2.09)
7.66 (0.394)

ND
493 (1.88)
18.2 (1.47)
2.57 (0.393)
30.5 (5.89)
461 (2.33)
9.2 (0.393)

ND
1380
24-27
12-17
250-538
742-852
6.2

5.8
5.6
5.9

36^ (7.85)
16.6^ (6.23)
197 (5.43)

ND (8.68)
19.7^ (3.44)
162 (2.38)

1220-1760
1690-2610
162

411-578
1160-4550

Table 3.6 Concentrations of pharmaceuticals and alkylphenols detected in freeze-dried
oyster tissues from controls and 25% effluent exposures from both treatment plants after
12 weeks of exposure. Each sample is a composite of three half oysters from one tank
that were homogenized prior to splitting. Concentrations reported in nanograms/gram wet
weight (ng/g ww). Reporting limit (RL) for each compound is reported in parentheses.
Bioaccumulation factors (BAF) provided for compounds also detected in effluent. Codes:
ND=not detected; ^=less than 2x lab blank or reporting limit; *=less than lab blank.
Analyte
PPCPs
Azithromycin
RL
BAF
Carbamazepine
RL
BAF
Clarithromycin
RL
BAF
Diphenhydramine

WWTP1 25% (n=3)
Tank 1
Tank 2 Tank 3

WWTP2 25% (n=3)
Tank 1 Tank 2 Tank 3

Control (n=2)
Tank 1 Tank 2

4.72
(1.98)
0.04
10.8
(1.30)
0.06
ND

4.62
(1.61)
0.04
14.0
(1.61)
0.08
ND

3.91
(2.17)
0.03
12.9
(1.45)
0.07
ND

ND

3.01
(1.51)
0.04
6.39
(1.51)
0.11
ND

ND

ND

ND

ND

ND

ND

40.0

44.9

26.4

79.6

43.0

ND

ND

4.23^
(2.59)
0.07
ND

3.60
(1.46)
0.04
7.63
(1.46)
0.13
2.08^
(1.46)
0.07
44.2
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RL
BAF
Diltiazem
RL
BAF
Fluoxetine
RL
BAF
Gemfibrozil
RL
BAF
2-Hydroxyibuprofen
RL
BAF
Ofloxacin
RL
BAF
Sulfamethoxazole
RL
BAF
Thiabendazole
RL
BAF
Triclocarban
RL
BAF
Trimethoprim
RL
BAF
Alkylphenols
NP1EO
RL
BAF
NP2EO
RL
BAF
4-NP
RL
BAF
4n-OP
RL
BAF

(0.521)
0.57
6.26
(0.520)
0.32
14.0
(4.16)
1.13
2.27^
(2.08)
0.04
14.2^
(10.4)
0.09
1.89*
(1.72)
0.52
9.97^
(7.90)
0.10
14.1
(1.30)
3.36
3.50
(1.04)
2.95
3.92
(1.30)
0.26
8.51^
(3.62)
0.95
4.75^
(1.64)
1.14
159*
(1.64)
3.23
16.7^
(1.64)

(0.659)
0.64
11.2
(0.732)
0.57
28.7
(1.61)
2.31
ND

(0.581)
0.38
3.14
(0.775)
0.16
9.57
(1.45)
0.77
ND

(1.03)
0.57
8.56
(0.967)
0.43
50.9
(2.59)
8.18
ND

ND

ND

ND

2.4^
(1.61)
0.66
ND

ND

21.4
(1.61)
5.10
3.20
(1.29)
2.69
2.37^
(1.61)
0.16

19.1
(1.61)
4.55
1.91^
(1.16)
1.61
2.35^
(1.45)
0.16

17.7
(2.76)
1.97
44.8
(2.27)
10.80
451*
(2.27)
9.16
8.65*
(2.27)

4.80*
(2.61)
0.53
5.12^
(1.85)
1.23
203*
(1.85)
4.12
18.8^
(2.02)

ND

5.21
(2.59)
0.24
ND

(0.584)
0.32
8.73
(0.425)
0.44
24.1
(1.46)
3.87
2.45^
(2.33)
0.03
ND

(0.602)
0.31
4.85
(0.552)
0.25
12.7
(1.51)
2.04
ND

ND

ND

ND

ND

ND

ND

ND

12.8^

20.7

(11.1)

(7.91)

ND

ND

ND

ND

ND

4.65^
(2.51)

ND

31.9
(2.59)
7.01
ND

2.37
(1.07)
0.02
16.7
(1.46)
3.67
ND

10.8
(1.51)
2.37
ND

1.40*
(1.39)

ND

ND

ND

27.9
(2.59)
0.24

23.3
(1.46)
0.20

18.3
(1.51)
0.16

ND

ND

6.20*
(4.22)

9.69^
(2.00)

ND

11.2^
(3.00)

2.97*
(1.56)

7.48
(3.85)
1.52
264*
(3.85)
6.52
16.1^
(3.85)

13.2
(2.00)
2.68
291*
(2.00)
7.19
5.13*
(2.00)

17.6
(2.08)
3.57
201*
(2.08)
4.96
11.7^
(2.08)

13.9
(1.79)

4.79^
(1.33)

211*
(1.79)

151*
(1.33)

15.4^
(1.79)

9.97^
(1.33)

Table 3.7 Results of power analysis for each variable from WWTP1 and WWTP2 based
on three treatments (0%, 10%, and 25% effluent). Analysis was based on one-way
ANOVA for the week 12 sample measurements. Cohen’s f was used to calculate effect
size from the results of the experiment.
Response Variable

One-way ANOVA
Results

Cohen's f

Recommended
Sample Size
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WWTP1
Change in mass
Change in height
Wet tissue weight
Condition Index
Algal Clearance Rate*
WWTP2
Change in mass
Change in height
Wet tissue weight
Condition Index
Algal Clearance Rate*

F2,9 = 0.05, p=0.96
F2,9=0.42, p=0.66
F2,9=0.57, p=0.59
F2,9= 0.62,p=0.56
F2,6=10.27, p=0.01

0.10
0.30
0.35
0.37
1.86

322
37
27
24
2

F2,9=1.16, p=0.36
F2,0=3.09, p=.095
F2,9=1.77, p=0.22
F2,9=0.88 ,p=0.44
F2,6=1.09, p=.40

0.51
0.83
0.63
0.44
0.60

13
6
9
17
10

3.4 Discussion
Experimental exposure to environmentally relevant concentrations of wastewater
effluent had a significant effect on oyster shell growth. Control oysters experienced more
shell growth than those exposed to effluent from WWTP1, indicating that effluent
suppressed shell growth. This effect was not evident in WWTP2, where all treatments
experienced significant shell growth. The pattern here could be due to presence of other
harmful compounds that we didn’t test for in WWTP1 effluent or presence of two
antibiotics in WWTP1 effluent that were not in WWTP2 effluent. In both treatment
plants, oysters in the 10% treatment experienced marginally less shell growth than those
in the 25% treatment. These patterns demonstrate that lower effluent concentrations may
affect shell growth more than higher concentrations, emphasizing the importance of
including lower concentrations in toxicological studies. Other lab experiments with
contaminants of emerging concern have observed non-monotonic responses, where the
measured effect does not increase with concentration, including two compounds detected
in effluent in the present study (4-NP and BPA) (Fagin 2012). Condition index decreased
over time from week 0 to 6, and then remained steady through week 12, and was not
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affected by treatment. Oysters lost weight from week 0 to 6, and then recovered slightly
from week 6-12, never reaching their original weight. It is important to note that the
amount of shell height growth was low overall (max of 6 mm) and condition index and
mass decreased over time in all treatments, indicating that all oysters, including controls,
were likely experiencing stress and possibly food limitation. This may be attributed to
tank conditions or food availability. Though the age of the oysters is unknown, their
height range (52-119 mm) indicates that many were below market size of 4-6 inches
(101-152 mm) (Galtsoff 1964). In good conditions, Pacific oysters continue to grow
regardless of age or size (Galtsoff 1964), yet low incidence of mortality indicates that
tank conditions were sufficient for survival, though apparently not optimal for growth or
oyster health. Smaller tank environments are more difficult to keep stable and healthy for
longer periods of time and though we performed frequent water changes, there may have
been inadequate space and replenishment of clean water. Two other lab experiments
involving this species reported lack of shell growth with low food quality and quantity
being possible reasons (Di Poi et al. 2016; Mottier et al. 2015). In both studies, they fed
oysters one species of cultured algae, Isochrysis galbana (T-Iso clone), and claimed that
this may only be sufficient for oyster spat, and not nutritive enough for adults. In the
present study, oysters were fed “Shellfish Diet 1800,” which consists of five marine
microalgal species and has been shown to provide proper nutrition in oyster rearing
(Reed Mariculture n.d.). Therefore, it is unlikely that food quality was poor but possible
that improper mixing in the small tanks led to insufficient food availability preventing
adequate feeding. Effects of this ambient stress on oyster fitness may have overshadowed
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impacts of effluent exposure, and reduced the ability to detect significant results.
Additionally, results of the power analysis indicate that the lack of effects observed for
many responses may also be due to low sample size, rather than effluent having no
effects on oysters at these concentrations.
With the exception of one incidence, we did not detect a significant change in
oyster feeding rate after exposure to wastewater effluent. There was a higher feeding rate
in the 10% exposure than in the control and 25% treatment from WWTP1 (Figure 3.4),
though the pattern was not evident in WWTP2 exposures and diminished in the next
sampling trial (week 7). Feeding rate data were noisy and inconsistent and therefore
should be interpreted with caution. These errors are likely due to poor mixing in the tanks
from using small, slow flowing filters and potentially inaccurate cell counts from the
Coulter counter. The filters we employed were designed for the tank size used (2.5
gallons), but did not provide sufficient flow for proper mixing, which is important for
both food delivery to study organisms and algal cell count (Gray and Langdon 2018). It is
advised that future studies consider tank mixing when designing feeding rate trials.
Previous studies have reported similar outcomes in lab experiments where Pacific
oysters were exposed to anthropogenic contaminants and experienced a lack of effects
ranging from cellular to organism levels. Revel et al. (2020) exposed oysters to three
concentrations of microplastics with no significant effects on a range of physiological
factors, including feeding rate, condition index, oxidative stress, tissue alteration, and
DNA damage. A study that exposed Pacific oysters to three concentrations of fluoxetine
(anti-depressant) found some significant responses, but overall concluded that fluoxetine
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had minimal effects on physiological functions of oysters at environmentally relevant
concentrations (Di Poi et al. 2016). Adult oysters can survive a wide range of
environmental conditions (Pauley et al. 1988) and therefore may be more resistant to
stressors- including chemical stressors - than other organisms. There is evidence of this at
the cellular level whereby a study that compared cellular level biomarker responses to
beta-blocking pharmaceuticals determined oysters were less sensitive than clams in
measured biomarkers (Khan et al. 2018).
It is possible that effects occurred at biological levels - such as molecular,
cellular, and tissue - not measured in this experiment. Two experiments that measured
Pacific oyster responses to environmentally relevant concentrations of herbicides at
multiple biological levels only identified effects at levels below the whole organism
(Akcha et al. 2016; Mottier et al. 2015). Mottier et al. (2015) exposed oysters to three
concentrations of glyphosate for 56 days and found no significant differences in organism
level responses (condition index, growth, and reproduction). Yet, a few significant
responses were identified at the molecular level (gene expression). Similarly, Akcha et al.
(2016) measured molecular, cellular, and tissue responses to diuron after 7 days and
reported significant effects at molecular (e.g., gene expression) and cellular levels, but no
effects at the tissue level (e.g., gametogenesis course, sex ratio, reproductive effort).
Several recent studies that only measured effects of contaminants on oysters at lower
biological levels (molecular, cellular, tissues) consistently identified effects (e.g., Serrano
et al. 2015; Park et al. 2016; Bebianno et al. 2017; Khan et al. 2018). All of these studies
had short exposure durations (1-7 days) which may not allow for detecting changes at the
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organismal level, but demonstrate that oysters may, indeed, be susceptible to pollution
with detectable effects at molecular, cellular and tissue levels. Unfortunately, it is
challenging to interpret the implications of these effects for organism, population, and
ecosystem level policy and management decisions.
To our knowledge, only two other lab studies have evaluated effects of direct
exposure to WWTP effluent on Pacific oysters. Both had one effluent exposure level,
lasted 36-48 hours, and detected alterations in gene expression (Flores-Nunes et al. 2015;
Medeiros et al. 2008). Due to the short duration and lack of organism level effects
measured, it is difficult to compare our results directly. Additionally, two lab experiments
have examined effects of effluent on other bivalve species. A study conducted in Spain
exposed Manila clams (Ruditapes philippinarum) to five concentrations of effluent
ranging from 3.15-50% (Díaz-Garduño et al. 2018). Effects on cellular biochemical
responses were identified in several treatments, including very low concentrations (3.1212.5%) and many of these effects were reduced following tertiary treatment. Another
study showed that exposure to urban WWTP effluent for seven days altered metabolism
at the molecular level in male marine mussels (Mytilus galloprovincialis) (Dumas et al.
2020). These studies demonstrate that effluent has the potential to significantly affect
physiological function in marine bivalves, but these effects are variable, occur at multiple
biological levels, and appear to be species and concentration specific. In addition,
because effluent constitutes an unknown mixture of compounds, there could be
simultaneous synergistic and antagonistic effects, increasing the complexity of
interpreting results (e.g., Almeida et al. 2018). More research is needed to examine whole
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effluent toxicity on bivalves using a multiple biomarker approach under environmentally
relevant conditions.
We found a broad array of PPCPs in effluent from two coastal WWTPs. PPCP
detections and concentrations in effluent were relatively similar among the two treatment
plants. With the exception of six compounds (caffeine, dehydronifedipine, glyburide,
miconazole, roxithromycin, sulfamethazine), the same PPCPs were detected in effluent
from both WWTPs and the average combined concentrations of PPCPs were statistically
equivalent. All of these PPCPs have been identified in coastal effluent in previous work
(e.g., Hedgespeth et al. 2012; Vidal-Dorsch et al. 2012; Lara-Martín et al. 2014; Meador
et al. 2016; Biel-Maeso et al. 2018). Therefore, the similarity in detections and
concentrations among the two treatment plants could be due to these compounds being
commonly used and thus found in effluent across locations. Also, both treatment plants
use the same type of secondary treatment, which would likely result in similar removal
rates. Caffeine was only found in WWTP2, but 1,7-dimethylxanthine, a caffeine
metabolite, was detected in WWTP1, indicating that caffeine was likely present and may
have been broken down more effectively in this treatment plant. The other five unique
compounds were found at low concentrations (<9 ng/L) which may be due to lower usage
within the surrounding population, or different removal efficiencies at each WWTP.
Alkylphenols were detected in WWTP effluent, with 4-NP and 4-NP2EO in both
WWTPs, and 4-NP1EO in WWTP1 only. Nonylphenol ethoxylates with more polar
groups, indicated by the number in the abbreviated name, are more hydrophilic (Priac et
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al. 2017), which could explain the lack of 4-NP1EO in WWTP2. It is also possible that
all of the NP1EO in WWTP2 was transformed into 4-NP.
The concentrations reported here in effluent are generally lower than previous
studies characterizing PPCPs and alkylphenols in effluent. However, it is important to
note that our samples were comprised of a mixture of 24-hour composites collected over
12 weeks, and most studies report single 24-hour composite effluent samples. We
compared concentrations to a study in Puget Sound, WA that reported effluent
concentrations for all but one of the compounds in the present study (sulfamethazine)
(Meador et al. 2016). Of the 33 chemicals detected, 25 were lower than the minimum
concentration in Meador et al. (2016). Notably, NP1EO and NP2EO were approximately
30 and 100 times lower in this study, respectively. This is expected given the difference
in treatment plant discharge size and surrounding populations for these two studies. The
permitted discharge capacity for the WWTP in Puget Sound was 60 mgd, compared to
>1-2 mgd in this study, and Puget Sound is more populated than the Northern OR coast.
Five compounds were within the same range, and the pharmaceuticals,
hydrochlorothiazide and warfarin, had higher concentrations in our study than Meador et
al. (2016). Notably, hydrochlorothiazide was three times higher in the present study.
Twenty of the compounds in this study were detected in previous WWTP effluent studies
with higher discharge capacities and larger surrounding populations, and as expected,
most concentrations reported here are lower, though a few are within the same
concentration range (Biel-Maeso et al. 2018; Hedgespeth et al. 2012; Kostich et al. 2014;
Lara-Martín et al. 2014; Meador et al. 2016; Vidal-Dorsch et al. 2012). Notably,
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carbamazepine was within the same range and higher in WWTP1 than other studies. This
drug is frequently detected in effluent and water due to its hydrophilicity, with reported
WWTP removal rates of 18% (Brose et al. 2019) and 42.3% (Lara-Martín et al. 2014).
Several PPCPs found in the WWTP effluent were detected in oyster tissues,
indicating that oysters accumulated contaminants from the surrounding water. Ten of the
13 detected PPCPs have moderately high log Kow values (>2) which means they are more
likely to accumulate in organism tissue. Ofloxacin and sulfamethoxazole, which have log
Kow values less than one, had few detections and low concentrations. Trimethoprim (log
Kow = 0.9) was detected in all wastewater exposed oyster samples, with high
concentrations in WWTP2 oysters. This could be explained by the high concentration of
this drug in WWTP2 effluent. Overall, oysters exposed to effluent from WWTP1 had
more detections than those exposed to WWTP2 effluent, but only by five compounds.
This is contrary to the expected pattern since WWTP1 has a lower discharge capacity and
serves a smaller population. For most PPCPs, higher tissue concentrations and detection
frequency were associated with higher concentrations in the effluent of the corresponding
WWTP.
Three PPCPs were detected in one control sample (2-hydroxy-ibuprofen,
sulfamethoxazole, thiabendazole) and one of these was detected in the second control
sample (2-hydroxy-ibuprofen). Sulfamethoxazole and thiabendazole concentrations were
very close to the detection limit, and thiabendazole was lower than the lab blank
concentration. However, 2-hydroxy-ibuprofen was well above the detection limit. Several
measures were taken to reduce contamination, but it is impossible to completely avoid.
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Additionally, PPCPs can be exhaled onto samples, and have been found in drinking water
(Loraine and Pettigrove 2006), thus some could be present in the ambient artificial
seawater used in the experiment. Though the source of these PPCPs is unknown, the few
detections and low concentrations compared to effluent exposed oysters indicate that
contamination and exposure to PPCPs in the controls was minimal.
Four alkylphenols were detected in oyster tissue samples, one of which was not
detected in effluent (4n-OP). Of the 32 reported concentrations in tissues, 13 were less
than the lab blank, and 12 were less than two times the lab blank or reporting limit,
indicating that alkylphenols accumulated in oysters at very low levels. Only NP1EO and
NP2EO had concentrations outside of this range, with NP2EO having the most detections
in WWTP2 and the highest concentration in WWTP1 exposed oysters. All four
alkylphenols were detected in controls and concentrations were similar to wastewater
exposed oysters. These compounds are frequently detected in lab blanks and controls
because they can be found in common lab equipment and products (Salgueiro-González
et al. 2017). For example, alkylphenols are associated with plastics which can be a major
source of lab contamination (Salgueiro-González et al. 2017). Given the low
concentrations in effluent and the ubiquity of these compounds, it is possible that
alkylphenol concentrations in tissues may simply represent lab contamination.
We detected several compounds with documented effects on organisms.
Bisphenol A (BPA) and 4-NP are known endocrine disruptors and show evidence of nonmonotonic responses in mammals (Bulayeva and Watson 2004; Jenkins et al. 2011).
Previous studies have demonstrated their effects on marine organisms as well. For

100

example, BPA and 4-NP negatively affected marine mussel larval development after 48hour exposure to environmentally relevant concentrations (Fabbri et al. 2014). Significant
effects were identified for 4-NP at the same concentration we found in effluent (100
ng/L). The antimicrobials triclosan and triclocarban are known as “emerging endocrine
disruptors” (Olaniyan et al. 2016; Vimalkumar et al. 2019) and though their use has been
widely reduced due to US regulations limiting branding of products containing
antimicrobials (Brose et al. 2019), they are still detected in effluent and environmental
matrices. Triclosan has been shown to induce lysosomal membrane destabilization, an
indicator of cellular stress, in two species of marine mussels (Canesi et al. 2007; Cortez et
al. 2012). One of these studies found significant effects at a concentration of 12 ng/L
(Cortez et al. 2012), which is lower than the concentrations found in effluent in this
study. Several pharmaceuticals have shown significant negative effects on marine
mollusks at environmentally relevant concentrations. The antibiotics sulfamethoxazole
and trimethoprim, which are frequently prescribed together, reduced marine microalgal
and mussel growth after 12-week exposure (Teixeira 2016; Teixeira and Granek 2017).
Similarly, marine mussel growth, reproductive potential, and feeding rate were
suppressed by long-term exposure to fluoxetine, an antidepressant (Peters and Granek
2016). Fluoxetine exposure can also lead to foot detachment in marine snails (Fong and
Molnar 2013) and induce spawning in clams (Honkoop et al. 1999). The anticonvulsant,
carbamazepine, lowered marine mussel gonadosomatic and condition indices after 28
days of exposure (Oliveira et al. 2017). Further effects of pharmaceutical and personal
care products on marine organisms have been reviewed by (Fabbri and Franzellitti 2016;
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Mezzelani et al. 2018; Prichard and Granek 2016). In the present study, trimethoprim,
fluoxetine, and carbamazepine were detected in every tissue sample exposed to 25%
effluent, with few effects observed. Given these examples in the literature and detections
in effluent and tissue in the present study, we hypothesize that there may have been
sublethal sub-organismal effects that we did not measure or detect. Additionally, other
marine organisms exposed to this concentration of effluent may experience sublethal
effects not detected in the oysters studied here.
PPCP and alkylphenol detections in effluent and accumulation by oysters
emphasize the need for monitoring, environmental risk assessment, and pollution
reduction. In the US, pollutants in waterways are assessed and regulated through the
Clean Water Act, using water quality criteria that specify maximum allowed
concentrations of contaminants in surface water based on potential effects on wildlife.
With the exception of nonylphenol, PPCPs do not yet have set water quality standards
(US EPA 2015). In 2008, the US Environmental Protection Agency (EPA) drafted
recommendations for developing water quality criteria for contaminants of emerging
concern, including PPCPs, but these criteria have yet to be developed (US EPA 2008). In
2007, Oregon passed Senate Bill 737 in an effort to identify and assess persistent
pollutants in WWTP effluent. This bill required the development of a priority pollutant
list (including some PPCPs), testing of effluent from 52 large municipal wastewater
treatment plants, and development of pollution reduction plans for compounds detected
above Plan Initiation Levels (Hope et al. 2012). Three pharmaceuticals detected in a
majority of Hope et al. (2012) samples (sulfamethoxazole (92%), carbamazepine (82%),
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and diphenhydramine (76%) were found in this study as well. Two PPCPs were included
in the Plan Initiation Level list, triclosan and roxithromycin, but the maximum levels
were in the ug/L range (OR DEQ personal communication Oct. 2020), higher than
concentrations detected in this study. Improvements to wastewater treatment technology
are one option for reducing PPCP loadings to the environment, particularly by adding
tertiary treatment. Removal efficiencies are 20-60% higher using tertiary compared to
secondary treatment (Rout et al. 2021) and tertiary treatments can reduce overall toxicity
of effluent to aquatic organisms (Schlüter-Vorberg et al. 2017). Tertiary treatment is not
widely implemented in the US, and is costly, presenting a huge barrier to reducing these
pseudo-persistent compounds. Improper disposal of leftover pharmaceuticals by flushing
and throwing in the trash can also pollute waterways and there is a need to implement
convenient and safe disposal methods to reduce pollution (Ehrhart et al. 2020). Policies
that prioritize funding for enhancing wastewater treatment and proper drug disposal,
among other interventions, and identification of long-term effects of mixtures are
necessary in moving forward and addressing these emerging pollutants in the
environment.
There were several practical limitations in this study that affected the design, and
potentially the results. Here we explain these limitations and propose an improved
experimental design to address some of these issues. The major obstacle to this
experiment was balancing available resources and adequate replication. With limited
aquaria in the lab and composite effluent provided by the WWTPs, we adjusted the
number of replicate tanks, tank size, filters, and number of oysters per tank. We also had
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very limited funding to analyze effluent and tissues, resulting in compositing of samples
at one time point, and only analyzing oysters exposed to one concentration (25%). We
suggest that future experiments utilize larger tanks w/proper filtration and mixing,
increase replication of tanks and oysters, and analyze effluent and tissue samples at each
sampling point and concentration, as funding allows. Our power analysis indicated that
sample sizes of 6-10 tanks could be adequate for most response variables. To obtain
enough effluent for more replication, combining effluent from multiple treatment plants
or purchasing a composite sampling system that can collect more effluent per hour, are
some potential options. These adjustments would require ample funding and resources
and may help with designing future studies with a more ideal setup than ours.

3.5 Conclusion
In this study we evaluated effects and accumulation of PPCPs in Pacific oysters
exposed to coastal WWTP effluent. Several PPCPs were identified in effluent from two
small coastal WWTPs with low surrounding populations, providing occurrence data for
populations that represent this region. Oysters exposed to 25% effluent from both
treatment plants accumulated PPCPs in their tissues over the 12-week period; and
effluent from the smaller WWTP at both concentrations (10% and 25%) suppressed
oyster shell growth. Over time, all oysters experienced reduced mass and condition,
indicating that stressful tank conditions may have overshadowed other potential effects
from effluent exposure. This study provides important insights on uptake of PPCPs by
marine bivalves and complexity in evaluating toxic effects of mixtures, which represent
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environmentally relevant conditions. We recommend that future studies increase
replication, take more measures to decrease ambient stress in tank environments, and
analyze for contaminants at multiple time points and concentrations.
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Abstract
Production and use of pharmaceuticals in the United States is high and continues
to grow. This combined with poor wastewater removal rates for drugs in excreted waste,
and improper pharmaceutical disposal leads to the presence of pharmaceuticals in freshand marine waters and wildlife. In the United States, safe drug take-back boxes, or
dropboxes, were established in pharmacies after federal legislation passed in 2014,
allowing for year-round safe collection of leftover pharmaceuticals. The overarching
objective of this work was to identify opportunities for improving access to proper
pharmaceutical disposal. We assessed consumer behavior regarding drug disposal choices
and knowledge of dropboxes at pharmacies, investigated pharmacist recommendations
and attitudes towards leftover drug disposal, and compared responses at locations with
and without dropboxes. We also explored obstacles to dropbox adoption and usage. We
found that customer awareness of dropboxes as well as knowledge about risks of
improper disposal are low, however awareness was greater at pharmacies with
dropboxes. Additionally, pharmacists at dropbox locations were more consistent in their
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messaging to customers, more likely to recommend proper disposal methods, and more
supportive of drug take-back programs. Through the focus group, we learned that further
consumer education would overwhelm the capacity of the existing dropboxes. Based on
our findings, we recommend solutions to improper disposal focus on legislation
mandating dropboxes at pharmacies and pressure on the pharmaceutical industry to fund
proper disposal of unused pharmaceuticals.

4.1 Introduction
4.1.1 Leftover Drug Disposal Estimates
Pharmaceutical production constitutes a multi-billion-dollar industry in the United
States (US), with total spending of $424.8 billion in 2015 (Aitken 2016). The number of
dispensed prescription drugs has increased by about one to two percent each year and
reached 4.37 billion in 2015 (Aitken 2016). From 2008-2016, the US Food and Drug
Administration approved an average of 31 new drugs per year (U.S. FDA CDER 2017).
According to a study that estimated annual wastage costs from unused medication in
consumer homes, approximately 1.6 billion prescription medications and $117.4 billion
worth of drugs are disposed of annually in the US (Law et al. 2015). However, the actual
number and economic value of unused medicines in the US is unknown. Consumed and
wasted drugs enter the aquatic environment through two major pathways: excretion from
the body of unmetabolized compounds and disposal of unused medications via sewage
and landfills (Gaw et al. 2014). Pharmaceuticals and their metabolites are not completely
removed by wastewater treatment plants before effluent is released to rivers, estuaries,
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and coastal waters (Vidal-Dorsch et al. 2012) and can leach into groundwater from
landfill sites (Slack et al. 2005). Limited data on disposed quantities has led to
skepticism about disposal being a significant source of pollution in comparison to
excretion (Ruhoy and Daughton 2007). However, modeling, consumer drug disposal
estimates, and wastewater concentration tracking research continue to suggest and
highlight that disposal contributes to environmental presence (e.g., Stoddard and Huggett
2015, Kümmerer 2010, Daughton and Ruhoy 2009, Bound and Voulvoulis 2005). For
example, estimates from 2005 coroner reports in Clark County, Nevada, indicate that
17.9 metric tons of drugs are likely disposed of annually in the US from homes of
deceased individuals alone (Ruhoy and Daughton 2007). In 2005 there were
approximately 267,500 deaths in the US that would require a coroner report (Ruhoy and
Daughton 2007). Most of these drugs (92% in Clark County) are flushed down the toilet
at the residence (Ruhoy and Daughton 2007). Additionally, the volume of drugs collected
at drug take-back events demonstrates that large quantities are being stored and disposed
of by consumers, constituting a likely source of pollution. Since the fall of 2010, the US
Drug Enforcement Administration has collected a total of 5,908 tons of unwanted drugs
at bi-annual take-back events across the US (Martin 2019), which has a population of
329.1 million people. In September 2015, alone, the most recent event for which data are
available, 4.5 tons of leftover medications were collected in Oregon (population of 4.02
million) through the annual drug take-back event (Oregon Health Authority n.d.). Studies
on consumer disposal have reported that up to 94-97% of consumers have leftover drugs
in their home (Abahussain et al. 2006, Kusturica et al. 2012).
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4.1.2 Drugs in the Environment
Pharmaceuticals and their metabolites are consistently detected in marine and
aquatic environments and species worldwide (Arpin-Pont et al. 2016, Hughes et al.
2013). Since medications are consumed regularly and therefore continually discharged
from municipal wastewater year-round, they have been deemed “pseudo-persistent” in
the environment (Daughton and Ternes 1999). Exposure to environmentally relevant
concentrations of some pharmaceuticals has demonstrated negative effects on biota. For
example, the antidepressant, fluoxetine (Prozac), represses growth, feeding rate, and
reproductive output in marine mussels (Peters and Granek 2016) and antibiotics such as
trimethoprim and sulfamethoxazole affect growth of algal species consumed by bivalves
(Teixeira and Granek 2017). Reducing pharmaceutical pollution into aquatic and marine
systems will require multiple interventions, including wastewater treatment
improvements, increased proper disposal, and changes to drug prescription practices and
drug formulation (Kümmerer 2010, Daughton and Ternes 1999). While prioritizing
upgrading of wastewater treatment plant technology would likely lead to the highest
reduction in pharmaceutical pollution, this is costly and infeasible for most areas in the
US to implement in the short-term. Proper disposal is a feasible option to reduce partial
loadings to the environment and provides public health benefits (Kümmerer 2010).
Understanding pharmaceutical disposal guidelines and resultant practices can shed light
on the needs and potential effectiveness of this intervention.
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4.1.3 Drug Disposal Recommendations
In the US, recommendations for disposal of leftover medications are provided by
the following federal agencies: Food and Drug Administration (FDA), Drug Enforcement
Administration (DEA), and Environmental Protection Agency (EPA). Recommendations
vary among agencies and include methods that pose threats to the environment (Table
4.1) such as putting in the trash and flushing down the toilet/sink (for harmful substances;
US FDA), as well as environmentally safer methods including taking to a semi-annual
take-back event organized by the US DEA (U.S. FDA 2019). While the US FDA
recommends flushing, the US EPA discourages flushing (US EPA 2015) and the US
DEA directs customers to the FDA and EPA websites for household disposal (US DEA
n.d.a).
Table 4.1 Pharmaceutical disposal recommendations from federal agencies in the United
States.
Place in trash
Flush down sink/toilet
Take to semi-annual drug take-back event
Place in trash with undesirable substance
Direct to other federal websites for
instructions

Food and Drug
Administration
✓
✓
✓

Drug Enforcement
Agency

Environmental
Protection Agency

✓

✓
✓

✓

Many of the federally recommended disposal options pose environmental and public
health risks. Flushing of drugs contributes directly to contamination of waterways as
many pharmaceuticals have low removal rates in wastewater treatment plants (Vieno et
al. 2007). Drugs in landfills can leach into groundwater, causing contamination over
longer periods of time (Gaw et al. 2014). Storing medications at home for a drug takeback event increases risk of illegal or accidental ingestion (Stewart et al 2015).
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4.1.4 Drug Take-Back Boxes
Drug take-back boxes, or dropboxes, located within pharmacies are one option for
increasing safe disposal rates. Until recently, pharmacies in the United States were not
permitted to collect unused medication from customers. The only safe disposal method
was to take drugs to a law enforcement agency (e.g., police station) or a bi-annual drug
collection event (US DEA 2014). Federal legislation in 2014 allowed retail pharmacies to
become authorized collectors of unused pharmaceuticals and establish dropboxes within
the store to collect leftover medications year-round (US DEA 2014). Pharmacies
throughout the US have taken advantage of this opportunity. For example, Walgreens
currently has dropboxes in 1,500 locations throughout 46 states (Walgreens 2019).
Dropbox contents are collected by a DEA-authorized vendor and are typically incinerated
or disposed of as hazardous waste, considered the most environmentally sound disposal
methods available (US DEA 2014). Improving proper disposal of pharmaceuticals with
dropbox usage could provide a convenient, year-round system to alleviate public health
concerns and address environmental contamination. Such contamination is evident by
occurrence of drugs in landfill leachate, where the known source is landfill disposal. In
2010, leachate from three landfills in Maine that only receive household waste contained
pharmaceutical concentrations of 117,000 ng/L for acetaminophen (pain reliever), 169
ng/L for ciprofloxacin (antibiotic), and 57 ng/L for cocaine (Lubick 2010). These
concentrations are comparable to those found in treated municipal wastewater effluent
(Meador et al. 2016, Fent et al. 2006), which is a demonstrated major source of
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pharmaceuticals to the environment due to low removal rates of many drugs during
treatment (Jones et al. 2005). Similar concentrations in leachate indicate that disposed
drugs may have an impact on aquatic pollution, and proper disposal could be effective in
reducing environmental contamination.

4.1.5 Pharmacist Communication: Drug Use and Disposal
Pharmacists in retail pharmacies play an important role in the dissemination of
customer medication use and disposal information. Research demonstrates that
pharmacists can increase efficient use of drugs through patient education and reduction of
over-prescription (Singleton et al. 2014), indicating their potential to increase safe drug
disposal through communication with their customers. Current research shows that
communication about drug disposal between pharmacists and customers occurs variably.
In a study in which 142 California pharmacists reported frequency of giving medication
disposal information to patients, 13.6% said they gave instructions once a year, 50.7%
said once a month, and 23.6% said every week (Tai et al. 2016). Yet only 15.9% of
pharmacists in the same study had knowledge of all appropriate disposal methods (Tai et
al. 2016). Interventions to improve frequency and accuracy of pharmacist communication
with customers require improved overall knowledge by pharmacists regarding drug
disposal to inform recommendations (Singleton et al. 2014).

4.1.6 Study Objectives
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Given the recent changes in authority to allow dropboxes in retail pharmacies, we
examined customer disposal behavior, pharmacist recommendations and attitudes
regarding disposal of leftover drugs in the context of dropbox presence, and proper drug
disposal implementation challenges. We addressed the following objectives:
1) Assess customer disposal practices for leftover drugs and awareness of dropboxes
in retail pharmacies.
2) Investigate pharmacist recommendations and attitudes regarding leftover drug
disposal.
3) Compare customer and pharmacist responses at pharmacies with and without
dropboxes.
4) Explore obstacles to dropbox adoption and usage and identify information to
provide to legislators, pharmacies, and/or the public to increase availability,
awareness, and use of dropboxes.
This research was undertaken to identify potential outreach and/or policy decisions to
improve proper drug disposal and reduce environmental and human impacts from current
disposal methods.. Knowledge of disposal patterns when dropboxes are available can
identify their effectiveness in improving proper drug disposal, which in turn, may
improve public health outcomes (e.g., reduction in accidental or intentional ingestion of
unprescribed pharmaceuticals) and reduce pollution.

4.2. Methods
4.2.1 Study Area
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Research was conducted in the Portland metropolitan area, which includes the
major cities of Portland, Beaverton, and Hillsboro, OR and Vancouver, WA, and the
surrounding suburbs in seven counties (Clackamas, Columbia, Multnomah, Washington,
Yamhill, Clark, and Skamania) (OMB 2006). The most recent census data show a
population size of 2,478,996 for this area (US Census Bureau 2018). Our study took
place within the four quadrants of the city of Portland (Southwest, Southeast, Northwest,
Northeast) and the following surrounding suburbs in Oregon: Tigard, Beaverton,
Gresham, Hillsboro. Of the roughly 500 pharmacies in this area, approximately 30 (~6%)
are registered as authorized collectors with dropboxes (US DEA n.d.b).
4.2.2 Surveys and Interviews
This research was approved by the Institutional Review Board (IRB) at Portland
State University and consent was obtained from all participants prior to conducting
surveys and interviews. From October 2017 to February 2018, we conducted interviews
with pharmacists and surveys with customers at retail pharmacies. We identified
pharmacies with and without onsite dropboxes in each quadrant of the city and four
surrounding suburbs using Google maps and the DEA registry of authorized drug
collectors. Pharmacies were randomly chosen with 1-5 pharmacies in each quadrant and
suburb. This resulted in a list of 40 pharmacies, 14 with dropboxes and 26 without
dropboxes. At each pharmacy, we contacted the pharmacist or pharmacy technician over
the phone and requested a five-minute interview. If the pharmacist agreed to an
interview, we asked the following five questions about their recommendations for
leftover drug disposal and their attitudes about drug take-back programs:
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1. What is your role in the distribution of pharmaceuticals to patients?
2. What do you typically tell your patients to do with their leftover pharmaceuticals?
3. What do you know about your employer’s policies regarding drug take back
programs?
4. What are your attitudes regarding drug take-back programs? What do you see as the
pros and cons?
5. From your perspective, what are the general attitudes of your co-workers regarding
drug take-back programs?
During each interview, we took detailed notes while the pharmacists were speaking that
were later entered into a spreadsheet. Responses to each question were reviewed and
thematically coded.
At the end of the interview, we asked permission to visit the pharmacy and
conduct surveys with customers. Some pharmacists granted permission, some refused,
and others directed us to the store or pharmacy manager to obtain permission. At
pharmacies where we were permitted to distribute onsite surveys, we identified our
sample by standing outside of the store with the pharmacy (e.g., Walgreens) and asking
entering and exiting customers to fill out anonymous paper surveys about leftover drug
disposal practices. Only participants that were 18 years or older were given the survey.
The survey consisted of 19 multiple choice questions organized into the following topics
(Figure C2): customer leftover drug disposal practices, recommendations received from
pharmacists/doctors/nurses for medication disposal, obstacles to using a drug take-back
box, knowledge of the nearest drug take-back box, importance of disposing of drugs
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properly, and demographic information. Questions generally instructed participants to
choose one answer. Two questions requested a follow up open-ended response if the
participant answered yes: 1) what is the location of the drug take-back box nearest to
you? and 2) why is it important to dispose of drugs properly? When appropriate, multiple
choice questions included an “other” option with a blank space for a written response.
We entered all answers from customer surveys into an electronic Google form, which
compiled responses into a spreadsheet that was reviewed for consistency and accuracy
before analysis. R Studio version 3.4.1 and Microsoft Excel were used to calculate
summary counts and percentages for each question following the methods of similar
studies that reported disposal rates (Law et al. 2015, Wieczorkiewicz et al. 2013,
Kusturica et al. 2012, Seehusen and Edwards 2006, Abahussain et al. 2005). We
compared responses of customers that took the survey at locations with and without
dropboxes, though customers may have encountered dropoxes at other locations
previously. Due to the small sample size (n=129), data analysis beyond summary
statistics was not employed.

4.2.3 Focus Group
On February 21, 2018, we facilitated a focus group consisting of individuals with
expert knowledge on pharmaceutical disposal practices, dropbox implementation at
pharmacies, and current legislation efforts. The overarching goal of the focus group was
to explore obstacles for pharmacies to establish drug take-back boxes and obtain input on
what type of information would be helpful to provide to pharmacies and/or the public to
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increase the presence, awareness, and use of dropboxes. We identified potential
participants by contacting pharmacy managers who had given permission for a site visit
and through discussion with medical professionals involved in project development.
Some invitees put us in touch with other organizations that would be interested and able
to provide relevant information in the focus group. We contacted a total of ten individuals
via email to assess their interest in participating, and sent an official invitation to seven
people. The two-hour evening focus group occurred at Portland State University and
included an overview presentation of the research context and preliminary interview and
survey results, and a facilitated discussion of the following questions:
1. What are the challenges to improving proper disposal of leftover drugs?
2. What did you/do student pharmacists learn in your/their training about leftover
drug disposal?
3. In your experience, what have you seen that works to improve public use and
awareness of dropboxes and proper leftover drug disposal?
4. How could information about dropboxes best be delivered to customers and
pharmacists (e.g., pamphlet, stickers for bags/pill bottles)?
The focus group discussion was recorded and detailed notes, including quotes and major
themes discussed, were taken during the focus group. Notes were summarized into a
narrative following the focus group and from this summary, we identified major themes
relevant to our goals and the body of literature regarding leftover drug disposal. The
summary and themes were reviewed by the three facilitators for accuracy.
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4.3 Results
4.3.1 Customer Surveys
We collected a total of 129 customer surveys from 14 pharmacies, five with a
dropbox, and nine without a dropbox. A roughly equal number of participants were male
and female (48.1%, n=62) with 3.9% (n=5) identifying as other genders. The majority of
respondents were white (76.7%, n=99) and from the age ranges of 45-54 (32.6%, n=42)
and 55-64 (20.9%, n=27) years old. Annual household income mode was $75,000$95,000 at 26.8% (n=34). Detailed demographic characteristics are presented in Table
4.2.
Table 4.2 Demographic information of survey respondents. Difference in sample size by
question is due to exclusion of unanswered questions.
Variable
Gender
Female
Male
Other

Frequency - % (n)
48.1% (62)
48.1% (62)
3.9% (5)

Age
18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65-75 years
Over 75 years

8.5% (11)
13.2% (17)
10.9% (14)
32.6% (42)
20.9% (27)
9.3% (12)
4.7% (6)

Race
White
Hispanic/Latino
Black or African American
American Indian/Alaska Native
Japanese
Korean
Other Asian

76.6% (99)
11.6% (15)
8.5% (11)
0.8% (1)
0.8% (1)
0.8% (1)
0.8% (1)

Education
Graduate School
4-year College
Associates Degree
Some College

11.7% (15)
36.7% (47)
10.2% (13)
14.8% (19)
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Vocational School
High School or Diploma
Elementary/Junior High

8.6% (11)
17.2% (22)
0.8% (1)

Household Annual Income
$10,000-$14,000
$15,000-$24,000
$25,000-$34,000
$35,000-$49,000
$50,000-$74,000
$75,000-$95,000
$100,000-$149,000
$150,000 and above

3.9% (5)
3.1% (4)
12.6% (16)
19.7% (25)
19.7% (25)
26.8% (34)
12.6% (16)
1.6% (2)

Household Size (n=129)
1
2
3
4
5
6 to 7
8 to 9
10 or more

10.9% (14)
34.9% (45)
30.2% (39)
14.7% (19)
7.0 % (9)
0.8% (1)
0.8% (1)
0.8% (1)

When asked about leftover drug disposal, 41.7% of customers reported storing
drugs at home (n=50), with a negligible difference at locations with (40.4%, n=19) and
without dropboxes (42.5%, n=31). For the remaining disposal methods, 27.5% put them
in the trash (n=33), 15.8% flushed down the toilet (n=19), 8.3% used a dropbox (n=10),
and 4.2% took to a police station (n=5) (Table 4.3). Differences were apparent based on
dropbox presence in all categories; notable among customers surveyed at dropbox
locations, 6.7% fewer respondents reported throwing away leftover pharmaceuticals and
3.8% more respondents reported using dropboxes than respondents at locations without a
dropbox (Table 4.3). To further explore customer disposal, we grouped responses by
behaviors that were safe (taking to a dropbox, police station, or pharmacy) and unsafe
(storing at home, flushing, throwing away). Overall, most customers used unsafe options
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, but a higher percentage of safe disposal behaviors were reported at dropbox sites than
at locations lacking a dropbox (Table 4.3).
With respect to obtaining information about disposal, 60% (n=75) of customers
said they received instructions from pharmacists, doctors, or nurses, with the majority
reporting that these individuals recommended throwing in the trash (25.6%, n=32),
followed by flushing (20%, n=25) and using a dropbox (8.8%, n=11). At locations with
dropboxes, 11.8% (n=6) of customers reported being told to flush, compared to 25.7%
(n=19) at locations without dropboxes (Table 4.3). Additionally, a higher percentage of
customers reported being told to use a dropbox at locations with dropboxes (15.7%, n=8)
compared to those without dropboxes (4.1%, n=3) (Table 4.3). When grouped into safe
and unsafe recommendations, a similar pattern emerges with four times as many
customers at dropbox sites reportedly receiving instructions for safe disposal (Table 4.3).
Customers stated that they would seek varied sources of information for disposal
instructions, including online sources (51.6%, n=63), asking a pharmacist (30.3%, n=37),
and checking the medicine label (18.0%, n=22) (Table 4.3). Online sources were the
preferred method at both location types, but at locations with dropboxes more customers
preferred checking the medicine label (dropbox: 24.5%, n=12; no dropbox: 13.5%,
n=10), and fewer preferred asking a pharmacist (dropbox: 22.4%, n=11; no dropbox:
35.1%, n=26) (Table 4.3).
In general, customers had low awareness of dropboxes and drug disposal
implications; this was marginally improved by dropbox presence. When asked about
knowledge of the nearest drug take-back box, only 14.0% (n=18) of customers said they
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knew the nearest location. A higher percentage reported knowledge of a dropbox at
dropbox locations (23.5%, n=12) compared to non-dropbox locations (7.7%, n=6),
indicating that presence of a dropbox may increase awareness (Table 4.3). However,
awareness was surprisingly low considering the proximity of the dropbox at these
locations during survey administration. Just over a third of customers (35%, n=46) said
they knew why it was important to dispose of drugs properly (Table 4.3). This percentage
was higher at locations with dropboxes (42.1%, n=21) compared to locations without
dropboxes (32.5%, n=25) (Table 4.3). Thirty customers listed a reason to dispose of
drugs properly and five individuals listed two reasons (n=35). The highest percentage
mentioned environmental concerns or pollution (51.4%, n=18), and others listed safety
(45.7%, n=16) and drug expiration (2.9%, n=1). When asked about obstacles to using
dropboxes, 56% (n=70) of customers said they did not know dropboxes existed until
taking the survey, again showing low awareness. However, this percentage was lower at
locations with dropboxes (dropbox: 50%, n=25; no dropbox: 60.0%, n=45). When
examining relationships between awareness and behavior, we find that there is a
disconnect between these factors. Many more customers reported awareness of
importance of proper disposal (dropbox: 41.2%, n=21 ; no dropbox: 32.5%, n=25) and
knowledge of dropbox locations (dropbox: 23.5%, n=12; no dropbox: 7.7%, n=6), than
actually said they used a dropbox (dropbox: 10.6%, n=5; no dropbox: 6.8% , n=5 ) (Table
4.3), indicating that other factors may inhibit consumer use of dropboxes. This gap was
larger at locations with dropboxes.

135

Table 4.3 Responses to multiple-choice customer survey questions at locations with and
without dropboxes. In the first two questions, responses are split into safe and unsafe
disposal behaviors with subtotals reported in bold for each category. Sample size
differences between questions are due to exclusion of unanswered questions.
Total % (n)

Dropbox % (n)

No Dropbox % (n)

What do you do with leftover drugs?
Store at home
Throw in trash
Flush
Unsafe Disposal
Use a Dropbox
Take to Police Station
Return to pharmacy
Safe Disposal
Other1

41.7% (50)
27.5% (33)
15.8% (19)
85.0% (99)
8.3% (10)
4.2% (5)
1.7% (2)
14.2% (17)
0.8% (1)

40.4% (19)
23.4% (11)
14.9% (7)
78.7% (37)
10.6% (5)
6.4% (3)
4.3% (2)
21.3% (10)
0% (0)

42.5% (31)
30.1% (22)
16.4% (12)
89.0% (65)
6.8% (5)
2.7% (2)
0% (0)
9.5% (7)
1.4% (1)

What do doctors, nurses and pharmacists
recommend for drug disposal?
Throw in trash
Flush
Unsafe Disposal
Use a dropbox
Return to pharmacy
Take to Police Station
Safe Disposal
Never been told1

25.6% (32)
20.0% (25)
45.6% (57)
8.8% (11)
4.8% (6)
0.8% (1)
14.4%(18)
40.0% (50)

23.5% (12)
11.8% (6)
35.3% (18)
15.7% (8)
7.8% (4)
2.0% (1)
25.5% (13)
39.2% (20)

27.0% (20)
25.7% (19)
52.7% (39)
4.1% (3)
2.7% (2)
0% (0)
6.8%(5)
40.5% (30)

Where would you look for information regarding
disposal of leftover drugs?
Online
51.6% (63)
Ask a pharmacist
30.3% (37)
Check the medicine label
18.0% (22)
Other
0.8% (1)

51.0% (25)
22.4% (11)
24.5% (12)
2.0% (1)

51.4% (38)
35.1% (26)
13.5% (10)
0% (0)

Do you know where the nearest dropbox is
located?
No
Yes

76.5% (39)
23.5% (12)

92.3% (72)
7.7% (6)

What are the obstacles for you for using a
dropbox?
Until now, did not know about droboxes
56.0% (70)
Take them somewhere else
14.4% (18)
Usually flush drugs or throw them in the trash 12.8% (16)
Keep them for the future
8.0% (10)
Never remember to bring them with me
7.2% (9)
Other
1.6% (2)

50.0% (25)
20.0% (10)
10.0% (5)
14.0% (7)
6.0% (3)
0% (0)

60.0% (45)
10.7% (8)
14.7% (11)
4.0% (3)
8.0% (6)
2.7% (2)

If asked, could you explain why it matters where
leftover pharmaceuticals are disposed?
No
64.1% (82)
Yes
35.9% (46)

58.8% (30)
41.2% (21)

67.5% (52)
32.5% (25)

86.0% (111)
14.0% (18)
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1

Excluded from unsafe/safe disposal
categorization

4.3.2 Pharmacist Interviews
Of the 42 pharmacists and pharmacy technicians we contacted, 29 at 25
pharmacies agreed to an interview (response rate = 69%), eight with a dropbox and 17
without a dropbox. At four locations, we interviewed two pharmacists and at all other
locations we interviewed one pharmacist (n=9 dropbox; n=20 no dropbox). Pharmacists
gave the following responses for recommendations to customers: using a pharmacy
dropbox (onsite or at a nearby pharmacy), taking to a police station, looking at the DEA
website, throwing in the trash with an undesirable substance (e.g., kitty litter, coffee
grounds), contacting garbage/recycling collectors, flushing, taking to a drug take-back
day, and throwing directly in the trash (Figure 4.1). Many pharmacists shared two or
more ways to dispose of drugs, often including both environmentally safe and unsafe
methods, such as throwing drugs in the trash and taking them to a police station (n=1).
Two pharmacists explicitly stated disposal methods should depend on the type of drugs
and recommended flushing for dangerous drugs and throwing away or saving for a
collection event for others. Many pharmacists redirected customers to look elsewhere,
such as the DEA website, (n=7) or their local garbage collector (n=3) for the answer.
At locations with dropboxes, pharmacist recommendations were more consistent
and environmentally sound than at locations without dropboxes (Figure 4.1). Pharmacists
with dropboxes onsite only suggested three methods for disposal: using an onsite dropbox
(89.9%, n=8), contacting law enforcement (55.6%, n=5), or looking at the DEA website
for instructions (11.1%, n=1). They never recommended flushing or throwing drugs in
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the trash. Except for one individual, the first recommendation given by all pharmacists at
locations with dropboxes was to bring their drugs to the onsite dropbox (n=8). Four
pharmacists included additional recommendations of contacting the police station or
looking at the DEA website, but only for liquids, sharps, and narcotics which are not
accepted in these pharmacy dropboxes. One pharmacist recommended calling local law
enforcement, rather than bringing drugs to the onsite dropbox. Although this one
pharmacist's onsite dropbox was not the subject of their first recalled recommendation,
the individual did recall the presence of the onsite dropbox when discussing employer
policy for leftover drug disposal. This individual also had a positive attitude towards the
dropbox indicating that the pharmacist was aware and understood its value, but could
benefit from some training to commit to its use.
At locations without dropboxes, pharmacist recommendations were highly
variable (Figure 4.1). The most common response was contacting or taking drugs to a
police station (55.0%, n=11), followed by using a dropbox (35.0%, n=7), throwing in the
trash with an undesirable substance (30.0%, n=6) and checking the DEA website (30.0%,
n=6). Using a dropbox was mentioned, especially by pharmacists working in the same
chain of stores that had dropboxes at other locations (20.0%, n=4). Only two pharmacists
(10.0%) recommended flushing drugs and two others shared that customers should avoid
flushing because drugs may enter the water system, indicating some awareness of
environmental impacts of improper disposal.
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Figure 4.1 Percent of pharmacists that recommended each type of disposal method to
customers at locations with (n=9) and without (n=20) dropboxes.

We asked pharmacists about their attitudes regarding drug take-back programs
and categorized these responses into positive, neutral, and negative attitudes. If a
pharmacist explicitly said that programs were “good,” “great,” “necessary,” or another
positive sentiment, this was categorized as a positive attitude. A total of 19 pharmacists
(65.5%) expressed positive attitudes. Pharmacists that either stated they had no opinion or
did not express a strong positive or negative attitude were classified as a neutral attitude.
A total of nine pharmacists (31.0%) had neutral attitudes. One pharmacist (3.4%)
working at a dropbox location had a negative attitude sharing that drug take-back
programs are a “hassle” and it is preferred to take drugs to a police station. All other
pharmacists at dropbox locations expressed positive attitudes towards take-back
programs (n=8). When asked about their co-workers’ attitudes toward drug take-back
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programs, most pharmacists stated that their co-workers agreed with their opinion
(Appendix C1).
Pharmacists mentioned several pros and cons to drug take-back programs (Table
4.4). Three reported benefits were safety (the most common; n=12), followed by an even
number of pharmacists mentioning pollution reduction (n=2) and easy disposal for
customers (n=2). Pharmacists also shared several hindrances to establishment and use of
dropboxes. The most common response was cost (n=7), followed by lack of public
education/awareness (n=5), and liability for the pharmacy (n=3), among others (see Table
4.4 for full list).
Table 4.4 Pharmacist responses to open-ended phone interview question regarding pros
and cons of drug take-back programs at locations with (n=9) and without (n=20)
dropboxes.
Total #

Dropbox #

No Dropbox #

Pros
Safety
Reduces pollution
Easy disposal for customers
No Answer

12
2
2
15

5
1
1
4

7
1
1
11

Cons
Cost
Lack of public education
Liability for pharmacy
Hassle for pharmacist/pharmacy
There are no cons
Inconsistent information from regulatory agencies
Cannot accept all medications
Inconvenient for customers
Requires a third party
Time to implement
Regulations
No Answer

7
5
3
2
2
1
1
1
1
1
1
11

2
2
0
1
1
1
1
0
0
0
0
3

5
3
3
1
1
0
0
1
1
1
1
8

4.3.3 Focus Group
With such varied information from pharmacists regarding challenges of drug takeback programs, we aimed to explore the major obstacles to dropbox implementation and
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use through discussion with individuals that held expertise in establishment or policies
surrounding dropboxes in Oregon. The focus group consisted of five participants, three in
person and two remotely. Participants discussed three major challenges to implementing
dropboxes: cost, floor space, and policy inconsistencies. The primary issue identified was
the cost of long-term maintenance of an onsite dropbox, as stores are responsible for
paying a fee for each pick up, approximately $275 in Oregon. One participant stated that
when dropboxes were installed at a chain of pharmacies in Portland, OR, they were
popular and heavily used, which was described as expensive to empty frequently and
resulted in dropboxes being temporarily closed while waiting for dropbox servicing. This
individual shared that initial setup of the box, which costs around $2,000, was more
affordable because it is a one-time fee and grant money was provided to some pharmacies
to cover half the cost. Focus group participants indicated that the high costs of installation
and maintenance of a dropbox and a lack of revenue for the pharmacy disincentivizes
pharmacies from establishing dropboxes. Focus group participants also highlighted a
need for legislation or funding opportunities to increase dropbox installation. Participants
emphasized that the pharmaceutical industry should be responsible for the costs of
dropbox setup and maintenance, rather than the retail pharmacies, but there is currently
strong industry opposition. The participants noted that the pharmaceutical industry
already collects and disposes of unsold expired drugs from the pharmacy, and therefore
should already have protocols in place that could be applied to customer disposal. Floor
space can present a significant problem for small stores but could be worked around if
dropbox installation and disposal costs were not an issue. Policy inconsistencies in terms
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of variability in drug types and forms permissible for collection at different dropboxes
can lead to contamination at dropboxes with more restrictive third-party collection
policies. For example, if controlled substances (drugs that are regulated under US federal
law based on medical use, potential for abuse, and safety) are found in a dropbox with
restrictions on drug type (per DEA regulations; U.S. DEA 2014), that shipment of
disposed drugs is considered contaminated and may not be properly disposed of.
When asked about training for pharmacists, participants shared concerns about
“ignorance among pharmacists” because they are prohibited from collecting drugs, but
also noted the great opportunity for improvement by adding such training to pharmacy
schools. One individual was instructed at pharmacy school to mix drugs with an
undesirable substance (e.g., kitty litter or coffee grounds) and throw away ten years prior
to the focus group. Shifting the pharmacy school curriculum and new pharmacy
employee training to focus on appropriate disposal methods could improve
communication to customers. In general, participants expressed a need for better initial
training and continuing education for pharmacists.
When asked about public use and awareness of dropboxes, participants said the
predominant issue is a lack of dropboxes, and that increasing public awareness without
more infrastructure would be problematic. One focus group participant reported
dropboxes fill up within 3-7 days with little to no educational intervention. Participants
shared that once a dropbox is established, its presence acts as an educational tool, and
customers are likely to use it. Pamphlets, brochures, and stickers on medication bottles
were discussed as options to deliver information to customers about proper disposal.
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Stickers on the medication bottle or associated materials from the pharmacy with a QR
code or link were the most favorable option to focus group participants. However, it was
further emphasized that a successful educational campaign would likely increase dropbox
disposal beyond the capacity of current retail pharmacies; thus increased availability of
dropboxes is needed before education will be useful.
One focus group participant felt strongly that state legislation requiring dropboxes
in every pharmacy is needed in order to install an adequate number of dropboxes to meet
the needs of consumers. Participants emphasized that the current messaging used in
lobbying for legislative efforts is focused on the opioid crisis, with little information on
environmental issues. Participants mentioned legislation might be more successful if the
environmental perspective was added to the opioid risks information, particularly on the
US West Coast where environmental issues are important to the public (Mazur and
Welch 1999). This point is important as dropboxes take most drug types and therefore
benefit multiple consumers, not just those concerned about opioid abuse.

4.4 Discussion
Customer drug disposal practices are variable and differ among pharmacies with
and without dropboxes. Over a third of customers in our sample (41.7%) are storing
unused medications at home, with potential safety and environmental implications. The
most common disposal methods reported by our participants were throwing in the trash
(27.5%), flushing (15.8%), and using a dropbox (8.3%). These rates are lower than other
studies investigating customer disposal of various drug types in the United States, but this
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is likely due to the high number of customers surveyed that reported storing drugs at
home. Three studies reported that 45-62% of customers throw drugs in the trash and 1831% flush drugs down the toilet or sink, with only 12-17% never disposing or storing at
home (Law et al. 2014, Wieczorkiewicz et al. 2013, Kotchen et al. 2009). These studies
were published prior to legislation permitting dropboxes within pharmacies, so it is
difficult to compare dropbox usage. However, 6-11% of customers in these studies
reported returning drugs to a pharmacy, which is within the range of dropbox usage in
our study (Law et al. 2014, Wieczorkiewicz et al. 2013, Kotchen et al. 2009). Customer
disposal methods were improved at dropbox locations with more customers reporting
using a dropbox, and fewer customers throwing drugs in the trash, indicating that
dropbox presence may well increase proper disposal. Although we found low customer
awareness of dropboxes and risks of improper disposal, awareness was greater in
pharmacies with a dropbox present, supporting the idea that pharmacy dropboxes act as
educational tools. The few customers that reported awareness and understanding of
dropboxes but not use also reported flushing, throwing away, storing at home and
forgetting to bring drugs with them to the dropbox. This shows that a marketing
campaign to raise awareness and focus on intent could be useful.
Pharmacists can be an important source of information to increase proper
disposal, particularly with expansion of onsite dropbox locations. Several customers
reported never receiving instructions from pharmacists regarding drug disposal (40.0%),
but 30.3% said pharmacists are their preferred source of information. Hence, customer
drug disposal could be improved with small educational efforts, especially directly from
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pharmacists. For example, in a study in New York, nearly 60% of surveyed pharmacy
customers (N=242) indicated that they would change disposal behavior to a safer method
following pharmacy student-facilitated education (Abrons et al. 2010). Those that
reported no intention to change behavior mentioned inconvenience and a lack of takeback locations as reasons (Abrons et al. 2010). Although customer education is
important, it may have limited impact until more dropboxes are established for yearround collection to provide easy access to open dropboxes (full dropboxes are ‘closed’ to
collection until emptied).
Pharmacists gave variable recommendations for customer drug disposal, but this
variability was substantially reduced at locations with dropboxes (Figure 4.1).
Pharmacists at dropbox locations recommended proper disposal methods, primarily to
use the onsite dropbox, and never told customers to flush or throw away drugs. This
indicates pharmacy dropbox presence greatly improved pharmacist communication with
their customers about leftover drug disposal. Direct educational interventions may further
improve pharmacist recommendations to patients. A pre- and post-survey of 158
pharmacists in Massachusetts provided an educational brochure to pharmacists and found
that this reduced recommendations to flush and wash drugs down the sink by 5% and
13% respectively, and increased knowledge of environmental impacts of improper
disposal by 10% (Jarvis et al. 2009). Just over a third of these pharmacists had never
learned about proper disposal of drugs (36%), and only 19% said they learned about
disposal in pharmacy school (Jarvis et al. 2009). This study demonstrated that an
educational intervention increased pharmacist knowledge and changed recommendations
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(Jarvis et al. 2009), hence further initial education at pharmacy school and onboarding
education for new hires at pharmacies could be a powerful driver of change. Participants
in our focus group reported similar views, specifically that it is most valuable to teach
pharmacists before they establish a routine by encouraging changes to pharmacy school
curricula. Despite a general lack of education on drug disposal, most pharmacists are
supportive of drug take-back programs and showed particularly high enthusiasm at
locations with dropboxes. They recognized the benefits of take-back programs in
increasing public safety but were relatively unaware of environmental concerns.
Additionally, they focused less on cost, liability, and inconvenience as obstacles
compared to no dropbox locations, indicating that these views are more associated with
establishment of a program. Once a dropbox is established in the pharmacy, pharmacists
are more supportive and informed about drug take-back, and fewer barriers are apparent.
Several major themes surrounding proper drug disposal were identified in the
focus group with pharmacy professionals. The first was that dropboxes serve as important
educational tools in pharmacies. Customers notice them, ask questions, and use
them frequently. While changes in customer disposal based on presence of dropboxes
were smaller than expected, the positive effect on pharmacist recommendations was
strong. Although the predominant issue identified was a lack of dropboxes, rather than
education or awareness, some useful educational methods were identified. Specifically a
sticker on medication bottles was identified as a good option. In our surveys, a higher
percentage of customers said they seek information online or from a pharmacist than on a
medication bottle, indicating that educational interventions focused on streamlining
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online information from agencies and improving pharmacist knowledge and
communication are at least as important as clear labeling on medication. The lack of
reliance on medication packaging could be due to the current absence of information on
pill bottles regarding disposal. Adding consistent instructions could make this a more
convenient option for seeking information.
A major hindrance to dropbox adoption is cost. Options to address cost include
government grants, customer fees, and the pharmaceutical industry fronting the costs. As
explained by one pharmacy manager in the focus group, grants were provided in Oregon
to cover 50% of the cost of establishing dropboxes, indicating that even cost shares can
be effective. A California study of 1,008 people found consumers would be willing to pay
approximately $1.50 per prescription to go towards disposal, an amount that would
support a year-round drug take-back program within pharmacies (Kotchen et al. 2009).
There is some evidence that dropboxes could increase profit by attracting more customers
that want to dispose of drugs properly. In a survey of consumer perceptions of a drug
take-back program within a pharmacy, 84% of respondents said they would be more
likely to choose a pharmacy offering this service and 59% said they would be willing to
pay for disposal on a per weight basis (Thach et al. 2013). Our focus group participants
heavily emphasized that the pharmaceutical industry should be responsible for costs, yet
we could find little evidence that the industry or the federal government currently
supports this recommendation. Focus group participants felt that the lack of support is
due to the industry position that excretion is the major contributor to environmental
pollution and disposal is negligible. However, the documented quantities of collected
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drugs, particularly from drug take-back events, indicate a potentially large environmental
impact of improper disposal. Moreover, recent studies find pharmaceutical disposal can
contribute significantly to contamination of waterways. Bound and Voulvoulis (2005)
used a model to evaluate excretion and disposal routes of certain drugs based on percent
consumed, body metabolism, and wastewater treatment removal, and found that for drugs
with low metabolic and wastewater treatment removal rates, and those for which
consumers do not finish the whole prescription, disposal may contribute a similar
percentage as excretion. Additionally, the concentration of hydrocodone in wastewater
treatment plant effluent decreased after a drug take-back event in Texas, indicating that
proper disposal has the potential to reduce pharmaceutical loadings to the environment
(Stoddard and Huggett 2015). More research examining the effects of disposal on
environmental contamination may be needed to convince drug distributors of the role
improper disposal plays in environmental contamination.
Although our study reports findings based on a small sample size, uneven site
numbers between dropbox and no dropbox pharmacies, and the short timescale since
dropbox implementation, our results provide a useful understanding of our study sample
and were similar to findings from other studies in the US. The few dropbox sites
available resulting in uneven sampling represent the reality of an uneven distribution of
dropboxes across our study area and across the US. Finally, as pharmacy dropboxes are a
relatively new innovation, their long-term impacts may not yet be apparent, and our
results may reflect the challenges of transitioning to pharmacy-based leftover drug
disposal. Despite these limitations, this study provides useful information as the first
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research to evaluate effects of dropbox presence on customers and pharmacists. We
recommend that future studies seek to validate our findings with larger samples over a
longer term as dropboxes become more prominent in retail pharmacies. Additionally,
future studies could benefit from asking pharmacists how drug take-back programs could
be improved and including customer questions to assess factors that limit use of
dropboxes among those who are aware of but don’t use dropboxes.

4.5 Conclusion
Our findings indicate high rates of drug storage and an overall lack of awareness
of dropboxes among customers, with high variation in leftover drug disposal
recommendations by pharmacists, particularly at pharmacies without dropboxes. The
presence of a dropbox at a pharmacy was associated with greater customer awareness of
proper drug disposal and safer pharmacist recommendations to customers. These findings
support the value of legislative efforts to increase the number of established dropboxes at
pharmacies in Oregon and throughout the country. Based on feedback from customers,
pharmacists, and other pharmacy professionals, we recommend: (1) further efforts focus
on the increased establishment of dropboxes in pharmacies, (2) development of pharmacy
school and employment training programs on appropriate drug disposal that include
communication recommendations for pharmacists to patients, (3) changes to online
information from federal and local agencies to improve consistency, and (4) addition of
safe disposal information on medication bottles.
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Chapter 5: Conclusion
Marine ecosystems face challenges of multiple stressors, many of which have the
potential to interact, and upend delicate ecological interactions that allow these systems
to thrive. The ocean provides abundant resources to humans, including food, oxygen, and
climate regulation, and is essential to human life. Understanding the impacts of
anthropogenic pollution on marine ecosystems is important for managing and conserving
these diverse and valuable places. Many marine contaminants are invisible, difficult to
measure, and come with huge challenges in identifying long-term impacts. PPCPs and
other emerging contaminants are present in our oceans, yet little is known about their
effects on organisms, communities, and ecological interactions. Additionally, remediation
options, such as WWTP improvements, are expensive, impractical, and/or require more
data to inform appropriate methods. In my dissertation research, I set out to fill some of
the gaps in quantifying PPCPs in marine environments, identifying effects on
commercially important species, and exploring a possible remediation opportunity.

Summary of Research Findings
In chapter 2, I conducted a field experiment in which Pacific oysters were
transplanted to sites near WWTP outfalls and aquaculture to compare bioaccumulation
and health effects. I found that Pacific oysters accumulated PPCPs in OR and WA
estuaries, at sites near and far from wastewater sources, including areas where they are
being commercially produced. Distance to WWTP outfalls did not drive variation at a
small spatial scale, though pharmaceutical detections were more frequent at wastewater
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sites compared to oyster growout sites. In chapter 3, I exposed oysters directly to effluent
from coastal WWTPs in a lab experiment to evaluate organismal effects and uptake, and
quantify PPCP levels in effluent. I found that oysters experienced more PPCP uptake in
the lab when exposed directly to WWTP effluent, compared to the field. An array of
PPCPs were detected in effluent from two small coastal wastewater treatment plants,
adding to the body of literature on occurrence in effluent and providing concentration
ranges from less populated regions. Effluent and tissue detections support other research
showing that PPCP contamination is ubiquitous, even in areas with low development.
Overall, concentrations of PPCPs in tissue and effluent were lower than previously
published ranges, which makes sense given the lack of urbanization, small surrounding
populations, and associated usage patterns.
Based on examination of growth, health, and feeding rates in the field and lab,
exposures to these toxins resulted in a few detectable effects on oysters at the organism
level. In the field, oysters transplanted to aquaculture sites had higher condition index
than those near wastewater. In the lab, oysters exposed to effluent from one WWTP (<1
mgd discharge capacity) had slower shell growth rates and higher feeding rates (10%
effluent exposure only). These results suggest that even at low, environmentally relevant
concentrations, PPCP mixtures have some subtle effects on oysters. I found that the
different concentrations of effluent did not drive these differences and expected more
effects to be present following effluent exposure. To explain the lack of effects on
oysters, I have three hypotheses: 1) oysters are less sensitive to pollutants; 2) effects were
not detectable at the organism level, but may be present at lower biological levels (e.g.,
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molecular, cellular, tissue, organ), and 3) stress induced by the tank environment
overshadowed concentration level effects. Prior research supports these hypotheses and it
is possible that all contributed to the results. Pacific oysters can thrive in variable
environmental conditions and Oregon estuaries are relatively pristine compared to those
on the U.S. East and South coasts. Additionally, previous experiments examining
pollution effects on Pacific oysters tend to detect effects at lower biological levels more
often than at the organism level (e.g., (Mottier et al. 2015; Akcha et al. 2016).
In chapter 4, I conducted surveys with pharmacy customers and interviews with
pharmacists about drug disposal practices and recommendations. Drug disposal may be a
prominent route of pharmaceuticals to the environment and improving disposal practices
is a practical method to reduce loadings from this source. Customer surveys revealed that
most consumers store leftover drugs at home and have low awareness of drug take-back
boxes. Pharmacist recommendations for drug disposal were highly variable, but were
substantially more consistent and safer at locations with established drug take-back
boxes. Additionally, customer use of dropboxes was marginally improved at these
locations. Federal recommendations for disposal continue to include throwing away,
flushing, and saving for a take-back event which pose risks to public health and the
environment. My research findings indicate that establishment of drug take-back boxes in
a majority of pharmacies in Oregon, and eventually the country, is a promising path to
improve drug disposal practices. This issue is of importance to local communities and in
2019, the OR legislature passed a bill to establish a drug manufacturer funded drug take
back program in the state by summer of 2021 (OR DEQ 2020).
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Future Research Directions
Future research on PPCP occurrence, effects, and remediation could expand on
the findings of this dissertation in several ways. Organism transplantation and collection
from the wild is important to document detections and concentrations for contaminant
monitoring. In future transplant studies, I would recommend measuring multiple sample
matrices (e.g., sediment, seawater, and tissue concentrations) at each site to improve the
ability to detect and quantify PPCPs with varying chemical properties. This may also
elucidate exposure routes when tissue detections are low and allow for clearer
conclusions about whether or not organisms are exposed even if they are not
accumulating toxins. Lab experiments that address mixtures of PPCPs and examine
environmentally relevant effects are necessary to identify toxicity of these compounds to
sensitive organisms and ecosystem processes. I recommend that these studies include as
many biological levels as possible (spanning DNA to whole organism), and take the time
to explain the significance of observed effects to management and policy decision
makers. Previous toxicological studies that examine cellular and subcellular endpoints
often fail to highlight the significance of their findings at organism, population, and
ecosystem levels. Partnerships among biologists, toxicologists, and ecologists and
environmental managers could facilitate better identification and communication of
large-scale impacts. Toxicity experiments can be expanded to include the effects of
multiple stressors and how other major ocean changes (e.g., ocean acidification, elevated
temperature, eutrophication, etc.) interact with PPCPs. These stressors are occurring
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simultaneously and therefore should be evaluated in tandem for major management
decisions. The potential human health effects of consuming small amounts of PPCPs in
seafood remain unknown. Examining human exposure through consumption, potential
effects, and setting safe consumption standards should be priorities for future work.
Lastly, drug take-back boxes may reduce pharmaceutical loadings from disposal routes
and their effectiveness should be evaluated on a larger scale as they become more
established in communities.

Remediation Options and Recommendations
PPCPs have received little recognition as pollutants from regulators and the
public and are typically not considered a predominant stressor in aquatic and coastal
ecosystems. While PPCPs are unlikely to cause immediate and substantial damage, they
present a potential long term threat to ecosystem health (Richmond et al. 2017). Despite
the limited number of studies documenting the occurrence of PPCPs, especially in
developing countries and coastal areas with lower populations, their occurrence appears
to be widespread in aquatic and marine systems. Few other compounds are used and
discharged year-round, regardless of season or rain events, and have such low removal
rates from WWTPs. This continual deposition into marine ecosystems at low
concentrations may be having subtle, largely undetected chronic effects on wildlife.
Challenges are abundant in revealing and describing these impacts due to a lack of acute
toxic effects, possible synergistic and antagonistic effects from exposure to multiple
compounds, and the potential for effects to occur over multiple generations. These
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impacts are difficult to observe and measure and may be overshadowed by impacts from
other prominent stressors (e.g., climate change, habitat loss, fisheries) that are more
apparent.
Several options may be considered for reduction of PPCP loadings to aquatic and
marine environments. Pharmaceutical use and production are increasing and regulations
are not limiting this growth. Therefore, with excretion of drugs as a major contributor to
loadings in wastewater, changes to prescription practices and drug formulation may be
beneficial. For example, Daughton and Ruhoy (2013) recommend implementation of
environmentally sustainable prescription practices, which includes prescribing lower
doses of certain drugs, choosing drug types that are more likely to biodegrade, and
considering the duration of treatment. There are a few known drugs that deliver the
desired therapeutic response at a lower dose, but information is limited and most
physicians don’t have consistent access to data from clinical trials (Daughton and Ruhoy
2013). More research is needed to identify lower doses that are effective, along with data
access for physicians, and continued physician education on the advantages of sustainable
prescription practices (Daughton and Ruhoy 2013; Klatte et al. 2017). Another important
change to prescribing practices is reduction of unnecessary antibiotic prescriptions in
humans, and only as necessary use in agriculture (Klatte et al. 2017).
Many currently available pharmaceuticals are relatively stable during metabolism
and wastewater treatment, but recent research shows that innovative drug development
could produce pharmaceuticals that readily degrade. For example, (Kümmerer 2019) used
three design approaches to improve the biodegradability of three common pharmaceutical
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classes, beta-blockers, antibiotics, and a cytotoxic. Development of these “Green
Pharmaceuticals” that are pharmacologically potent, but environmentally benign, could
result in reduced pharmaceutical loadings, but will require incentives for the
pharmaceutical manufacturers to participate (Straub 2016). Improvements to wastewater
treatment technology, and upgrades to tertiary treatment would improve the removal of
PPCPs by wastewater treatment plants, but may be impractical with associated costs.
While excretion is likely the prominent contributor to environmental pollution,
disposed drugs should not be overlooked as an influential source. Pharmaceutical
presence in the environment could be reduced with implementation of drug take-back
boxes in more pharmacies and additional education such as drug disposal training for
pharmacists during pharmacy school and stickers on medicine bottles with disposal
instructions. For personal care and cleaning products with alkylphenols, cultural changes
that lead to reductions in public usage patterns will be essential. This would require
increasing public awareness about presence and potential effects of chemicals in
products, encouraging use of fewer personal care products, and education about
purchasing household products that contain non-toxic compounds. Unfortunately, many
labels on household products do not list ingredients, which presents challenges for
consumers trying to make informed choices. The EPA has begun to address this issue by
implementing a “safer choice” label, mainly on detergents, soaps, and cleaners, to
indicate that the product does not contain environmentally harmful ingredients, including
alkylphenols (US EPA 2020). More transparent labeling on a variety of products,
combined with education about potential harm to humans and the environment could
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reduce consumer use of certain products. Educational campaigns could be led by
scientists and environmental organizations/groups to target consumers. Overall,
remediation and reduction of PPCPs in the environment will require a combination of
implementation of best practices regarding drug prescription and use, improved consumer
choices, and legislation to support better product labeling, proper drug disposal, and
when feasible, improvements to wastewater treatment. Implementing and improving
these interventions will require continued research from ecological, toxicological, social,
and human health perspectives to determine if actions are having an impact on
prescribing practices, consumer behaviors, and pollution reduction.
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Appendix A: Supporting tables, figures, and information for chapter 2
Table A1. Shell height and length for 1 bag of oysters from each rack collected in April
2017. Oysters were transplanted for 9 months at wastewater sites (Coos, North Bend) and
oyster growout sites (Westport, Netarts, Valino Island). Distance from the nearest
wastewater treatment plant outfall is listed in meters for each oyster rack at the
wastewater sites.
Site
Coos Bay
Coos Bay
Coos Bay
North Bend
North Bend
North Bend
North Bend
Valino Island
Valino Island
Valino Island
Netarts Bay
Netarts Bay
Netarts Bay
Westport
Westport

Distance to
WWTP
Outfall (m)
250 m
750 m
1,500 m
245
265
465
480
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Rack
COOSa
COOSb
COOSc
NBc
NBb
NBa
NBd
VALa
VALb
VALc
NETa
NETb
NETc
WESTa
WESTb

Oyster
Count (1
bag)
181
151
301
71
55
125
184
144
189
145
202
224
208
402
340

Avg Shell Height
(mm) (SD)
37.17 (12.09)
36.62 (10.92)
30.02 (9.05)
34.08 (10.21)
37.54 (10.38)
30.92 (10.12)
34.67 (11.09)
41.63 (12.73)
40.38 (14.99)
43.87 (13.01)
35.54 (9.45)
37.49 (12.15)
29.69 (8.08)
32.91 (8.96)
35.04 (8.63)

Avg Shell
Length (mm)
(SD)
25.21 (8.04)
26.59 (7.56)
21.82 (6.15)
24.07 (6.63)
26.30 (5.98)
23.34 (9.02)
23.57 (8.51)
27.65 (7.59)
24.18 (9.41)
30.05 (9.12)
25.36 (6.63)
24.70 (7.34)
20.88 (5.98)
21.96 (6.13)
23.15 (6.30)

Table A2. Shell dimensions (height, length, width) for two bags of oysters from each rack
collected in July 2017. Oysters were transplanted for 1 year at wastewater sites (Coos,
North Bend) and oyster growout sites (Westport, Netarts, Valino Island). Distance from
the nearest wastewater treatment plant outfall is listed in meters for each oyster rack at
the wastewater sites.

Site

Rack

Bag

Distance to
WWTP
Outfall
(m)

Coos Bay

COOSa

Bag 1

250

303

Coos Bay

COOSa

Bag 2

250

183

Coos Bay

COOSb

Bag 1

750

203

Coos Bay

COOSb

Bag 2

750

406

North Bend

NBc

Bag 1

245

95

North Bend

NBc

Bag 2

245

47

Oyster
Count

Avg
Shell
Height
(mm)
(SD)
41.05
(13.04)
46.9
(13.19)
44.5
(13.7)
50.6
(11.94)
42.52
(13.71)
45
(10.16)

Avg
Shell
Length
(mm)
(SD)
31.4
(10.17)
35.91
(8.79)
33.23
(12.04)
35.08
(9.26)
33.56
(10.81)
39.88
(12.6)

Avg
Shell
Width
(mm)
(SD)
11.77
(3.34)
14.38
(3.79)
12.38
(3.98)
15.4
(3.87)
14.06
(4.22)
12.16
(2.93)

Avg
Whole
Mass
(g)
(SD)
9.53
(4.99)
11.3
(5.69)
12.12
(6.7)
13.35
(6.55)
12.9
(8.83)
16.18
(8.12)
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North Bend

NBb

Bag 1

265

51

North Bend

NBb

Bag 2

265

111

North Bend

Nba

Bag 1

465

71

North Bend

Nba

Bag 2

465

155

North Bend

NBd

Bag 1

480

115

North Bend

NBd

Bag 2

480

83

Netarts Bay

NETa

Bag 1

N/A

201

Netarts Bay

NETa

Bag 2

N/A

220

Netarts Bay

NETb

Bag 1

N/A

183

Netarts Bay

NETb

Bag 2

N/A

288

Netarts Bay

NETc

Bag 1

N/A

148

Netarts Bay

NETc

Bag 2

N/A

183

Valino Island

VALa

Bag 1

N/A

248

Valino Island

VALa

Bag 2

N/A

217

Valino Island

VALb

Bag 1

N/A

203

Valino Island

VALb

Bag 2

N/A

256

Valino Island

VALc

Bag 1

N/A

363

Valino Island

VALc

Bag 2

N/A

392

Westport

WESTa

Bag 1

N/A

425

Westport

WESTa

Bag 2

N/A

578

Westport

WESTb

Bag 1

N/A

445

Westport

WESTb

Bag 2

N/A

516

40.54
(9.19)
38.76
(10.84)
47.96
(13.65)
41.56
(12.77)
42.28
(12.17)
43.86
(13.38)
44.41
(13.1)
42.4
(9.53)
44.79
(12.8)
44.34
(12.6)
41.39
(10.74)
36.89
(10.6)
46.93
(14.76)
43.07
(13.59)
49.51
(14.92)
46.09
(14.58)
48.64
(16.14)
51.31
(14.78)
40.83
(11.63)
45.37
(12.07)
44.68
(14.22)
43.02
(12.17)

32.23
(9.36)
30.32
(9.44)
37.5
(10.95)
28.19
(7.8)
34.07
(11.39)
33.72
(8.54)
31.34
(9.06)
30.45
(9.18)
33.09
(9.36)
28.61
(7.61)
30.63
(6.88)
29.51
(9.73)
32.46
(10.72)
28.4
(8.43)
31.93
(11.61)
29.9
(9.91)
32.51
(9.93)
33.81
(7.71)
29.87
(9.63)
32.45
(8.45)
29.61
(8.7)
27.92
(7.79)

10.36
(3.02)
13.2
(4.15)
13.51
(4.33)
12.26
(3.55)
11.8
(3.98)
10.61
(3.12)
11.84
(4.23)
11.74
(3.8)
12.76
(4.62)
13.16
(3.81)
10.47
(2.38)
10.26
(2.94)
10.97
(3.48)
11.94
(4.14)
10.98
(3.74)
12.28
(3.75)
10.72
(3.17)
14.53
(3.67)
11.53
(3.47)
11.5
(3.53)
11.16
(2.94)
10
(2.94)

10.71
(4.91)
9.97
(5.32)
14.67
(8.63)
11.31
(7.66)
11.31
(6.94)
12.55
(6.39)
12.7
(7.58)
11.46
(10.85)
13.59
(7.58)
13.21
(7.57)
9.56
(4.44)
7.88
(4.12)
13.83
(9.67)
11.11
(7.15)
14.38
(9.38)
12.73
(7.78)
13.82
(7.05)
12.66
(6.44)
10.63
(6.78)
13.07
(6.26)
11.05
(5.84)
10.02
(5.81)

Table A3. Fouling organisms (FOs) present in oyster bags collected in April and July
2017. For the July bags, the three most abundant FOs were identified. In some instances,
only one or two dominant fouling organisms were identified.
Site
April

Rack

Bag

Top 3 FOs

Remaining FOs
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Coos Bay

COOSa

Bag 1

Not identified

Coos Bay

COOSb

Bag 1

Not identified

Coos Bay

COOSc

Bag 1

Not identified

North Bend

NBa

Bag 1

Not identified

North Bend

NBb

Bag 1

Not identified

North Bend

NBc

Bag 1

Not identified

North Bend

NBd

Bag 1

Not identified

Netarts Bay

NETa

Bag 1

Not identified

Netarts Bay

NETb

Bag 1

Not identified

Netarts Bay

NETc

Bag 1

Not identified

Valino Island

VALa

Bag 1

Not identified

Valino Island

VALb

Bag 1

Not identified

Valino Island

VALc

Bag 1

Not identified

Westport

WESTa

Bag 1

Not identified

Westport

WESTb

Bag 1

Not identified

July
Coos Bay

COOSa

Bag 1

Coos Bay

COOSa

Bag 2

Coos Bay

COOSb

Bag 1

Coos Bay

COOSb

Bag 2

North Bend

NBa

Bag 1

North Bend

NBa

Bag 2

North Bend

NBb

Bag 1

Amphipods, barnacles,
bryozoan
Amphipods, barnacles,
bryozoan
Barnacles, bryozoan,
microalgae
Barnacles, bryozoan,
isopods
Bryozoan, mussels,
polychaetes
Barnacles, bryozoan,
mussels
Barnacles, bryozoan,
mussels

Barnacles, bryozoan, crabs,
isopods, mussels
Amphipods, barnacles, bryozoan,
crabs, isopods, mussels,
polychaetes
Amphipods, barnacles, bryozoan,
crabs, isopods, mussels,
polychaetes
Anemone, barnacle, bryozoan,
crab, mussel, polychaete
Amphipods, barnacles, crabs,
limpet, mussels, polychaetes
Barnacles, bryozoan, crabs,
isopods, mussels
Barnacles, bryozoans, crabs,
mussels, polychaetes
Amphipods, barnacles, bryozoan,
crabs, mussels, polychaetes
Amphipods, barnacles, bryozoan,
crabs, isopods, mussels, tunicate
Amphipods, barnacles, bryozoan,
crabs, gastropod, mussels,
polychaetes
Amphipods, barnacles, bryozoan,
crabs, mussels, tunicate,
polychaetes
Amphipods, barnacles, bryozoan,
crabs, isopods, mussels,
polychaetes
Amphipods, barnacles, bryozoan,
crabs, mussels, polychaetes
Amphipods, barnacles, bryozoan,
crabs, hermit crabs, macroalgae,
mussels, nudibranch, polychaetes
Amphipods, barnacles, bryozoan,
crabs, hermit crabs, macroalgae,
mussels, polychaetes
Crabs, isopods, mussels,
polychaetes
Crabs, isopods, macroalgae,
polychaetes
Amphipods, crabs, isopods,
mussels
Amphipods, mussels, polychaetes
Tunicates, crabs
Polychaetes
Crabs, polychaetes
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North Bend

NBb

Bag 2

Barnacles, bryozoan,
mussels
Barnacles, bryozoan,
crabs
Barnacles, bryozoan,
mussels
Barnacles, bryozoan,
mussels
Barnacles, mussels,
polychaetes
Barnacles, mussels
Amphipods, barnacles,
microalgae
Barnacles
Barnacles, tunicate

North Bend

NBc

Bag 1

North Bend

NBc

Bag 2

North Bend

NBd

Bag 1

North Bend

NBd

Bag 2

Netarts Bay
Netarts Bay

NETa
NETa

Bag 1
Bag 2

Netarts Bay
Netarts Bay

NETb
NETb

Bag 1
Bag 2

Netarts Bay
Netarts Bay
Valino Island
Valino Island

NETc
NETc
VALa
VALa

Bag 1
Bag 2
Bag 1
Bag 2

Valino Island

VALb

Bag 1

Valino Island

VALb

Bag 2

Barnacles
Barnacles, microalgae
Barnacles, bryozoan
Barnacles, bryozoan,
mussels
Barnacles, bryozoan,
mussels
Barnacles, bryozoan

Valino Island

VALc

Bag 1

Barnacles, bryozoan

Valino Island

VALc

Bag 2

Westport

WESTa

Bag 1

Westport

WESTa

Bag 2

Westport

WESTb

Bag 1

Westport

WESTb

Bag 2

Barnacles, bryozoan,
crabs
Barnacles, bryozoan,
isopods
Barnacles, bryozoan,
isopods
Barnacles, bryozoan,
polychaetes
Barnacles, isopods,
polychaetes

Amphipods, crabs, limpets,
polychaetes
Amphipods, limpets, polychaetes
Crabs, isopods, polychaetes
Crabs, polychaetes
Crabs
Crabs, isopods, polychaetes
Mussels
Isopods, mussels
Amphipods, crabs, mussels,
polychaetas, sponge
Microalgae, mussels, polychaetes
Amphipods, polychaetes
Amphipods, mussels, polychaetes
Amphipods, bryozoan, crabs,
isopods, polychaetes
Amphipods, isopods, crabs,
polychaetes, sponge
Amphipods, crabs, mussels,
polychaetes, sponge
Amphipods, crabs, mussels,
polychaetes
Amphipods, microalgae, mussels,
nudibranch
Hermit crabs, macroalgae, mussels,
polychaetes
Hermit crabs, polychaetes
Amphipods, isopods, microalgae,
mussels
Bryozoan, hermit crabs,
microalgae, mussels

Appendix A4: Reflections on what I have learned from this field study
(requested by dissertation committee)
When I conducted this field experiment, there were some things I could have done
differently to improve the outcomes of the research. Therefore, this work was a learning
experience for future studies. Below is a list of lessons that I would implement in future
research:
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Lesson 1: Scope out field sites in advance
When I planned this study, I chose to compare sites near wastewater and
aquaculture in OR and WA. To identify appropriate wastewater sites, I searched for
places with outfalls and adjacent mudflat (suitable habitat for oysters) using Google
Earth, internet sources, and personal communication with agency staff from Oregon and
Washington Departments of Fish and Wildlife (ODFW/WDFW) and the South Slough
National Estuarine Research Reserve (NERRS). However, I did not visit all of the chosen
sites before setting up the experiment. I had limited research funding that was only
enough to pay for the supplies and travel to set things up and take them down the
following year, but did not allow for an additional site scoping trip. I also had a deadline
to spend this money and needed to set up the experiment by July 2016. I was able to visit
one site (Netarts Bay) thanks to ODFW taking me on a day trip while they conducted
field work. This visit resulted in the setup going relatively smoothly and as planned.
When I got to Grays Harbor, WA and Coos Bay, OR, I ran into several issues, mainly
due to my unfamiliarity with the proposed sites and having to rush to make decisions
about the study. Upon reflection of this field work, I think it would have been worth the
time, effort, and perhaps revisiting the budget to visit the sites beforehand and plan the
study accordingly in advance. If I conduct future field work, I now recognize the
importance of this step and would be very hesitant to start a field study without visiting
the proposed and potential backup sites first.

Lesson 2: Implement randomization and replication at the right level into the field design
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The overarching goal of this study was to look at effects and concentrations of
PPCPs along a pollution gradient, and also compare wastewater and oyster growout sites.
While I had ample replication of individual oysters at each rack, the replication at the site
level could have been improved to draw higher order conclusions about exposure to
wastewater. Ideally, there should have been an even number of site types (wastewater and
oyster growout), at least three replicates of each site type, and randomly chosen sites.
More specifically, multiple appropriate sites should have been identified, and then a few
randomly chosen from each category. I do think that having racks at multiple distances
from the outfall may be helpful in examining small scale spatial variation, but these
distances should be the same at every outfall for better comparison. This was not possible
at the sites I chose, but this could potentially be fixed with improved site identification
(as discussed above). Lastly, it is important to consider data analysis from the beginning
of the experiment. I had little experience in this area and would have benefited from
taking the ESM univariate data analysis course in my first year, something I often
recommend to incoming graduate students, or consulting with an expert (e.g., Dr. Pan).

Lesson 3: Utilize consistent sampling when comparing seasons
In this experiment, I planned to compare oyster growth and health between two
seasons, spring and summer. I wasn’t able to do this effectively because the oysters I
collected in the spring were too small/brittle to separate without breaking most of them.
Therefore, I couldn’t get an adequate sample to measure mass and condition index.
Originally, I only had funding to run PPCP analyses on spring samples, but I acquired
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some additional funding to analyze some summer samples, though not enough to repeat
the same sampling. So instead I ran analyses for different compounds at a few sites.
While this resulted in some interesting findings, it was impossible to compare to the
spring samples. This was an unfortunate situation, primarily driven by funding, and it is
difficult to say what I could have done differently, but in the future, I would certainly
consider the importance of having consistent sampling data when comparing seasons.

Lesson 4: Collaborate with stakeholders
The one thing that made this work successful was collaboration with stakeholders.
I relied heavily on advice and field assistance from experts working in marine science
and management in OR and WA. Being a student at inland PSU made it especially
challenging to do coastal field work, but partnerships with agency staff made it happen.
These experiences really emphasized the importance of collaboration in science and I
would hesitate to do any coastal research without consulting stakeholders. Additionally, I
think it would have been beneficial to consult with more diverse stakeholders about the
research questions and study design.
These important lessons have allowed me to reflect on how I would do this
experiment differently with the knowledge I have now, and with increased resources. If I
were to redo this experiment, and had the resources to make improvements, I would:
•

Identify all possible wastewater and oyster growout sites in OR and WA

•

Randomly choose 5 (or more) sites of each type (wastewater/oyster growout)

•

Visit potential sites to make sure they are adequate for the field design
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o If not, identify backup sites or adjust study design to be consistent across
sites
•

At wastewater sites, make sure I could put the first oyster rack at the same
distance from each outfall to compare wastewater to oyster growout, and put
remaining racks at consistent distances from the outfall

•

Rather than placing racks at different distances at oyster growout sites, measure
environmental covariates that could add confounding variation to the results

•

Reach out to more stakeholders for input on research objectives and study design
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Appendix B: Supporting tables, figures, and information for chapter 3

Figure B1. Comparison of oven dried tissue weights (DTW) and freeze dried tissue
weights (FDTW) of oysters with similar wet tissues weights.
Appendix B2: Summary of lab experiment challenges
(requested by dissertation committee)
This lab experiment had many external challenges and unforeseen issues that
influenced the experimental design and data collection. First of all, it was difficult to get
two treatment plants on board for a full experiment. One treatment plant operator agreed
to provide effluent for 12 weeks, and then asked to be recused from the experiment after
the third week. At that point, I did not have enough funding or resources to start the
experiment over and therefore had to replace the treatment plant with another.
Additionally, I planned the experiment to take place during the summer tourist season,
which would have higher human populations and lower rain events with resulting sewer
overflows. Changing the timing of the experiment could have affected the results more
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than switching the treatment plant early in the experiment. Secondly, both treatment
plants were able to provide a very limited amount of composite effluent, which resulted
in using small tanks with small/slow filters, and fewer organisms per tank (lower
replication) to get the desired effluent dilutions (10% and 25%). With two tanks in our
lab not in working condition and no budget to fix them, there were not enough to include
a 50% effluent exposure from both treatment plants, resulting in an unbalanced design.
Because of the small tanks with low flow filters, and malfunctions with the Coulter cell
counter, the feeding rate trials resulted in inconsistent algal clearance rate data. Lastly,
gaining access to a reliable freeze drier was exceedingly difficult and took months of
searching, coordinating, setting up a machine and testing the methods. I spent several
weeks working with USGS (emails, meetings, taking online and in-person lab safety
assessments) to find out that their freeze drier could not handle the capacity of samples
that I needed to run. Eventually I learned that a former professor in our department (Dr.
Strecker) had an available freeze drier and I spent weeks setting it up and testing my
methods. I started the process of finding a freeze drier in November 2019 and was
preparing to dry my samples in March 2020, when covid-19 restrictions were put in
place, further delaying the process.
Changes made to the experiment to troubleshoot these issues led to low
replication, limited high effluent treatments, inadequate water flow, stressful tank
conditions, different methods for oyster drying at different time points, and introducing
potentially confounding factors (e.g., replacing WWTP2). Despite these challenges, the
experiment ran for a full 12 weeks with low mortality. Oyster growth measurements were
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deemed reliable and some significant effects were identified. Effluent and tissue analysis
resulted in several PPCP detections. Therefore, this experiment had some interesting
outcomes and adds important information to the literature.
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Appendix C: Supporting tables, figures, and information for chapter 4
Appendix C1: Pharmacist answers to question about co-workers’ attitudes regarding drug
take-back programs.
When asked about their co-workers’ attitudes toward drug take-back programs,
pharmacists generally felt that their co-workers agreed with their opinion. At locations
with dropboxes, one pharmacist said their co-workers had no opinion, but all others said
co-workers had positive attitudes and rarely mentioned issues or hindrances associated
with drug take-back programs. At locations without dropboxes, pharmacists said their coworkers were supportive of drug take-back programs but were very likely to mention the
many difficulties associated with dropboxes. Some commonly mentioned issues were a
need for education, better and clearer options to recommend to customers, and consistent
information from regulatory agencies. Two said this issue was not discussed among coworkers, and two said they did not know.

Figure C2. Customer survey questions.
PSU Public Opinion Survey Version 10.2
Location_________

Date_________

Pharmaceutical Waste Drop-off
This questionnaire is part of a pilot research study being conducted by Portland State
University aimed to better understand public disposal practices around leftover
pharmaceuticals (prescription and over the counter) in the greater Portland area. Thank
you for consenting to participate by completing this brief questionnaire. The survey takes
about 10 minutes to finish. If you have any questions or are interested in our results
please contact Dr. Elise Granek (graneke@pdx.edu). Please note that your responses are
anonymous and you are not identified in any way with this information.
By participating in the survey you consent to participating in this interview (or
questionnaire) and have been made aware of the potential risks and benefits of
participations.
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1. How did you get to the pharmacy today?

□ By Car
2.

□ By foot

□ By Bicycle

□ By Bus

□ Other ___________

Home (primary residence) zip code: __________

3. Is this current pharmacy trip typical for you (in terms of location, time onsite)?

□ Yes □ No
4. How many times have you been to the pharmacy in the last month?

□0

□1

□ 2-3

□ 4-10

□ more than 10

5. If you answered zero to question number 4, then approximately how many trips

to the pharmacy have you made in the last 6 months?
□0 □1
□ 2-3
□ 4-10
□ more than 10
6. How many members of your household have used pharmaceuticals over the past

6 months?
□0 □1

□ 2-3

□ 4-10

7. What is the main reason for your trip to the pharmacy today (choose one)?

□ Pick up a new prescription
□ Pick up a prescription refill
□Drop off left over medication
□ Ask the pharmacist a question
□ Other __________

Pharmaceutical Disposal: As mentioned above, the focus of this study is on disposal of
leftover pharmaceuticals. The following question are about your knowledge and
practices with your leftover medicine.

8. When you have leftover medications, what do you typically do with them?
(choose one)
□ Drop at a pharmaceutical drop location
□ Return to pharmacy
□ Flush down toilet
□ Throw away in trash
□ Store at home
□ Other______________________________________________________________

8. What does your doctor, nurse or pharmacist typically tell you to do with

leftover medications?
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□ Drop at a drop location
□ Return to pharmacy
□ Flush down toilet
□ Throw away in trash
□ I have never been told what to do with them
□ Other____________________________________________________________
10. If you wanted to find the information or instructions on how to dispose of
unused medication where would you look?
□ I would read the label on the medicine
□ I would look it up online
□ I would ask my pharmacist, nurse, or doctor
□ Other____________________________________________________________
11. Drug take back boxes are a good way to dispose of unneeded pharmaceuticals.
What are the main obstacles for you for using a drug take back drop box
(choose one)?
□ Until now, I didn’t know about the drug take back box
□ I never remember to bring them with me
□ I take them somewhere else (e.g., the police station)
□ I usually flush extra drugs down the drain or put them in the trash
□ I keep them in case I need them in the future
□ Other____________________________________________________________
12. Do you know where the nearest drug take back location is to you?
□ YES □ NO
If yes, please provide approximate name and location:
_____________________________________________________________________

13. If you were asked, could you explain why it matters where left over
pharmaceuticals are disposed of?
□ YES □ NO
If yes, what would you say:
______________________________________________________________________
Demographic Information: The following questions are designed to give us a better
idea of the characteristics of visitors to this pharmacy. Please note that your responses
are anonymous and you will not be identified in any way with this information.
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14. What is your age:
□ 18 to 24 years
□ 45 to 54 years
□ 75 years and over

□ 25 to 34 years
□ 55 to 64 years

15. Do you identify as: □ Male

□ Female

□ 35 to 44 years
□ 65 to 74 years

□ Other___________

16. Race/Ethnicity (choose all that apply):
□ White
□ Hispanic or Latino
□ Black or African American
□ American Indian or Alaskan Native
□ Pacific Islander
□ Indian/South Asian
□ Chinese
□ Filipino
□ Japanese
□ Korean
□ Vietnamese
□ Other Asian
□ Other ________________

17. What is your highest level of education completed (choose only one):
□ No formal education
□ Elementary/Junior High
□ High School or Diploma □ Vocational School
□ Some College
□ Associates Degree
□ Four-year College
□ Graduate School

18. Including yourself, how many people live in your current household?
□1
□2
□3
□4
□5
□ 6-7
□ 8-9
□ 10 or more
19. What was your total annual household income for the 2016 calendar year
before taxes:
□ Less than $10,000
□ $10,000 to $14,999
□ $15,000 to $24,999
□ $25,000 to $34,999
□ $35,000 to $49,999
□ $50,000 to $74,999
□ $75,000 to $99,999
□ $100,000 to $149,999
□ $150,000 or more
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Appendix D: PPCP Analyte Lists
Figure D1. SGS AXYS PPCPs list 1 analyte list.

Figure D2. SGS AXYS PPCPs list 3 analyte list.
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